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Investigating the Functional Interaction between RhoGDI Family Proteins and Activated 
Cdc42 associated-kinase (ACK) 
Ana Masara Binti Ahmad Mokhtar 
ACK is a non-receptor tyrosine kinase and an effector protein for Cdc42. ACK has been implicated 
in carcinogenesis events especially in promoting cell migration and invasion, indicating a need for 
a fuller understanding of the cellular roles of ACK both in normal and pathological conditions. A 
previous yeast-2-hybrid screen in the lab identified RhoGDI-3 as an interacting partner for ACK. 
RhoGDI-3 is a member of RhoGDI family of proteins, which are negative regulators that maintains 
Rho-family GTPases in the inactive GDP-bound state and sequesters them in the cytosol. RhoGDIs 
have also been found to become deregulated in cancer and it is possible therefore that they play 
role in ACK-driven cancer progression.  
In this work, it is shown that ACK binds but does not phosphorylate the RhoGDIs in cells or in 
vitro. ACK was shown to shuttle between the cytoplasm and the nucleus. RhoGDI-1 and -2 have 
been found only in the cytoplasm, while RhoGDI-3 is localized to both cytoplasm and the nucleus, 
under the conditions tested. The interaction between RhoGDI-3 and ACK occurs predominantly 
in the nucleus and RhoGDI-3 levels were shown to decrease following co-expression with ACK, 
especially in the nucleus. Data generated here shows that ACK-mediates RhoGDI-3 proteasomal 
degradation potentially by regulating RhoGDI-3 ubiquitination.  
In order to determine the cellular effects of the interaction between ACK and the RhoGDIs, all 
possible Rho-family GTPases that interact with the RhoGDIs were determined in a systematic 
study. RhoGDI-1 and 2 were found to have relatively restricted activity, mainly binding members 
of the Rho and Rac subfamilies. RhoGDI-3 displayed wider specificity interacting with several 
novel interacting partners within the Rho, Rac and Cdc42 subfamilies. Unexpectedly RhoGDI-3 
was found to form complexes with the atypical Rho GTPases such as RhoD, Wrch2, Rnd2, Miro2 
and RhoH which are not regulated by standard GDP/GTP cycling. The GTP levels of these target 
proteins were found to decrease following co-expression with RhoGDI-3, confirming its role as a 
negative regulator of these Rho GTPases. ACK was shown to regulate the activation of these target 
proteins, including RhoA, RhoB, Rac1 and RhoH, which are known to be involved in cell 
proliferation and migration. Aberrant activation of these target protein is frequently observed in 
cancer, suggesting a role for RhoGDI to drive ACK oncogenicity.  
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Chapter 1  
Introduction 
 
1.1 Small GTPases 
Small GTPases, are monomeric guanine nucleotide binding proteins related to the α subunit of 
heterotrimeric G proteins. All small GTPases belong to a superfamily, often named as the Ras 
superfamily because the founding members are encoded by human ras genes that were initially 
discovered as cellular homologs of the viral ras oncogene (Harvey, 1964). The Ras superfamily 
can be further divided into five major families: Ras, Rho, Arf, Ran and Rab. Table 1.1 shows some 
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Table 1.1: The Ras superfamily of small GTPases and their functions  
 
1.2 The structure of small GTPases 
Small G proteins regulate a multitude of signalling pathway by acting as molecular switches. They 
have the ability to cycle between an inactive guanosine diphosphate (GDP)-bound form and an 
active guanosine triphosphate (GTP)-bound form to function (Goitre et al., 2014). All Ras 
superfamily proteins shared a conserved guanine nucleotide binding domain or “G domain”, 
containing five sequence motifs G1-G5 that mediate interaction with nucleotides and effector 
proteins (Figure 1.1) (Bourne et al., 1991). The G1 motif also known as the Walker A motif or P-
loop, is involved in phosphate binding, while the G3 motif binds to the nucleotide-associated Mg2+ 
ion. G4 and G5 are important in recognizing the guanine base of GTP. The G2 motif makes 
contacts with both the γ-phosphate of GTP and the Mg2+ ion (Colicelli, 2004).  
Family Subfamily Function 
Ras 
Ras 
Cell proliferation, differentiation, survival, apoptosis and gene 
expression (Barbacid, 1987; Lowy and Willumsen, 1993) 
Ral Exocytosis, cell motility and actin cytoskeletal rearrangement (Shirakawa and Horiuchi, 2015) 
Rap Cell adhesion, phagocytosis, cell morphology and cell junction formation (Caron, 2003) 
Rad 
Insulin-stimulated glucose uptake (Moyers et al., 1996) and actin 
cytoskeleton rearrangement (Ward et al., 2002) 
Rheb mTOR pathway activation (Inoki et al., 2003), cell growth and cell-cycle progression (Patel et al., 2003) 
Rit Cell proliferation (Rusyn et al., 2000), differentiation and survival (Spencer et al., 2002) 
Rho 
Actin-cytoskeletal rearrangements, intracellular membrane trafficking 
(Ridley and Hall, 1992), cell-cycle progression (Olson et al., 1995) and 
transcriptional activation (Sulciner et al., 1996) 
Rab Intracellular vesicular transport (Zerial and McBride, 2001) 
Arf Vesicular trafficking (Volpicelli et al., 2005) 
Ran DNA replication (Yamaguchi and Newport, 2003)  
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The conformations of the “on” and “off” states of these small GTPases are similar but display 
pronounced differences that are confined primarily to two flexible loop regions called switch 1 
and switch 2. In the GTP-bound state, both switch regions adopt conformations that allow 
downstream effector proteins to recognise and interact with the small GTPases (Milburn et al., 
1990). All small G proteins undergo these changes but some of the families undergo additional 
rearrangement such those seen in the N-terminus of Arf (1-17) and the C-terminus of Ran (173-
216) (Antonny et al., 1997; Vetter et al., 1999).  
Small G proteins also have a hypervariable region at their C-termini (Figure 1.1) that is essential 
for facilitating membrane association and subcellular localization. For instance, polybasic region 
in the hypervariable region of K-Ras4B and Rab35 facilitate their association with the plasma 
membrane (Hancock et al., 1990; Welman et al., 2000;  Li et al., 2014), while similar sequence 
target R-Ras to focal adhesions (Furuhjelm and Peränen, 2003). Rac1 membrane association and 
nuclear localisation has also been shown to be regulated by its C-terminal polybasic region 
(Lanning et al., 2004).  
Besides being involved in subcellular targeting, the hypervariable region has been shown to be 
involved in some protein-protein interactions and can target certain small GTPases to different 
signalling complexes. For example, phosphatidylinositol-4-phosphate 5-kinase (PIP5K) and 
diacylglycerol kinase (DGK) were found to interact with Rac1 via its hypervariable region (van 
Hennik et al., 2003). Phosphorylation of the hypervariable region of K-Ras4B by PKC also results 
in the interaction between K-Ras4B and Bcl-XL (Bivona et al., 2006).  
 
 









Figure 1.1: The architecture of the Ras superfamily proteins. Most of Ras superfamily 
proteins, including Rho, Ras and Rab share a conserved G domain, containing five conserved 
sequence G motifs: G1/P-loop (G10xxxxGKS/T17), G2 (T35), G3 (D57xxGQ/H/T61), G4 
(N/T116KxD119) and G5 (S/C145AK/L/T147). The switch 1 and switch 2 regions involved in the 
conformational changes induced by the GDP/GTP cycle. The effector binding region is critical for 
direct association with downstream effector proteins. The CAAX box (C: Cys, A: aliphatic residue, 
X: any residue) is the site of lipid modification.  
 
1.2.1 Lipid modification of small G proteins 
Most of the Ras superfamily undergo prenylation at their C-termini, which terminate with a CAAX 
(C: Cys, A: aliphatic residue, X: any amino acid) tetrapeptide sequence. This process involves 3 
main steps which are isoprenylation, proteolysis and carboxyl methylation (Choy et al., 1999). 
Firstly, an isoprenoid lipid is attached to the CAAX box by a prenyltransferase such as 
geranylgeranyltransferase (GGTase) or farnesyltransferase (FTase). Both of these enzymes 
recognise the CAAX sequence before adding a 20-carbon geranylgeranyl or 15-carbon farnesyl to 
the cysteine residue of the CAAX sequence via a thioether linkage. Prenylation is followed by the 
proteolysis of the three C-terminal residues (AAX) by a prenyl protein peptidase, for example from 
the Rce1 family, to release –AAX. The prenylated cysteine is then methylated by isoprenyl-
cysteine carboxyl methyl-transferase (ICMT). Unlike Ras and Rho-family members, Rab small 
GTPases can undergo double geranylgeranylation at the C-terminus, which is important for their 
correct localization (Pfeffer and Aivazian, 2004). 16-carbon palmitate acids can also be added to 
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various small G protein which contain further target cysteine residues in their sequence by 
palmitoyltransferase. This lipid modification is reversible (Smotrys and Linder, 2004). Instead of 
prenylation, Arf small GTPases undergoes myristoylation at their N-terminus (D'Souza-Schorey 
and Stahl, 1995), while the Ran small GTPase does not undergo any lipid modification 
(Wennerberg and Der, 2004).  
1.3 Regulation of small GTPases activity  
Even though each small G protein has a distinct molecular sequence and cellular function, most of 
them utilize a shared conformational switch between the GTP and GDP bound forms (Goitre et 
al., 2014). Generally, in the GTP-bound form, the small GTPases form a hydrogen bond between 
the NH group of a threonine (Thr) in switch 1 and a glycine (Gly) in switch 2 with an oxygen from 
the g-phosphate of GTP (Figure 1.2). These bonds hold the switches in a specific configuration. 
The release of g-phosphate following GTP hydrolysis breaks the hydrogen bonds and allows both 
of the switches to relax (Vetter and Wittinghofer, 2001). The extent of the conformational changes 
is unique to each small GTPases. For instance, most of the Ras-family members show modest 
changes restricted only to their switch regions, whereas Arf and Ran experience larger changes 









Figure 1.2: Schematic diagram of the 
universal switching mechanism of small 
G proteins. The γ-phosphate of the GTP 
forms a hydrogen bonds with a Thr in 
switch 1 and a Gly in switch 2 of small G 
proteins. This configuration is known as the 
loaded-spring mechanism where the release 
of the γ-phosphate, allows both of the 
switches to relax into their GDP-bound 
conformation. (Adapted from Vetter and 
Wittinghofer, 2001). 
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The intrinsic GDP/GTP switching of these small GTPases is relatively slow, thus they require 
three classes of regulatory proteins to allow them to function. These are known as the guanine 
nucleotide-exchange factors (GEFs), GTPase-activating proteins (GAPs) and guanine nucleotide-
dissociation inhibitors (GDIs). GEFs facilitate GDP dissociation and promote binding of the more 
abundant GTP in the cytoplasm, thus allowing the small GTPases to become activated and bind to 
their specific effectors in order to trigger signalling pathways (Cherfils and Zeghouf, 2013). In 
contrast, GAPs are responsible for terminating small GTPases signalling by stimulating their 
intrinsic GTPase activity so enhancing the hydrolysis of GTP to GDP (Bos et al., 2007). Unlike 
Ran and Arf family proteins, Ras, Rho and Rab require a third regulator family known as the GDIs. 
GDIs are bifunctional negative regulators of small GTPases and act to maintain the small G 
proteins in their GDP-bound state and also physically sequester small GTPases out of membranes 
by interacting with their prenyl group. A summary of the regulatory roles of all proteins involved 









Figure 1.3: The regulatory cycle of Rho-family proteins. Small GTPases, for example the Rho-
family small G proteins, cycle between an active GTP-bound and an inactive GDP-bound state. 
GEFs function to activate these small G proteins, facilitating the exchange of GDP for GTP, which 
in turn interact with specific effector proteins to mediate diverse biological effects. In contrast, 
GAPs stimulate the intrinsic GTPase activity of the small G proteins, accelerating their 
inactivation. GDIs are negative regulators that maintain small GTPases in GDP-bound state in 
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1.3.1 Guanine nucleotide exchange factor (GEFs) 
The intrinsic nucleotide exchange rate of small G proteins is relatively slow. Thus, the GEFs are 
required to increase the rate of exchange by several orders of magnitude (Vetter and Wittinghofer, 
2001). Different families of GEFs have been shown to regulate different families of small GTPases 
(Table 1.2). Most of the Ras family are regulated by GEFs containing a CDC25 homology domain 
(CDC25-HD) (Lai et al., 1993), while GEFs that regulate Rho-family proteins often contain a DH-
PH tandem di-domain (Hart et al., 1991). Rho-family proteins can also be regulated by DOCK 
family proteins containing DOCK-homology regions 1 (DHR1) and 2 (DHR2). GEFs for members 
of the Arf-family contain a Sec7 domain (Chardin et al., 1996). The regulator of chromosome 
condensation 1 (RCC1) protein acts as a GEF for Ran (Bischoff and Ponstingl, 1991) and has a ß- 
propeller structure unique amongst GEFs. There are two main families of GEFs for Rab proteins 
which contain either a Vps9 domain (Carney et al., 2006) or DENN domain (Allaire et al., 2010).  
Despite the large amount of structural diversity amongst the GEFs, in general they all share a 
similar mechanism to accelerate the dissociation of the nucleotide from the small GTPases. Briefly, 
the GEFs interact with the switch 1 and/or switch 2 regions and this binding results in 
conformational changes in both the switch regions and the P-loop of the small GTPases. This 
disturbs phosphate and Mg2+ binding, weakening the interaction between the small G proteins and 
GDP, resulting in release of GDP and binding of GTP (Vetter and Wittinghofer, 2001).  
G proteins are structurally stabilised by their associated nucleotide and a major function of a GEF 
is to stabilise the nucleotide free form of the small G proteins during exchange. For instance, Sos1 
stabilises Ras in its nucleotide-free state by inserting an α-helix from its catalytic domain near to 
switch 1 and by contacting the side chains of residues in switch 2. This opens up the nucleotide-
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Table 1.2: List of selected examples GEFs  




K-Ras, N-Ras Sos1/ 2, RasGRF1/2, RasGRP1/ 2 
Buday and 
Downward, 
2008; Besray et 
al., 2018 
M-Ras Sos1, RasGRP1/ 2/ 3, RasGRP3 
R-Ras RasGRP2/ 3 
H-Ras RasGRP4, PLCε, Sos1, RasGRF1/2, RasGRP1 
Rap1 RAPGEF1, RasGRP2/3 
Rho 
RhoA ARHGEF11/12/25/18/28, SmgGDS, AKAP13, IpgB2 
Toma-Fukai et 
al., 2019 Rac1 Tiam, Trio, Vav1, DOCK2, P-Rex1, Kalirin, ARHGEF28 
Cdc42 Dbs, ITSN1, DOCK7/8/9 
TCL ITSN1 Color-Aparicio 
et al., 2020 
Rab 
Rab1a/b TRAPP I 
Müller and 
Goody, 2018 











Arf1 GBF1, BIG1/2, Cytohesin-1/2/3/4 
Donaldson and 
Jackson, 2011; 
Sztul et al., 
2019 
Arf3 GBF1, BIG1/2, Cytohesin-2 
Arf4 BIG1/2 
Arf5 GBF1, Cytohesin- 4 
Arf6 BRAG1/2/3, Cytohesin-1/2/3, EFA6A-D 
Arl1 BIG1/2 
Arl4A/4D Cytohesin-1/2/3 
Ran Ran RCC1 
Bischoff and 
Ponstingl, 1991 
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1.3.2 GTPase-activating proteins (GAPs) 
The inactivation of small GTPases requires stimulation by GAPs. Similar to GEFs, there are 
specific GAPs for each family of small GTPases (Table 1.3). The structural details of how the 
GAPs stimulate intrinsic GTPase activity were initially described for the Ras-p120GAP (Scheffzek 
et al., 1997) and RhoA-RhoGAP complexes (Rittinger et al., 1997).  
p120GAP was shown to neutralise the negative charge building up on the γ- and ß- phosphates of 
GTP and to stabilise switch 2 of H-Ras by inserting an arginine side chain (Arg789) into the active 
site of Ras. This arginine residue also known as the arginine finger is conserved among all Ras 
GAPs and is required to orientate Ras Gln61, which catalyses GTP hydrolysis. Ras Gln61 
coordinates a reactive water molecule in the catalytic site which then performs the nucleophilic 
cleavage of the γ-ß-phosphoanhydride bond of GTP, resulting in the release of the γ-
phosphate (Scheffzek et al., 1997). Similarly, p50RhoGAP was shown to enhance the GTP 
hydrolysis on RhoA through the insertion of Arg85 into the active site of RhoA, resulting in the 
stabilisation of Gln63 to participate in the GTP-hydrolysis (Rittinger et al., 1997).  
The involvement of the arginine finger and the catalytic glutamine and is conserved in the Rab 
proteins. However, the details of Rab GAPs activity are slightly different. Studies on Gyp1p in 
yeast showed the involvement of a dual-finger mechanism where both the arginine finger and 
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Table 1.3: List of selected examples GAPs  





Jeong et al., 
2007; Besray et 
al., 2018 
Vigil et al., 
2010 
N-Ras, H-Ras, Rab48 DAB2IP 
N-Ras, K-Ras, H-Ras NF1, RASAL2 
H-Ras PLXNB1 
Rap1A IQGAP1 
Rheb2, Rap1A, RalA TSC2 




p50RhoGAP, ARAP1, ARAP3, 
BPGAP1, p73RhoGAP, MgcRacGAP, 









p50RhoGAP, ARAP1, ARAP3, Bcr, 
Abr, MgcRacGAP, ArhGAP10, 
srGAP3, p190RhoGAP 
Cdc42 p50RhoGAP, ARAP1, ARAP3, Bcr, Abr, MgcRacGAP, ArhGAP10, srGAP3 
Rac2 Bcr, Abr 
Rnd1/Rnd3 p190RhoGAP 
Rab 









Rab13, Rab33a/b TBC1D25 
Rab17, Rab21 TBC1D7 
Arf 
Arf1/2/3/4/5 ArfGAP1/ 2/ 3 Donaldson and 
Jackson, 2011; 
Sztul et al., 
2019 
Arf6 Acap1, Adap1, Agap1, Arap2, Asap1, Git1, Smap1 
Arl3 RP2, ELMOD2 
Ran Ran RanGAP1 Bischoff et al., 1994 
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1.3.3 Guanine nucleotide-dissociation inhibitors (GDIs) 
Within the Ras superfamily, Ras, Rho and Rab small GTPases are known to be regulated by the 
third class of regulatory protein known as GDIs (Table 1.4). Rho and Rab GDIs contain two 
domains. The first, a smaller N-terminal domain, interacts with the switches on the G domain of 
small G proteins to prevent nucleotide exchange. The second, larger, C-terminal domain has a 
hydrophobic cleft that interacts with the lipid-modified tail of the small GTPases and thus 
disallows membrane association. The GDIs maintain an inactive cytosolic pool of small G proteins 
(Wu et al., 1996; Olofsson, 1999) and also act as chaperones targeting the small GTPases to 
specific subcellular compartments (Brunet et al., 2002; Pfeffer and Aivazian, 2004).  
RabGDIa was first identified for Rab3A by Araki et al. (1990) and the structure of RabGDIs are 
conserved across species. Structural studies in yeast demonstrated that the RabGDIs interact only 
with the GDP-bound form of the Rab GTPases (Alory and Balch, 2000; Rak et al., 2003; 
Pylypenko et al., 2006).  
Unlike the RabGDIs, the RhoGDIs have been shown to interact with both the GDP- and GTP-
bound forms of Rho-family GTPases. For instance, RhoGDI-1 can accommodate both the GTP- 
and GDP-bound forms of Rac1, RhoA and Cdc42 (Hancock and Hall, 1993; Nomanbhoy and 
Cerione, 1996). In fact, RhoGDI-1 appears to be required to maintain Cdc42 in its active GTP-
bound form by preventing both intrinsic and GAP-stimulated GTP hydrolysis, and is crucial for 
Cdc42-mediated cellular transformation (Hart et al., 1992; Lin et al., 2003).  
Besides these two classes of GDIs, there are GDI-like proteins that have been shown to regulate 
the activation of Ras-family GTPases. The GDI-like solubilizing factor (GSF), PDEd, interacts 
with and solubilises farnesylated Ras small GTPases in the cytoplasm through its isoprenoid 
binding pocket (Alexander et al., 2009; Chandra et al., 2012). Galectin-3 and -8 also contain a 
hydrophobic pocket with the ability to interact with farnesylated K-Ras4B and this association is 
important in modulating K-Ras4B oncogenic signalling (Shalom-Feuerstein et al., 2008; Meinohl 
et al., 2019). 
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 Table 1.4: Complete list of Rho-, Rab- and RasGDIs  
 
1.4 The Rho-family small GTPases  
The Rho (Ras homologous) family of small GTPases is one of the families of the Ras superfamily. 
The Rho-family GTPases are best studied for their role in promoting actin cytoskeleton 
reorganization, however they also play roles in cell division, cell adhesion and motility, vesicular 




RhoA, Cdc42 RhoGDI-1, RhoGDI-2, RhoGDI-3 
 DerMardirossian and 
Bokoch, 2005; Adra et 
al., 1997 




Bokoch, 2005; Griner et 
al., 2015 
Rac1, Rac2 DerMardirossian and Bokoch, 2005 
Rac3 
DerMardirossian and 
Bokoch, 2005; Zhang et 
al., 2009 
RhoG RhoGDI-1, RhoGDI-3 
DerMardirossian and 
Bokoch, 2005; Adra et 
al., 1997 




Shapiro and Pfeffer, 1995 
Rab3B Sidhu and Bhullar, 2001 
Rab2A, Rab4A, Rab5A, 
Rab8A, Rab9A, Rab11A RabGDI-2 Shisheva et al., 1999 
Ras 
K-Ras4B Galectin-3 and -8 
Shalom-Feuerstein et al., 
2008; Meinohl et al., 
2019 
K-Ras, N-Ras, H-Ras PDEd 
Alexander et al., 2009; 
Chandra et al., 2012 
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trafficking, phagocytosis and transcriptional regulation (Ridley and Hall, 1992; Olson et al., 1995; 
Jaffe and Hall, 2005; Sulciner et al., 1996).  
In humans, there are 23 Rho-family GTPases members that can be further categorized into six 
major subfamilies (Figure 1.4). RhoD, RhoF and RhoH do not belong to any subfamily. The 
subfamilies are categorised based on their similarity in primary amino acid sequence (Appendix 














Figure 1.4: Phylogenetic tree of the Rho-family GTPases. A phylogenetic analysis of the amino 
acid sequences of the 23 Rho-family GTPases members made with Clustal Omega. The Rho-
family can be divided into 6 major subfamilies: Rho, Rac, Cdc42, Rnd, Miro and RhoBTB. RhoD, 
RhoH and RhoF does not belong to any subfamily.  
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Among these Rho-family GTPases, the most extensively studied members are RhoA, Rac1 and 
Cdc42. These proteins and their subfamilies are also known as classical Rho-family GTPases. The 
other Rho-family proteins are known as the non-classical or atypical Rho GTPases and include the 
RhoBTB, Rnd and Miro subfamilies. This classification is made based on the ability of the Rho-
family GTPases to undergo the classical GTPase cycle as described in section 1.2 (Wennerberg 
and Der, 2004; Aspenström, 2017).  
1.4.1 The classical Rho-family GTPases 
Compared to other Ras superfamily proteins, the defining feature of Rho-family small G proteins 
is the Rho insert region, a unique α-helical sequence located between the fifth β strand and the 
fourth α helix in the G domain (Valencia et al., 1991). The role for this insert region is still not 
well understood. However, previous studies show that this insert region regulates some RhoA, 
Rac1 and Cdc42 functions. For instance, the insert region of Rac1 is essential to support NADPH 
oxidase activity (Freeman et al., 1996). Deletion of the RhoA insert region also prevented the 
activation of Rho kinase (ROCK) in vivo and therefore the ability of RhoA to induce stress fibre 
formation (Zong et al., 2001).  
Most of the classical Rho-family GTPases are found to have only a Rho-type G domain with short 
N-terminal and C-terminal extensions (Wennerberg and Der, 2004; Citalán-Madrid et al., 2013). 
Similar to other Ras superfamily members, they also have a hypervariable region encoding a 
prenylation site at their C-termini (Figure 1.5) and sometimes a polybasic region. These signals 
allow them to associate with specific membrane compartment (Table 1.5) (Michaelson et al., 
2001). Some of the Rho-family GTPases also have cysteine residues upstream of the CAAX motif 
that can be palmitoylated.  
Most of the classical Rho-family GTPases are geranyl-geranylated or farnesylated, with only a few 
palmitoylated for example RhoB, TC10 and Rac1 (Table 1.5) (Adamson et al., 1992; Michaelson 
et al., 2001; Navarro-Lérida et al., 2012).  
 
 








Figure 1.5: The architecture of the classical Rho-family proteins. All classical Rho-family 
GTPases shared a conserved G domain, effector binding region, hypervariable region and CAAX 
box. They also have a Rho insert region that is exclusive to Rho-family GTPases.  
 
Palmitoylation is known to affect protein function by regulating membrane interactions and 
subcellular distribution (Salaun et al., 2010). For example, RhoB undergoes palmitoylation at both 
Cys189 and Cys192. However, only Cys192 has been shown to inhibit anchorage-independent 
growth and maintain proper distribution of RhoB to endosomes (Wang and Sebti, 2005). Inhibition 
of palmitoylation was also found to mis-localise TC10 to the endoplasmic reticulum rather than to 
the plasma membrane and endosomes (Michaelson et al., 2001; Watson et al., 2003). Rac1 
palmitoylation at Cys178 is also important to maintain correct distribution of Rac1 to the plasma 
membrane, cytosol and nucleus, which are required to regulate actin cytoskeleton remodelling 
(Navarro-Lérida et al., 2012). 
Interestingly, palmitoylation is exclusive to Rac1 in the Rac subfamily, despite all three Rac 
isoforms sharing a conserved cysteine at residue 178. This may be due to the distinct sequences 
between Cys178 and the prenylation site in the Rac isoforms (Table 1.5) that favour palmitoylation 
in Rac1 (Navarro-Lérida et al., 2012). TCL is also predicted to undergo palmitoylation since it is 
shown to possess two C-terminal putative palmitoylation sites. However, a biotin labelling assay 
suggest that it is not (Roberts et al., 2008).  
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Table 1.5: C-terminal sequences of the classical Rho-family GTPases and their subcellular 
distribution 
 
Putative palmitoylated cysteines are in boldface type and coloured red and CAAX prenylation 
motifs are underlined. (Data taken from: Adini et al., 2003; Ridley, 2006; Wennerberg and Der, 
2004; Roberts et al., 2008; Dubash et al., 2011; Kim et al., 2013; Murali and Rajalingam, 2014). 
GG: geranylgeranyl, F: farnesyl, P: palmitoyl, PM: plasma membrane, C: cytosol, N: nucleus, G: 
Golgi, E: endosomes, ER: endoplasmic reticulum, NE: nuclear envelope and EM: endomembrane. 
 
1.4.1.1 The Rho subfamily proteins 
The Rho subfamily consists of RhoA, RhoB and RhoC. RhoA and RhoC share 92% similarity 
while RhoA and RhoB share 85% sequence similarity (Appendix 1.1). The most divergent 
sequences between RhoA, B and C are located towards the C-termini (Wheeler and Ridley, 2004), 
with some of the differences also concentrated in the Rho insert region (Schaefer et al., 2014).  
As described previously, the C-termini of all Ras superfamily proteins are important for lipid 
modification and therefore the subcellular distribution of the small GTPases. Both RhoA and RhoC 
are geranylgeranylated, whereas RhoB can be either geranylgeranylated or farnesylated, and 
palmitoylated. These differences in lipid modifications are reflected in their subcellular 







RhoA KDGVREVFEMATRAALQARRGKKKSGCLVL GG PM, C, G, N 
RhoB VREVFETATRAALQKRYGSQNGCINCCKVL GG/ F, P PM, G, E, N 
RhoC KEGVREVFEMATRAGLQVRKNKRRRGCPIL GG PM, C, N 
Rac1 RGLKTVFDEAIRAVLCPPPVKKRKRKCLLL GG, P PM, C, N 
Rac2 RGLKTVFDEAIRAVLCPQPTRQQKRACSLL GG PM, G, ER, NE 
Rac3 RGLKTVFDEAIRAVLCPPPVKKPGKKCTVF GG PM, EM, N 
RhoG QDGVKEVFAEAVRAVLNPTPIKRGRSCILL GG PM, E, MT 
Cdc42 QKGLKNVFDEAILAALEPPEPKKSRRCVLL GG PM, G, ER, NE 
TCL AVFDEAILTIFHPKKKKKRCSEGHSCCSII F PM, E 
TC10 DEAIIAILTPKKHTVKKRIGSRCINCCLIT F, P PM, E 
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while RhoB is found at the plasma membrane, endosomes and Golgi (Adamson et al., 1992; 
Michaelson et al., 2001). Different forms of RhoB are shown to associate with different 
membranes. For instance, geranylgeranylated RhoB has been shown to localise to late endosomes, 
whilst the farnesylated form of RhoB localises to the plasma membrane (Wherlock et al., 2004). 
Geranylgeranylated and not farnesylated RhoB is crucial for stress fibre and focal adhesion 
formation (Allal et al., 2002). Palmitoylation is known to support the role of RhoB as a tumour 
suppressor by inhibiting anchorage-independent growth and stimulating apoptosis of PC3 tumour 
cells (Wang and Sebti, 2005). 
To date, there are a large number of effector proteins identified for Rho subfamily proteins (Table 
1.6). For instance, Rhotekin, Rhophilin and the PRKs have a Rho binding region at their N-termini, 
which share 27-40% sequence similarity (Reid et al., 1996; Watanabe et al., 1996). In contrast, 
the serine/threonine protein kinases, ROCK1 and ROCK2 have a Rho-binding domain at their C-
termini, located in between a coil-coil structure and a pleckstrin homology (PH) domain (Leung 
et al., 1996). Another family of Rho effector belong to the formin family and are known as mDia1, 
2 and 3. However, they are not specific for Rho subfamily members as they have also been found 
to interact with other Rho-family GTPases such as Cdc42, Rac1 and RhoF (Lammers et al., 
2008; Pellegrin and Mellor, 2005).  
RhoB was the first member of the Rho subfamily protein to be associated with endosomal 
trafficking by activating and translocating its downstream targets PRK1 and mDia1 to endosomes 
(Adamson et al., 1992; Mellor et al., 1998; Fernandez-Borja et al., 2005). RhoB was also found to 
facilitate the trafficking of several signalling molecules such as Akt (Adini et al., 2003), Src 
(Sandilands et al., 2004) and PDGFR-b (Minzhou et al., 2007) to the nucleus, plasma membrane 
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Table 1.6: The examples of interacting proteins for the classical Rho-family GTPases  
 
(Data taken from: Vignal et al., 2001; Cotteret et al., 2003; Pandey et al., 2002; Schwartz et al., 
2004; Ridley, 2006; Wang et al., 2007; Koh et al., 2008; Lam et al., 2013; Korkina et al., 2013; 
Fujita et al., 2013; Kühn and Geyer, 2014; Prudnikova et al., 2015; Farrugia and Calvo, 2016; 
Soriano-Castell et al., 2017; Siddique et al., 2019) 
 
All three Rho subfamily proteins are frequently deregulated in a variety of cancers. RhoA and 
RhoC are known as pro-oncogenic, whilst RhoB is anti-oncogenic. Overexpression of RhoA has 
been described in colon, breast, lung, ovarian, gastric and liver cancers (Fritz et al., 1999; Horiuchi 
et al., 2003; Pan et al., 2004; Li et al., 2006) with overexpression found to correlate with cancer 
progression. For instance, overexpression of RhoA promotes cervical cancer cell proliferation and 
migration via its effectors, ROCK1 and 2 (Liu et al., 2014). In contrast however, reduced RhoA 
was shown to increase breast cancer metastasis by promoting a pro-tumour microenvironment by 
increasing the infiltration of cancer-associated fibroblast (CAFs) and macrophages, and by 
increasing the CXCR4-CXCL12 and CCR5-CCL5 chemokine axes in primary tumour (Kalpana 
et al., 2019).  
RhoC has also been shown to associate with pancreatic cancer (Suwa et al., 1998), skin cancer 
(Clark et al., 2000), breast cancer (Kleer et al.,2002), gastric cancer (Kondo et al., 2004; Liu et al., 
Group Rho GTPases Interacting proteins 
Rho 
RhoA ROCK1/2, Rhotekin, Citron, CRK, Rhophilin, mDia1, mDia2, Daam1, MRK, PRK1 
RhoB ROCK1/2, Rhotekin, PRK1, mDia1, mDia2, Daam1 
RhoC ROCK1/2, Rhotekin, mDia1, Daam1, FMNL2, FMNL3, MRK, PRK1 
Rac 
Rac1 
PAK1-6, WAVE, IQGAP3, mDia1, mDia2, Daam1, 
FMNL1, IRSp53, PLC-b, p67phox, PRK1, ROCK1 
Rac2 PAK1-4, mDia1, mDia2 
Rac3 PAK1-4 
RhoG ELMO, Kinectin 
Cdc42 
Cdc42 
ACK, WASP, N-WASP, PAK1-6, PAR6, IQGAP3, 
BORG1-5, mDia2, mDia3, Daam1, FMNL1, FMNL2, 
SPEC1, SPEC2 
TC10/RhoQ WASP, N-WASP, PAK1-3, BORG1-3,5, Exo70 
TCL/RhoJ WASP, N-WASP, PAK1-3 
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2007) and cervical cancer (He et al., 2004). Despite its high similarity with RhoA, increased 
activation of RhoC but not RhoA was shown to stimulate the epithelial-mesenchymal transition 
(EMT) process and metastasis in colon cancer (Bellovin et al., 2006). Silencing RhoC, but not 
RhoA also decreased the anchorage-independent growth of LNCaP cells (Giang Ho et al., 2011). 
These opposing roles of RhoA and RhoC in regulating cell migration might be due to them acting 
on different effector targets. For example, RhoA was shown to be involved in migratory cell 
polarity by suppressing Rac1 activity in lamellipodia via ROCK2, while RhoC enhanced migration 
by restricting lamellipodia broadening through FMNL3 (Vega et al., 2011).  
In contrast to RhoA and RhoC, RhoB expression levels decrease during cancer progression, 
indicating a role for RhoB as a tumour suppressor (Huang and Prendergast, 2006). RhoB was 
shown to promote apoptosis and inhibit cell migration and invasion by antagonizing the 
Ras/PI3K/Akt pathway in vivo (Jiang et al., 2004). Loss of RhoB, induced by miR‐21 (microRNA 
21), enhanced cell proliferation and invasion in colon cancer (Liu et al., 2011). Different forms of 
RhoB have also been shown to be involved with cancer progression. Geranylgeranylated RhoB 
was found to prevent cell proliferation in Ras-transformed NIH3T3 mouse fibroblast (Mazières et 
al., 2005), while farnesylated RhoB supported cell survival (Milia et al., 2005).  
1.4.1.2 The Rac subfamily proteins 
All Rac subfamily proteins are known to stimulate the formation of membrane ruffles and 
lamellipodia (Ridley et al., 1992; Nobes and Hall, 1995) by interacting with the WASP (Wiskott–
Aldrich syndrome protein), WAVE (WASP-family verprolin homologue) or PAK (p21-activated 
kinases) families of effector proteins. These then activate the Arp2/3 complex and subsequently 
induce actin polymerization (Aspenström et al., 1996; Machesky and Insall, 1998; Eden et al., 
2002; Ten Klooster et al., 2006). Rac subfamily proteins are also involved in regulating 
cytoskeleton reorganization via LIM kinase-1 (LIMK-1), which in turn inactivates cofilin-induced 
actin depolymerization (Yang et al., 1998). 
Within the subfamily, Rac1, Rac2 and Rac3 share ³89% sequence similarity, with the major 
differences within the C-terminal region (Haataja et al., 1997). Despite their similarity, Rac1 is the 
only Rac subfamily member that can be palmitoylated at Cys178 and this has been shown 
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to regulate cell spreading and migration (Navarro-Lérida et al., 2012). The final subfamily 
member, RhoG is a bit different as it shares only ~70% sequence similarity with the other members 
(Vincent et al., 1992).  
The role of Rac1 in cell proliferation, apoptosis and migration has been described (Moore et al., 
1997; Lassus et al., 2000; Nikolova et al., 2007; Nishiya et al., 2005). For instance, Rac1 is 
involved in regulating cell cycle progression by activating the c-Jun kinase (JNK/SAPK) pathway 
(Olson et al., 1995). Active Rac1 was targeted to membrane ruffles and focal adhesions in the 
leading edge of migrating cells by its interaction with a GEF, β‐Pix (Ten Klooster et al., 2006). 
Thus, deregulation of Rac1 activity is highly correlated with cancer progression, with 
overexpression of Rac1 found to increase cell growth and invasion in gastric cancer cells (Ji et al., 
2015). Rac1 was also required for K-Ras-induced proliferation and tumorigenicity of lung cancer 
in vivo (Kissil et al., 2007).  
Several in vivo studies show that depletion of Rac2 results in hematopoietic defects such as a lack 
of integrin-directed migration (Pradip et al., 2003), adhesion (Yang et al., 2001) and angiogenic 
response (De et al., 2009). Overexpression of Rac2 induces the proliferation of quiescent cells in 
non-small cell carcinoma (NSCLC) by enhancing the expression of the transcription factor Jun-B 
(Pei et al., 2018). It was also found to associate with poor prognosis of renal cancer by increasing 
the proliferation, migration and invasion of renal carcinoma cells (Liu et al., 2019).   
Despite having 93% sequence similarity with Rac1, Rac3 has been shown to oppose Rac1 function 
in regulating cell adhesion and differentiation, with Rac1 promoting and Rac3 inhibiting cell 
adhesion in neuronal cells (Hajdo-Milašinović et al., 2007). Rac3 gene was mapped to 17q25.3, 
near the tumour suppressor gene BROV, that is frequently deleted in breast and ovarian cancer 
(Morris et al., 2000). This indicates possible transcriptional deregulation of Rac3 in these cancers, 
consistent with previous findings that showed Rac3 was hyperactive in a highly proliferative breast 
cancer cell line and was important in promoting tumour growth via the Rac3-PAK pathway (Mira 
et al., 2000).  
The last member of the Rac subfamily proteins, RhoG is known to promote actin polymerization 
by regulating nuclear factor of activated T cells (NFAT) gene transcription in lymphocytes 
(Vigorito et al., 2003) and stimulating macropinocytosis in fibroblasts in response to SH3-
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containing Guanine Nucleotide Exchange Factor (SGEF) activation (Ellerbroek et al., 2004). 
Several studies have shown an upstream role for RhoG in regulating Cdc42 and Rac1, with the 
activation of Cdc42 and Rac1 by RhoG necessary for the formation of membrane ruffles and 
filopodia (Gauthier-Rouvière et al., 1998). For example, the role of RhoG in regulating cell 
migration was shown to involve the activation of Rac1 via the RhoG effector, ELMO and the 
ELMO-binding protein Dock180, which functions as a Rac1-specific GEF (Katoh et al., 2006). In 
contrast, RhoG and Rac1 were found to have opposite roles in regulating the dynamics of 
invadopodia in breast cancer cells and this involved the activation of SGEF and adaptor protein, 
paxillin (Goicoechea et al., 2017).  
1.4.1.3 The Cdc42 subfamily proteins 
Among the Cdc42 subfamily proteins, Cdc42, TCL and TC10 are classified as classical small 
GTPases, whereas Wrch1 and Wrch2 belong to the non-classical or atypical class, due to their 
unique N- and C-terminal extensions and being constitutively active because of their high intrinsic 
GDP dissociation rate. All the classical Rho, Rac1 and Cdc42 subfamily proteins share a series of 
effector proteins including the PAKs and formins (Manser et al., 1994; Yasuda et al., 2004) except 
for ACK, the BORGs and the SPECs that are exclusive for Cdc42 subfamily members (Manser et 
al., 1993; Joberty et al., 1999; Pirone et al., 2000).  
Cdc42 is known to mediate the formation of filopodia and cell polarity (Kozma et al., 1995; Nobes 
and Hall, 1999). It is also shown to regulate cell cycle progression, growth, transformation and 
migration (Olson et al., 1995; Qiu et al., 1997; Raftopoulou and Hall, 2004). Cdc42 is also a 
negative regulator for Cbl-induced EGFR degradation (Wu et al., 2003) and disrupting this 
mechanism leads to cell proliferation and migration in breast cancer (Hirsch et al., 2006). 
Overexpression of Cdc42 has been found to promote cell migration and invasion in melanoma by 
regulating the E-cadherin and b-catenin expression (Tucci et al., 2007). Similarly, upregulation of 
Cdc42 was found to promote cervical cancer cell migration by promoting pseudopodia formation 
(Ye et al., 2014).  
TC10 and TCL share 76% sequence similarity. They have 14 and 18 amino acids N-terminal 
extensions, respectively, that have been shown to influence their membrane association (Chunqiu 
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Hou and Pessin, 2003; Ackermann et al., 2016). The N-terminus of TCL is also crucial in 
regulating the nucleotide binding pocket to allow effective GTP loading, however this was not 
observed for TC10 (Ackermann et al., 2016; Florke et al., 2017). TCL has been shown to be 
implicated in clathrin-mediated endocytosis and recycling of receptor-dependent internalized 
transferrin (De Toledo et al., 2003). It has also been shown to modulate vessel formation and cell 
migration (Sukhbir, et al., 2011), with overexpression of TCL found to promote angiogenesis and 
cancer cell migration through regulation of PAK1 (Kim et al., 2014; Ho et al., 2013).  
TC10 is the only classical member of the Cdc42 subfamily that is palmitoylated and this 
palmitoylation event is important for the correct distribution of TC10 to the plasma membrane and 
endosomes (Michaelson et al., 2001; Watson et al., 2003). Active TC10 has been shown to be 
involved in transmembrane trafficking of the cystic fibrosis transmembrane conductance regulator 
(CFTR) (Cheng et al., 2005) and exocytosis of GLUT4 (Chiang et al., 2001). In cancer, mutated 
TC10 (N136S) was also found to promote actin cytoskeletal reorganization and cell invasion in 
colorectal cancer (Han et al., 2014).  
1.4.2 The non-classical Rho-family GTPases 
The second group of Rho-family GTPases are known as atypical Rho GTPases and includes 
Wrch1, Wrch2, RhoD, RhoF, RhoH and the RhoBTB, Rnd and Miro subfamilies. Several 
comparative studies do not include Miro subfamily proteins and RhoBTB3 as genuine Rho-family 
members due to the lack of similarity between these proteins and the other members of the Rho-
family. For instance, Miro subfamily proteins lack the Rho insert region and are assumed to be 
non-catalytic as the sequence in the highly conserved G2-G5 loops responsible for nucleotide 
binding and hydrolysis is very different in comparison to canonical GTPase domains (Fransson et 
al., 2003; Boureux et al., 2006). RhoBTB3 shares 25% sequence similarity with, and contains the 
same BTB domains as RhoBTB1 and RhoBTB2. However, this protein is not considered to be a 
Rho GTPase by some studies due to its lack of similarity with Rho and Ras (Boureux et al., 
2006; Aspenström et al., 2007).   
The atypical Rho GTPases often contain extra domains and are therefore longer than classical Rho 
GTPases (Figure 1.5) and importantly, they are not regulated by the standard GDP/GTP cycling 
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of small G proteins. These atypical small GTPases are further divided into fast-cycling and GTPase 
defective G proteins (Table 1.7).  
 
Table 1.7: Selected amino acid sequences of the atypical and classical Rho GTPases  
 
 
Amino acid residues 12, 28, 59 and 61 are in boldface type and underlined (Aspenström, 2017). 
 
In resting cells, classical Rho-family GTPases are assumed to be in their inactive GDP-bound form 
either alone or in complex with RhoGDIs (Dovas and Couchman, 2005). Unlike the typical Rho-
family GTPases, RhoD, RhoF, Wrch1 and Wrch2 have been shown to have a rapid nucleotide 
exchange compared to standard GTP hydrolysis which classifies them as “fast-cycling” small G 
proteins (Jaiswal et al., 2012; Shutes et al., 2004; Shutes et al., 2006). Several studies identified 
Phe28 mutations of Ras, Rac1, Cdc42 and RhoA have rapid nucleotide exchange and can induce 
Amino acids 12, 59 and 61 
Group Subfamily Member Sequence 
Classic Cdc42 Cdc42 


















Amino acids 28 
Classic Rac Rac1 
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oncogenic transformation (Lin et al., 1997; Aspenström, 2018). Wrch1 and Wrch2 also have a 
mutated phenylalanine at position 28 (Table 1.7) and this might be one of the reasons to include 
both of these proteins as fast-cycling small G proteins. 
Moreover, the fast-cycling Rho GTPases do have GTPase activity and have been shown to be 
identical to Cdc42 at amino acids Gly12, Ala59 and Gln61 (Ras numbering) (Table 1.7) 
(Aspenström, 2017). Gly12 and Ala59 are important for GTP hydrolysis, while Gln61 is necessary 
to stabilise the transition state of hydrolysis (Prive et al., 1992). These amino acid residues have 
been reported to be mutated in GTPase-deficient Ras (Muñoz-Maldonado et al., 2019). In contrast, 
the GTPase defective atypical Rho-family members, including Rnd1, Rnd2, Rnd3, RhoBTB1, 
RhoBTB2 and RhoH do not possess the conserved Gly12, Ala59 and Gln61, compared to Cdc42 
(Table 1.7) (Aspenström et al., 2007; Aspenström, 2017).  
Many of the atypical small GTPases have been shown to have a functional CAAX box that allow 
them to undergo prenylation, the exceptions being Wrch1 and Wrch2, which have been shown to 
only undergo palmitoylation. Miro and RhoBTB subfamily proteins do not possess a canonical 
CAAX motif, except for RhoBTB3, which suggests this protein could undergo lipid modification, 
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Table 1.8: C-terminal sequences of the atypical Rho-family GTPases and their subcellular 
distribution 
 
Putative palmitoylated cysteines are in boldface type and coloured red and CAAX prenylation 
motifs are underlined. (Data taken from: Ridley, 2006; Fransson et al., 2006; Roberts et al., 2008; 
Espinosa et al., 2009; Murali and Rajalingam, 2014). GG: geranylgeranyl, F: farnesyl, P: 
palmitoyl, PM: plasma membrane, C: cytosol, N: nucleus, G: Golgi, E: endosomes, ER: 
endoplasmic reticulum, NE: nuclear envelope and EM: endomembrane. 
 
1.4.2.1 Wrch1 and Wrch2 
Wrch1 (RhoU) and Wrch2 (RhoV) belong to the Cdc42 subfamily due to sequence similarity. 
However, both have extended N-terminal and C-terminal regions (Figure 1.6). The N-terminus of 
Wrch1 contains 3 proline-rich motifs that are not crucial for nucleotide exchange activity (Shutes 












EHKARLEKKLNAKGVRTLSRCRWKKFFCFV P PM, E 
RhoD AVFQEAAEVALSSRGRNFWRRITQGFCVVT F, GG PM and E 
RhoF EDVFREAAKVALSALKKAQRQKKRRLCLLL F, GG PM 
Rnd1/ 
RhoS LSKRLLHLPSRSELISSTFKKEKAKSCSIM F PM 
Rnd2/ 
RhoN MQRSAQLSGRPDRGNEGEIHKDRAKSCNLM F E, C 
Rnd3/ 
RhoE KRISHMPSRPELSAVATDLRKDKAKSCTVM F PM, G, C 
RhoH/ 
TTF VFECAVRTAVNQARRRNRRRLFSINECKIF GG, F EM 
RhoBTB1 KREREKEDIALNKHRSRRKWCFWNSSPAVA Unknown V, G 
RhoBTB2 KRRWLFWNSPSSPSSSAASSSSPSSSSAVV Unknown V 
RhoBTB3 KHRWPSNMYLKQLAEYRKYIHSRKCRCLVM Unknown G 
Miro1 KSSTFWLRASFGATVFAVLGFAMYKALLKQR Unknown MT 
Miro2 SFWLRGLLGVVGAAVAAVLSFSLYRVLVKSQ Unknown MT 
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Grb2 and Nck1 (Risse et al., 2013). The interaction with Grb2 has been shown to promote Wrch1 
activation and Wrch1-PAK1 association (Shutes et al., 2004). Similarly, an N-terminally truncated 
mutant of Wrch2 has been found to promote transformation and increase anchorage-independent 
growth in NIH3T3 fibroblasts (Chenette et al., 2005).  
At their C-termini, Wrch proteins are modified by palmitoylation, which is essential for their 









Figure 1.6: The architecture of Wrch1 and Wrch2. Both Wrch1 and Wrch2 contain a conserved 
G domain with N- and C-terminal extensions. The N-terminal extension of Wrch1 contains 
proline-rich motifs. There is a CFV motif at their C-termini, the cysteine of which is modified by 
palmitoylation.  
 
Wrch1 has been found to regulate focal adhesion formation, potentially by modulating Myosin 
light chain (MLC) phosphorylation (Chuang et al., 2007). Interestingly, Saras et al. (2004) also 
show that Wrch1 is more efficient than Cdc42 in stimulating filopodia formation. In cancer, PAK4 
has been shown to interact with and protect Wrch1 from ubiquitination and degradation to drive 
breast cancer cell migration (Dart et al., 2015). In contrast, low levels of Wrch1 has been shown 
to promote cell migration in colorectal cancer by increasing RhoA signalling (Slaymi et al., 2019) 
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Wrch2 was initially discovered as an interacting partner for WASP and PAK2 in a yeast-two-
hybrid (Y2H) screen (Aronheim et al., 1998). Wrch2 was found to induce lamellipodia formation 
and apoptosis of PC12 cells by activating the JNK pathway (Aronheim et al., 1998; Shepelev et 
al., 2011) but the relevance of this to cancer progression is not known. Wrch2 mRNA levels have 
been shown to be upregulated in several cancer cell lines, including gastric, cervical, pancreatic, 
blood and lung (Katoh, 2002; Bhavsar et al.,2013; Shepelev and Korobko, 2013).  
1.4.2.2 RhoD and RhoF 
RhoD and RhoF were first classified as classical Rho-family GTPases due to their sequence 
similarity and overall architecture. However, a recent study by Jaiswal et al. (2012) proposes that 
both of these small G proteins should be classified as atypical Rho-family proteins due to their fast 
nucleotide exchange. They both also contain extra N-terminal sequences which are important for 
their correct subcellular distribution. For instance, the N-terminal extension of RhoD is important 
for regulating vesicle dynamics and plasma membrane localisation (Blom et al., 2018). Both of 
these proteins have been found to be involved in the reorganisation of the actin cytoskeleton (Ellis 
and Mellor, 2000).   
RhoD was initially shown to play a role in endosomal trafficking and dynamics through the 
activation of hDia2C and c-Src (Murphy et al., 1996; Murphy et al., 2001; Gasman et al., 2003). 
This is consistent with data from Nehru et al. (2013) that found RhoD interacted with Rab5 
effector, Rabankyrin‐5, and colocalize to Rab5‐positive endosomes. In addition, RhoD was also 
shown to promote actin filament formation through the FGF/RhoD/mDia3C pathway (Koizumi et 
al., 2012) and therefore be involved in cell migration (Blom et al., 2017). RhoD has been identified 
as a Golgi localized protein that is important in regulating Golgi homeostasis and is involved in 
vesicle trafficking from the endoplasmic reticulum to the plasma membrane (Blom et al., 2015). 
An in vivo study revealed that overexpression of RhoD promotes cell proliferation and 
overduplication of centrosomes, suggesting a role in promoting cancer progression, which is still 
not well studied (Kyrkou et al., 2013). 
Compared to the ubiquitously expressed RhoD, RhoF is more tissue specific with highest 
expression in colon, stomach and spleen (Ellis and Mellor, 2000). RhoF was shown to promote 
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filopodia formation by targeting its effector mDia2 to the plasma membrane, independent of Cdc42 
signalling (Pellegrin and Mellor, 2005; Gorelik et al., 2010). Hence, overexpression of RhoF has 
been found to promote cell migration and enhance chemoresistance of pancreatic cancer by 
increasing the activation of the EMT process (Yang et al., 2017).  
1.4.2.3 The Rnd subfamily 
Rnd subfamily proteins are most similar to the Rho subfamily compared to other Rho-family 
proteins, sharing ~40% sequence similarity. However, they possess a C-terminal extension and 
both Rnd1 and Rnd3 also have an additional 8 and 18 amino acids, respectively at their N-termini, 
which is important for plasma membrane targeting, These N-terminal extensions are also required 
for plasma membrane targeting of p190RhoGAP and correlated with its activity to mediate RhoA 
inhibition (Oinuma et al., 2012). They are modified by farnesylation, not geranylgeranylation, at 
their C-termini and this is important for plasma membrane association (Roberts et al., 2008). 
Within the subfamily, although they share more than 50% sequence similarity, the subcellular 
localization of the Rnd subfamily proteins is different, with Rnd1 and Rnd3 are plasma membrane 
associated and Rnd2 can be found in the cytosol or endomembranes (Roberts et al., 2008). Rnd1 
also shows mainly brain and liver expression, Rnd2 in testis, while Rnd3 is ubiquitously expressed 
but at low levels (Nobes et al., 1998). The difference in their subcellular localisation is due to 
distinct sequences upstream of the CAAX motif (Pacary et al., 2011). 
Since Rnd subfamily proteins lack intrinsic GTPase activity and constitutively active, they are 
assumed not to be regulated by standard GTP/GDP cycling but by expression and post-
translational modification (PTM). Several studies show that the expression of Rnd subfamily 
proteins is highly influenced by growth factors, for instance, Rnd1 transcript expression can be 
induced by VEGF (Suehiro et al., 2014). Rnd3 is also induced by multiple DNA damage-inducing 
stimuli such as UV irradiation (Boswell et al., 2007) and chemotherapeutic agents (Shurin et al., 
2008). The steroid hormone, oestradiol, upregulates both Rnd2 and Rnd3 expressions (Shimomura 
et al., 2009). Phosphorylation of Rnd3 at Ser240 by PKCa was shown to prevent Rnd3 membrane 
localisation and promote stress fibre disruption by competing binding to ROCK1 and therefore 
inhibiting the RhoA-ROCK1 pathway (Riento et al., 2005; Madigan et al., 2009).  
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Rnd1 and Rnd3 have been shown to prevent actin stress fibres, membrane ruffles and focal 
adhesions formation, leading to cell rounding (Nobes et al., 1998). This inhibitory effect was 
shown to involve Rnd1 interacting partners, including p190RhoGAPs and Syx (Table 1.9), which 
result in the inhibition of RhoA activity (Wennerberg et al., 2003; Goh and Manser, 2010).  
Table 1.9: List of examples interacting proteins for atypical Rho-family GTPases 
 
(Data taken from: Murphy et al., 1996; Murphy et al., 2001; Gasman et al., 2003; Saras et al., 
2004; Pellegrin and Mellor, 2005; Gorelik et al., 2010; Azzarelli et al., 2015; Tang et al., 2015; Ji 
and Rivero, 2016; Hodge and Ridley, 2017; Mino et al., 2018; Mouly et al., 2019) 
 
Rnd1 gene expression levels are frequently decreased or the genes deleted in cancer such as in 
breast cancer and hepatocellular carcinoma (HCC), in which low expression of Rnd1 has been 
shown to promote cell migration and invasion by increasing EMT via the MAPK pathway (Okada 
et al., 2015; Qin et al., 2018). Low levels of Rnd1 have also been shown to correlate with a 
decreased in overall survival of glioblastoma patients potentially by increasing cancer metastasis 






Wrch1 PAK1/4, ARHGAP30, Pyk2, PAR6, NCKβ 
Wrch2 PAK1/2/6, N-WASP, MLK 
RhoBTB 
RhoBTB1 Cullin 3, MUF1 
RhoBTB2 Cullin 3, Cullin 5, Hsp90, MUF1 
RhoBTB2 Cullin 3, Cullin 5, Cyclin B1, Cyclin E1, Hrs, 5-HT7a, LIMD1, Hsp90, MUF1, PHD2, Rab9A, Rab9B, TIP47 
Rnd 
Rnd1 
p190RhoGAP, Socius, Plexin A1, Plexin B1, FLRT1, SCG10, 
FRS2a/b, Syx, Grb7 
Rnd2 p190RhoGAP, Socius, Pragmin, Plexin D1, Rapostlin, Vps4-A, MgcRacGAP 
Rnd3 p190RhoGAP, Socius, ROCK1, MgcRacGAP, Syx, Plexin B2 
Miro 
Miro1 TRAK1, TRAK2, KIF5, Dynein, DISC1, Parkin, Pink1, Mfn1/2, Cenp-F, HUMMR, Myo19 
Miro2 TRAK1, TRAK2, Parkin, Pink1, Mfn1/2, DISC1, Cenp-F 
RhoH PAK1-6, Lck, Csk, Zap70, Syk, Kaiso 
RhoD hDia2, c-src 
RhoF mDia1/2 
Chapter 1  Introduction 
 30 
In contrast to Rnd1, active Rnd2 was shown to bind and activate p190RhoGAP but this does not 
result in stress fibre disassembly and cell rounding (Wennerberg et al., 2003). This suggests that 
Rnd2 acts differently to Rnd1 in regulating RhoA signalling especially in cancer. For instance, 
overexpression of Rnd2 has been found to stimulate RhoA-induced cell contraction in HeLa cells 
(Tanaka et al., 2006) and result in aberrant neuronal differentiation and migration (Avansini et al., 
2018).  
Similarly to Rnd1, Rnd3 has been shown to inhibit Ras- and Raf-induced fibroblast transformation 
(Villalonga et al., 2004). Reduced expression of Rnd3 was also found to be inversely associated 
with tumour progression in glioblastoma (Liu et al., 2015), suggesting a role as a tumour 
suppressor. This could be achieved by antagonizing RhoA signalling either by interacting with 
RhoA regulators and/or effector proteins. For instance, the interaction between Rnd3 and 
p190RhoGAP has been shown to stimulate GTP hydrolysis of RhoA (Wennerberg et al., 2003) 
and Rnd3 interaction with ROCK1 was found to prevent stress fibre formation and cell migration 
(Riento et al., 2003; Hidalgo-Carcedo et al., 2011). Rnd3 also has a role as a cell-cycle regulator 
that does not involve RhoA signalling but is due to a decrease in the expression of cell cycle 
regulators, cyclin D1 and p21cip1 (Villalonga et al., 2004).  
1.4.2.4 The RhoBTB subfamily  
Similar to the Rnd subfamily, RhoBTB subfamily proteins are constitutively active due to 
defective hydrolysis activity. There are 3 members of ubiquitously expressed RhoBTBs, however 
only RhoBTB1 and RhoBTB2 are widely accepted as members of the Rho-family GTPases; 
RhoBTB3 has a considerably divergent G domain and found to bind and hydrolyse ATP instead 
of GTP (Aspenström et al., 2007; Berthold et al., 2008; Espinosa et al., 2009).  
Among the Rho-family GTPases, the RhoBTBs are the only subfamily that contains broad 
complex, tramtrack, and bric-a-brac (BTB) domains (Figure 1.7). BTB domains have been shown 
to be involved in protein dimerization and stabilisation. These domains interact with Cullin 3, a 
scaffold protein of ubiquitin ligase complexes involved in protein ubiquitination (Berthold et al., 
2008). Missense mutations in this domain of RhoBTB2 have been found to cause a developmental 
and epileptic encephalopathy (Straub et al., 2018; Belal et al., 2018). RhoBTB proteins also 
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contain a proline-rich region which is a potential SH3 domain-binding site and a C-terminal BACK 
(BTB and C-terminal Kelch) domain that is probably involved with substrate-recognition and 
orientation of Cullin 3-based ubiquitin ligase complexes (Stogios and Privé, 2004; Pintard et al., 
2004; Ji and Rivero, 2016).  
RhoBTB3 also differs from RhoBTB1 and RhoBTB2 due to a short insert in the first BTB domain 
and a CAAX motif at its C-terminus, conferring the ability to undergo isoprenylation (Berthold et 







Figure 1.7: The domain architecture of RhoBTB proteins. The GTPase domain is followed by 
a proline-rich region, BTB domains and a carboxyl terminal BACK domain. The GTPase domain 
of RhoBTB3 is extremely divergent from other G domains. RhoBTB3 also has a shorter insert in 
the first BTB domain (BTB1) and contains a CAAX motif at the end.  
 
Little is known about the normal cellular functions of RhoBTB1. However, it has been shown to 
localise to vesicular structures and is not thought to be involved in the regulation of the actin 
cytoskeleton organization (Aspenström et al., 2004). RhoBTB1 is required to control Golgi 
integrity and inhibit breast cancer cell invasion by increasing METTL7B expression, a Golgi-
associated methyltransferase (McKinnon and Mellor, 2017). The role of RhoBTB1 as a tumour 
suppressor was also observed in head and neck squamous cell carcinomas (HNSCC) (Beder et al., 
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The second member, RhoBTB2 acts as a transcriptional regulator by regulating CXCL14 
expression, a chemokine that is involved in leukocyte migration and angiogenesis (McKinnon et 
al., 2008). It has also been shown to be involved in cell cycle progression and apoptosis (Freeman, 
et al., 2008), in which loss of RhoBTB2 was found to induce cell proliferation, colony formation 
and prevent apoptosis of breast cancer cells (Hamaguchi et al., 2002; Mao et al., 2011; Choi et al., 
2017). Loss of RhoBTB2 has also been found in several other cancers such as gastric (Gu Cho et 
al., 2008) and osteosarcoma (Jin et al., 2013). 
Golgi-associated RhoBTB3 has been shown to maintain Golgi structure and be associated with 
Rab9 to mediate protein trafficking from endosomes to the Golgi (Lu and Pfeffer, 2013; Espinosa 
et al., 2009). Similar to the other two RhoBTB proteins, loss of RhoBTB3 has been reported in 
several cancers such as breast and kidney (Berthold et al., 2008). 
1.4.2.5 The Miro subfamily 
Miro subfamily members are mitochondria- and peroxisome-associated small G proteins 
(Fransson et al., 2003; Covill-Cooke et al., 2020). They have been shown to control mitochondrial 
dynamics, motility and apoptosis (Frederick et al., 2004; MacAskill et al., 2009; Fransson et al., 
2003) and have been found to regulate peroxisomal size and morphology (Covill-Cooke et al., 
2020). Both Miro proteins have two GTPase domains, one each at the N- and C-termini (Figure 
1.8). The N-terminal GTPase domain has been shown to be involved in GTP hydrolysis and is 
required for regulating mitochondria morphology (Peters et al., 2018; Babic et al., 2015). 
They also contain a pair of calcium binding EF-hand motifs, that are important for the binding to 
Ca2+ to regulate mitochondrial motility, and a C-terminal transmembrane domain that is needed 
for association with the mitochondrial outer membrane and the cytosolic chaperone, Pex19 
(Fransson et al., 2003; Frederick et al., 2004; MacAskill et al., 2009; Covill-Cooke et al., 2020). 
Furthermore, Miro proteins also contain two non-canonical “hidden” EF (hEF) hand motifs, 
followed by LM helices that are important for stabilisation of the adjacent EF hands (Yamaoka 
and Hara-Nishimura, 2014; Klosowiak et al., 2013). Less is known about the C-terminal G domain 
of the Miro proteins but recent studies show that this domain is structurally similar to the Ras 
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homologue, Rheb and catalytically active as an NTPase with binding propensities towards both 








Figure 1.8: The architecture of Miro proteins. Miro subfamily proteins contain an N-terminal 
and a C-terminal GTPase domain, two EF hand motifs, two hidden EF hand (hEF) motifs, two 
ligand mimic (LM) helices and a C-terminal transmembrane domain.  
 
Within the subfamily, Miro1 shares 60% sequence similarity with Miro2. Miro1 was found to 
mediate mitochondrial trafficking through its interacting partners, the KIF5 motor proteins (Table 
1.9) (MacAskill et al., 2009; Schuler et al., 2017) and by stabilising a myosin, Myo19 (Oeding et 
al., 2018). Miro1 is also required to maintain correct mitochondrial morphology and intracellular 
distribution during embryogenesis (Yamaoka et al., 2011). Miro2 has been shown to promote 
mitochondrial motility and prevent mitochondria fragmentation by forming a multiprotein 
complex with PINK1 kinase and a motor adaptor protein, Milton/TRAK (Weihofen et al., 2009). 
Both Miro1 and Miro2 are subjected to PINK1- and Parkin E3 ligase-mediated degradation in 
mitophagy with Miro2 degradation occurring at a much slower rate compared to Miro1 (Liu et al., 
2012). This is necessary because Miro2 is required to facilitate Parkin translocation to depolarised 
mitochondria to induce ubiquitination and start the mitophagy process (Wang et al., 2019). 
Defects in mitochondrial motility and distribution due to aberrant regulation of Miro proteins have 
been reported in several neurological disease such as Parkinson disease and Alzheimer’s (Kay et 
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al., 2018). Miro proteins also have a role in cancer with high levels of Miro1 found to promote cell 
proliferation and migration by suppressing the expression of SMAD4 (Desai et al., 2013; Li et al., 
2015). Reduced expression of Miro1 but not Miro2 was shown to suppress tumour cell invasion 
in response to low levels of its interacting partner, the mitochondrial motility regulator, Syntaphilin 
(SNPH) (Caino and Altieri, 2017). 
1.4.2.6 RhoH 
RhoH contains a shorter Rho insert region that is more similar to classical Rho-family proteins but 
is GTPase defective due to the absence of conserved residues corresponding to Gly12, Ala59 and 
Gln61 (Ras numbering) (Table 1.7). RhoH does have a CAAX box at its C-terminus which allows 
isoprenylation and membrane targeting. RhoH also has a unique C-terminal region located in 
between its polybasic region and CAAX box that is important in regulating RhoH stability via 
chaperone-mediated autophagy (Troeger et al., 2013).  
Unlike other Rho-family proteins, RhoH does not regulate actin reorganisation in NIH3T3 or 
MDCK cells (Li et al., 2002). However, a study from Mino et al. (2018) showed that RhoH is 
involved in modulating the structure of the actin-cytoskeleton and transcriptional activity during 
T cell migration and adhesion by forming a multi-protein complex with p120 catenin and the 
transcriptional regulator, Kaiso, to attenuate Rac1 signalling. RhoH has also been shown to 
negatively regulate cell proliferation, survival and chemokine-induced migration of hematopoietic 
progenitor cells (HPCs) (Gu et al., 2005). However, RhoH has also been shown to promote cell 
migratory polarity in prostate cancer by directing Rac1 and PAK2 to membrane protrusions 
(Tajadura-Ortega et al., 2018).  
1.4.3 Regulation of Rho-family GTPases 
The classical or typical Rho-family GTPases are regulated by switching between an inactive GDP-
bound form and an active GTP-bound form in a similar fashion to other members of the Ras 
superfamily. This cycle is regulated by RhoGEF, RhoGAP and RhoGDI proteins, as described in 
Section 1.3. However, there are other ways in which their activation is modulated such as 
regulation by gene expression and post-translational modification.  
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1.4.3.1 RhoGEF proteins 
As described previously, most of classical Rho-family GTPases are regulated by GEFs from the 
Dbl-homology family, which containing a DH-PH tandem domain (Hart et al., 1991; Abdrabou 
and Wang, 2018). Examples of this family are the Vav-family members: Vav1, Vav2 and Vav3. 
Vavs behave as phosphorylation-dependent molecular switches and are controlled by several 
tyrosine kinases, including Syk, Src and Janus kinases (Bustelo, 2014). The Vav proteins are 
phosphorylated at tyrosine residues in their AC domain (Figure 1.9) and this activates their 
exchange activity towards target small GTPases. The link between phosphorylation and Vav1 
activation was initially found by Crespo et al. (1997), by comparing the ability of non-
phosphorylated Vav1 and phosphorylated Vav1 to catalyse GDP/GTP exchange on Rac1.  
The catalytic activity of Vav proteins towards Rho-family GTPases requires the cooperation of the 
DH and PH domains with the zinc finger (ZF) region. The DH domain functions to catalyse 
guanine nucleotide exchange and the PH domain is responsible for stabilising the DH domain for 
efficient GEF activity (Turner and Billadeau, 2002; Rapley et al., 2008). The ZF domain 
coordinates with the catalytic DH region to promote both the binding to Rho-family GTPases and 
the exchange of GDP for GTP (Movilla and Bustelo, 1999).  
All the Vav-family proteins share a similar domain architecture (Figure 1.9) and have been found 
to regulate Rac1, RhoA, RhoG and Cdc42 (Kaminuma et al., 2001; Rapley et al., 2008; Schuebel, 
1998; Movilla and Bustelo, 1999; Abe et al., 2000). 
 
Figure 1.9: Schematic representation of Vav protein domain architecture. CH: Calponin-
homology domain, AC: Acidic domain, DH: Dbl-homology domain, PH: Pleckstrin homology 
domain, ZF: Zinc finger domain, SH3: SRC-homology 3 domain and SH2: SRC-homology 2 
domain. 
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Vav1 was initially discovered as an oncogene due to its ability to induce tumorigenic growth in 
NIH3T3 mouse fibroblasts (Katzav et al., 1989). Later research also showed overexpression of 
Vav1 to be associated with several cancers, including pancreatic (Fernandez-Zapico et al., 2005) 
and lung (Lazer, et al., 2009). Vav2 has been found to be hyperactivated in HNSCC (Patel et al., 
2007), whilst overexpression of Vav3 has been identified in prostate cancer (Dong et al., 2006), 
breast cancer (Lee et al., 2008) and colorectal cancer (Uen et al., 2015). Aberrant expression of 
Vav family proteins has also been reported to inversely correlate with cancer patient survival rate 
by promoting carcinogenesis events such as increased tumour cell survival, proliferation, 
neoangiogenesis and invasion (Razidlo et al., 2015). 
1.4.3.2 RhoGAP proteins 
RhoGAPs function to terminate the signal transduction of most of Rho-family GTPases by 
stimulating their intrinsic GTP hydrolysis activity, which is relatively slow. ~70 RhoGAPs have 
been identified to date and this obviously outweigh the number of Rho-family GTPases 
considerably. A few of the RhoGAPs display a broad specificity but most are specific for a single 
Rho GTPases (Table 1.3). p50RhoGAP, ARAP1 and ARAP3 are examples of RhoGAPs that have 
broad specificity and have been found to interact with and inactivate RhoA, Rac1 and Cdc42, 
whereas GMIP only shows activity towards RhoA (Tcherkezian and Lamarche-Vane, 2007; Aresta 
et al., 2002). 
One of the best studied RhoGAPs is p190RhoGAP, which has been reported to bind and inactivate 
RhoA, RhoC, Rac1 and Rnd3. RhoA inactivation by p190RhoGAP is needed to stimulate cell 
spreading and migration (Arthur and Burridge, 2001). Rnd1 and Rnd3 have been shown to bind 
and activate p190RhoGAP to inhibit RhoA activity, indicating a role for p190RhoGAP in 
mediating Rho-family GTPases co-ordinated signalling (Oinuma et al., 2012). 
There are two isoforms of p190RhoGAP, known as p190A and p190B. Both of these are 
multidomain proteins, containing an N-terminal GTPase domain (N-GTPase) which has been 
recently classified as a pseudo-GTPase domain that binds to GTP/Mg2+ but have lacks intrinsic 
catalytic activity (Stiegler and Boggon, 2018). They also have four FF domains, which are 
important for binding interacting partners such as the transcriptional factor TFII-I (Jiang et al., 
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2005) and Rac1•GTP (Bustos et al., 2008), and two pseudo-GTPase domain (pG1/pG2), which 
have no nucleotide-binding activity (Stiegler and Boggon, 2018). The pG1/G2 domains and the 
FF domains are necessary for regulating GAP activity and lamellipodia targeting of p190RhoGAP 
(Bidaud-Meynard et al., 2019). The polybasic region interacts with acidic phospholipids and is 







Figure 1.10: Schematic representation of p190RhoGAP protein structure. N-GTPase: N-
terminal GTPase domain, four FF domains, pG1/pG2: pseudo GTPase domain 1 and 2, PBR: 
polybasic region and a GAP domain: GTPase activating proteins domain.  
 
p190RhoGAP was initially identified as a tumour suppressor by Wang et al. (1997) as its 
overexpression was shown to inhibit Ras-induced malignant transformation in fibroblasts. 
Furthermore, inactivation of Rho signalling by p190RhoGAP has been shown to induce apoptosis 
in breast cancer (Ludwig and Parsons, 2011). However, several studies have also reported the 
involvement of p190RhoGAP in promoting cancer progression as it was found to be upregulated 
in several cancers, including osteosarcoma, colorectal cancer, lung adenocarcinoma and breast 
cancer, where increased levels correlate with increased cell migration, invasion and poor survival 
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1.4.3.3 RhoGDI proteins 
While approximately 150 RhoGEFS and RhoGAPs are currently known, only three RhoGDIs have 
been identified in mammals and their roles are not yet fully understood (Rocks et al., 2018). Thus, 
it is interesting to know how the three RhoGDIs control the complexity of Rho GTPase signalling. 
As discussed in section 1.3.3, there is growing evidence showing the involvement of RhoGDIs not 
only as the negative regulators of Rho-family GTPases but also act as chaperones which target 
these small GTPases to their correct subcellular compartments. For instance, the interaction 
between RhoGDI-1 and Rac1 is needed to ensure the correct plasma membrane localisation of 
Rac1 in response to hepatocyte growth factor (HGF) stimulation (Chianale et al., 2010). Similarly, 
a Cdc42 mutant that failed to interact with RhoGDI-1 was found to accumulate in the perinuclear 
membrane region as opposed to the cytoplasm and therefore affect Cdc42-stimulated cellular 
transformation (Lin et al., 2003).  
RhoGDIs also function to protect the Rho-family GTPases from proteasome-mediated 
degradation. For example, RhoGDI-1 has been shown to stabilise RhoA, RhoB, Rac1 and Cdc42 
protein levels (Boulter et al., 2010; Ho et al., 2008). RhoGDIs also help to maintain both the 
inactive cytosolic pool and active membrane pool of Rho-family GTPases by forming a high 
affinity complex with the C-terminal isoprene of the small GTPases in the cytoplasm and 
mediating the correct delivery and extraction of Rho-family GTPases to and from membranes (Cho 
et al., 2019).  
The interaction between the RhoGDIs and the target Rho GTPases involves both major domains 
of the RhoGDIs; the N-terminal regulatory arm domain and the C-terminal immunoglobulin-like 
domain (Figure 1.11). Both domains contribute significantly to the binding and inhibitory actions 
of the RhoGDI proteins. The C-terminal IgG domain of the RhoGDIs forms a hydrophobic cleft 
that binds to the isoprenylated group at the C-termini of the Rho-family proteins (Figure 1.11B) 
thus disallowing membrane association. The N-terminal domain binds to the switch regions of the 
target small GTPases, preventing nucleotide exchange (Dransart, et al., 2005; Cho et al., 2019). 
The N-terminal domain was also found to target the RhoGDI-1-Rac1 complex to the phagosome 
(Ueyama et al., 2013). While all three RhoGDIs share the same domain architecture, RhoGDI-3 
has an N-terminal extension predicted to contain an additional amphipathic helix (AH) from 
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residues 5-28, crucial for Golgi targeting and stabilizing the cytoplasmic RhoG-RhoGDI-3 

















Figure 1.11: Structure and architecture of the RhoGDIs protein. (A) Each of the RhoGDIs 
shares an N-terminal regulatory arm domain (residues 1–69, RhoGDI-1 numbering) and a C-
terminal immunoglobulin-like domain (residues 70–204, RhoGDI-1 numbering). RhoGDI-3 has a 
small additional amphipathic helix (AH) (residues 1-26, RhoGDI-3 numbering) towards its N-
terminus. (B) Ribbon structure of RhoGDI-1-Cdc42 complex is adapted from Owen and Mott, 
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RhoGDI-1 and 2 share 70% sequence similarity, whereas RhoGDI-3 shows 60% identity with 
either RhoGDI-1 and RhoGDI-2. The most divergent amino acids between these three RhoGDIs 
are concentrated at their N-termini (Figure 1.12). Despite their sequence similarities, all three 









Figure 1.12: Sequence alignment of all three RhoGDIs. The sequence of all three RhoGDIs was 
aligned using the multiple sequence alignment programme, Clustal Omega. The regulatory arm 
and immunoglobulin-like domains are shared by all three RhoGDIs, and are shown by black and 
red lines, respectively. The additional N-terminal amino acids of RhoGDI-3 (1-26) are shown by 
the blue line. The amphipathic helix (AH) predicted to extends from residues 5-28 in RhoGDI‐3 
is highlighted in yellow. Asterisk (*) single, fully conserved residue, colon (:) conservation 
between groups of strongly similar properties and period (.) conservation between groups of 
weakly similar properties.  
 
RhoGDI-1 is ubiquitously expressed and was found to form complexes with RhoA, RhoC, Rac1, 
Rac2, Cdc42 and RhoG (Olofsson, 1999; Elfenbein et al., 2009). In contrast, RhoGDI-2 was 
 
RhoGDI-1      --------------------------MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKS 34 
RhoGDI-2      --------------------------MTEKAPEPH---VEEDDDDELDSKLNYKPPPQKS 31 
RhoGDI-3      MLGLDACELGAQLLELLRLALCARVLLADKEGGPP-----AVDEVLDEAVPEYRAPGRKS 55 
                                        ::::            ::   :   :*: * :** 
 
 
RhoGDI-1      IQEIQELDKDDESLRKYKEALLGRVAVSADPNVPNVVVTGLTLVCSSAPGPLELDLTGDL 94 
RhoGDI-2      LKELQEMDKDDESLIKYKKTLLGDGPVVTDPKAPNVVVTRLTLVCESAPGPITMDLTGDL 91 
RhoGDI-3      LLEIRQLDPDDRSLAKYKRVLLGPLPPAVDPSLPNVQVTRLTLLSEQAPGPVVMDLTGDL 115 




RhoGDI-1      ESFKKQSFVLKEGVEYRIKISFRVNREIVSGMKYIQHTYRKGVKIDKTDYMVGSYGPRAE 154 
RhoGDI-2      EALKKETIVLKEGSEYRVKIHFKVNRDIVSGLKYVQHTYRTGVKVDKATFMVGSYGPRPE 151 
RhoGDI-3      AVLKDQVFVLKEGVDYRVKISFKVHREIVSGLKCLHHTYRRGLRVDKTVYMVGSYGPSAQ 175 
                :*.: :***** :**:** *:*:*:****:* ::**** *:::**: :*******  : 
 
 
RhoGDI-1      EYEFLTPVEEAPKGMLARGSYSIKSRFTDDDKTDHLSWEWNLTIKKDWKD 204 
RhoGDI-2      EYEFLTPVEEAPKGMLARGTYHNKSFFTDDDKQDHLSWEWNLSIKKEWTE 201 
RhoGDI-3      EYEFVTPVEEAPRGALVRGPYLVVSLFTDDDRTHHLSWEWGLCICQDWKD 225 
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discovered to express primarily in hematopoietic and endothelial cells (Lelias et al., 1993). 
RhoGDI-2 has been shown to interact with several Rho-family GTPases, including RhoA, Rac1, 
Cdc42, Rac2 and RhoC (Scherle et al., 1993; Adra et al., 1993; Golovanov et al., 2001; Griner et 
al., 2015). However, RhoGDI-2 appears to be less potent than RhoGDI-1 (Adra et al., 1993) and 
this may be due to differences at the amino acid levels (Platko et al., 1995; Nomanbhoy 
and Cerione, 1996). The third member of the RhoGDI family is RhoGDI-3, which is widely 
expressed especially in brain, lung, kidney and testis. By Y2H screening, Zalcman et al. (1996) 
found that RhoGDI-3 bound to RhoB and RhoG, but not to RhoA, RhoC or Rac1 proteins.  
1.4.3.3.1 Regulation of the RhoGDI proteins 
The target binding specificities of the RhoGDIs suggest that different RhoGDIs might influence 
different signalling pathway but the molecular reason behind their selectivity is still not well 
understood. However, their interactions could be regulated by several mechanisms such as by 
phospholipids, interactions and post-translational modifications (Cho et al., 2019).  
Regulation involving several biological lipids has been shown to modulate the interaction between 
RhoGDIs and target Rho-family GTPases (Chuang et al., 1993). For example, binding between 
RhoA and RhoGDI-1 was shown to be affected by the presence of the phosphoinositides, PtdIns4P 
and PtdIns4,5P2, allowing the activation of RhoA (Fauré et al., 1999). The stability of the Rac1- or 
2-RhoGDI-1 complexes were also found to be regulated by phagocyte membranes enriched in 
anionic phospholipids (Ugolev et al., 2006). Furthermore, phosphatidic acid generated by DGKζ, 
(diacylglycerol kinase) has been shown to activate PAK1 which then leads to RhoGDI-1 
phosphorylation and subsequently promotes dissociation of Rac1 from RhoGDI-1 (Abramovici et 
al., 2009).  
The association between Rho-family GTPases and RhoGDIs can also be modulated by specific 
proteins, including the tyrosine kinase Etk, the Eph receptor ligand EphrinB1 and the adaptor 
protein 14-3-3τ. Etk was shown to interact with and phosphorylate RhoA at Ser88 and Thr100, 
resulting in RhoA dissociation from RhoGDI-1 and therefore stimulate membrane translocation 
and activation of RhoA and its activation (Kim et al., 2002; Tong et al., 2016). A recent study 
from Cho et al. (2018) also discovered that the interaction between EphrinB1 and RhoGDI-1 
Chapter 1  Introduction 
 42 
enhances RhoA-induced cell migration in lymph node and breast cancer cell lines by displacing 
RhoA from RhoA-RhoGDI-1 complex. The adaptor protein, 14-3-3τ has also been shown to 
interact with RhoGDI-1 and this disturbs its association with Rho-family GTPases. This then 
promotes breast cancer cell invasion and metastasis through EGF-induced RhoA, Rac1, and Cdc42 
activation (Xiao et al., 2014). 
Regulation involving post-translational modification of RhoGDIs either through phosphorylation, 
ubiquitination and sumoylation has also been observed (Table 1.10). For instance, 
DerMardirossian et al. (2006) found that Src binds and phosphorylates RhoGDI-1 at Tyr156. This 
phosphorylation event caused a dramatic decrease in the ability of RhoGDI-1 to form a complex 
with RhoA, Rac1 or Cdc42. Dephosphorylation of RhoGDI-1 by integrin-bound PTP-PEST 
stimulated the release of RhoGDI-1 from the membrane and promoted its interaction with GDP-
bound Rac1 or Cdc42 in the cytoplasm (Lee et al., 2015). Fei et al. (2010) have also shown that 
phosphorylation of RhoGDI-1 by Fer tyrosine kinase prevents the binding of Rac1 to RhoGDI-1 
and, as a result, promotes localization of Rac1 to the membrane where it can exert its function. 
Besides promoting the release of Rho-family GTPases from RhoGDIs, phosphorylation has also 
been shown to stabilise some complexes and this subsequently inhibits signalling. For instance, 
phosphorylation of RhoGDI-1 by PKA at Ser174 increased the binding between RhoA and 
RhoGDI-1, resulting in the inhibition of RhoA signalling and morphological changes in cardiac 
fibroblasts (Oishi et al., 2012).  
Ubiquitination and sumoylation of RhoGDIs can also regulate their interaction with Rho-family 
GTPases. Sumoylation of RhoGDI-1 at Lys138 is important for RhoGDI-1 to inhibit RhoA, Rac1 
and Cdc42 activation and this then prevents cancer cell motility (Yu et al., 2012; Cao et al., 2014). 
An E3 ligase, gene related to anergy in lymphocytes (GRAIL) has been shown to interact with and 
stimulate RhoGDI-1 poly-ubiquitination via Lys63 linkage. However, RhoGDI-1 ubiquitination 
did not lead to its degradation but rather increased RhoGDI-1 stability and therefore prevented 
RhoA activation by promoting association of RhoA-RhoGDI-1 (Su et al., 2006).  
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Table 1.10: Post-translational modifications of RhoGDIs  
(Data taken from: DerMardirossian et al., 2006; Wu et al., 2009; Griner et al., 2013; Luo et al., 
2013; Cho et al., 2019; Liu et al., 2019). ND: not determine 
 
1.4.3.3.2 Regulation of the RhoGDI-Rho-family target interactions  
RhoGDI-Rho complexes can also be regulated by the phosphorylation of Rho-family proteins. 
Phosphorylation of RhoA at Ser188 by PKA increases its association with RhoGDI-1 and this then 
terminates RhoA activity at the leading edge of migratory cells (Tkachenko et al., 2011). Rac1 
phosphorylation at Tyr64 by FAK and Src has also been shown to promote its association with 
RhoGDI-1 and prevent Rac1 association with focal adhesion complex and therefore prevent Rac1-
induced cell spreading (Chang et al., 2011).  
PTMs Regulator Target site RhoGDI Effect 
Phosphorylation 
Src Tyr27, Tyr156 
RhoGDI-1 
Dissociation of RhoA, 
Rac1 and Cdc42 
PKA Ser174 Association of RhoA 
PKCa Ser96, Ser34 
Dissociation of RhoA 
and Rac1 
Src Tyr24, Tyr153 
RhoGDI-2 
Dissociation of Rac1 
PKCa Ser34 Dissociation of Rac1 
Syk Tyr24, Tyr153 
Increase RhoGDI-2 
association with the 
membrane 




adhesion to VCAM-1. 
Dephosphorylation 
PTP-PEST Tyr156 RhoGDI-1 Inactivation of Rac1 and Cdc42 
PPM1B Ser174 
RhoGDI-1 Inactivation of RhoA, Rac1 and Cdc42 Sumoylation ND Lys138 





Dissociation of RhoA 
Oxidation ND ND Activation of RhoA 
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Correct RhoGDI-Rho protein interactions are also important to ensure proper signalling activation. 
For instance, the dynamic balance between RhoA and RhoC mediated by RhoGDI-1 has been 
shown to be important in regulating cancer cell growth and migration (Giang Ho et al., 2011). 
Furthermore, Golding et al. (2019) have shown that RhoGDI-1 differentially regulates Cdc42 and 
RhoA extraction from plasma membrane to ensure correct spatiotemporal patterning around cell 
wounds. Phosphorylation of RhoA by PKG was also shown to increase RhoA association with 
RhoGDI-1, leading to displacement of bound Rac1. Free Rac1 can then translocate to the 
membrane and be activated by, for example, the GEF, Vav3 (Rolli-Derkinderen et al., 2010).  
1.4.3.3.3 RhoGDI proteins in cancer 
 
The levels of RhoGDIs proteins appear to be approximately equal to the total levels of RhoA, Rac1 
and Cdc42 in the cell, suggesting that any condition that contributes to an imbalance in this system 
would affect the activation of Rho-family proteins, a situation frequently observed in 
cancer (Michaelson et al., 2001; Gildea et al., 2002). For instance, overexpression of RhoGDI-1 
was found to increase RhoA protein levels and therefore promotes RhoA-induced PI3K-Akt 
signalling pathway in hepatocellular carcinoma (Wang et al., 2014). In contrast, downregulation 
of RhoGDI-1 was found to promote the EMT process by stimulating the expression of the 
transcription factor, Snail (Song et al., 2014), suggesting its role as a tumour suppressor.  
RhoGDI-2 is also differentially expressed in cancer. Increased expression of RhoGDI-2 has been 
found in ovarian, gastric and pancreatic cancers (Tapper et al., 2001; Cho et al., 2009; Yi et al., 
2015). In gastric cancer, upregulation of RhoGDI-2 was shown to stimulate gastric cancer cell 
metastasis and chemoresistance by enhancing VEGF-C (vascular endothelial growth factor C) 
expression (Jun Cho et al., 2014). In addition, the regulation of multi-drug resistance in gastric 
cancer was reported to involve RhoGDI-2-mediated P-glycoprotein expression via Rac1 activation 
(Zheng et al., 2015). Decreased expression of RhoGDI-2 was found to be highly associated with 
invasive and metastatic phenotypes in bladder cancer, breast cancer and leukemia (Theodorescu, 
2004; Hu et al., 2007; Nakata et al., 2008). RhoGDI-2 has also been shown to suppress cell 
invasion in lung cancer by regulating the expression of genes involved in EMT, including E-
cadherin, Slug, Snail and a-SMA (Niu et al., 2014).  
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Compared to the other RhoGDIs, the role of RhoGDI-3 has been poorly studied. However, 
decreased expression of RhoGDI-3 expression has been found in breast cancer and in the late stage 
of pancreatic cancer, which correlate with metastasis (Jiang et al., 2003; de León-Bautista et al., 
2016).  
1.5 Cdc42 signalling 
As discussed previously, Cdc42 is a known regulator of the actin cytoskeleton, controlling basic 
physiological processes such as cell proliferation and migration (Gómez Del Pulgar et al., 2008). 
In response to various upstream signals which either come from cell surface receptors or cell 
adhesion molecules, Cdc42 activates a series of distinct effector proteins (Table 1.6), thus 
promoting diverse signalling cascades.  
1.5.1 Activated Cdc42-associated kinase (ACK) 
1.5.1.1 The domain architecture of ACK 
ACK was the first effector protein to be identified for Cdc42 and is a non-receptor kinase (NRTK) 
(Manser et al., 1993). There are 10 families of mammalian NRTKs: Src, Abl, Jak, ACK, Csk, Fak, 
Fes, Frk, Tec and Syk (Blume-Jensen and Hunter, 2001). Among the NRTKs, ACK is the only 
kinase with an SH3 domain located C-terminal to the kinase domain. Thus, it is likely that the 
regulation of ACK is different from other NRTKs.  
The TNK2 (ACK) gene encodes for 1038 amino acids (~120 kDa) and is located on human 
chromosome 3q29. Figure 1.13 shows the domain architecture of human ACK which includes an 
N-terminal SAM (sterile alpha motif) domain. SAM domains are generally known to be involved 
in self-association and facilitated protein-protein interaction (Kim and Bowie, 2003). In ACK, the 
SAM domain has been shown to mediate ACK dimerization and promote its autophosphorylation 
(Prieto-Echagüe et al., 2010). Lin et al. (2010) also found the SAM domain regulates ACK 
ubiquitination by NEDD4-1, which suggests the involvement of this domain in modulating ACK 
stability.  





Figure 1.13: Domain architecture of ACK. SAM: sterile α motif, NES: nuclear export signal, 
Kinase: tyrosine kinase domain, SH3: Src Homology 3 domain, CRIB: Cdc42/Rac interacting 
binding region, CL: Clathrin-interacting region, EBD: EGFR binding domain and UBA: ubiquitin-
association domain. 
 
ACK also contains an NES (nuclear export signal), suggesting a role for ACK in the nucleus 
(Ahmed et al., 2004) but how ACK enters the nucleus is still undefined. However, the interaction 
of ACK with Cdc42 has been shown to promote nuclear localisation of ACK (Ahmed et al., 2004). 
ACK has an SH3 domain that appears to be involved in the autoinhibition of ACK by forming an 
intramolecular interaction with proline-rich sequences, present within the C-terminus of the EBD 
region (Galisteo et al., 2006) (Figure 1.14), as discussed in section 1.5.1.2. A CRIB (Cdc42/Rac 
interacting binding) region is also found in ACK which is necessary for Cdc42 binding (Manser 
et al., 1993).  
The C-terminus of ACK consist of a clathrin binding region (CL), an EGFR binding domain (EBD) 
and a ubiquitin-association (UBA) domain. The clathrin binding region was shown to interact with 
clathrin and is involved in clathrin-mediated endocytosis especially during receptor internalization 
(Teo et al., 2001). The EGFR binding domain of ACK was shown to interact with the EGFR and 
this interaction is dependent on the phosphorylation or the kinase activity of the EGFR. Binding 
of ACK leads to EGFR ubiquitination and degradation, which required the UBA domain of ACK 
(Shen et al., 2007; Grøvdal et al., 2008). Collectively, these C-terminal regions/domains have been 
shown to be involved in ACK-mediated EGFR ubiquitination, endocytosis and degradation which 
will be described in section 1.5.1.3.  
SAM Kinase SH3NE
S EBDCRIB CLN C
2
UBA
69 126 386 449 489 561 593 731 873 941 1036
Proline-rich region
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1.5.1.2 The regulation and activation of ACK 
ACK is ubiquitously expressed and is activated by numerous extracellular stimuli such as integrin-
mediated cell adhesion, the M3 muscarinic receptor, the Mer receptor tyrosine kinase, the EGFR 
and the PDGFR, leading to activation of its kinase activity (Yang et al., 1999; Linseman et al., 
2001; Mahajan et al., 2005; Galisteo et al., 2006). The interaction between ACK and RTKs is 
usually direct but it also has been found to involve several adaptor proteins, including Grb2, H2S2 
and Nck (Satoh et al., 1996; Oda et al., 2001; Galisteo et al., 2006).  
ACK is thought to be constitutively active due to a lack of conformation changes in its kinase 
domain between the phosphorylated and non-phosphorylated forms (Lougheed et al., 2004). 
However, the kinase activity of ACK can be regulated by a series of intramolecular interactions. 
The SH3 domain of ACK, containing a non-canonical ligand-binding site (Gajiwala et al., 2013), 
has been shown to bind a proline-rich region (PRR) situated within the C-terminus of the EBD 
domain (Galisteo et al., 2006; Gajiwala et al., 2013) (Figure 1.14). The SH3-PPR interaction is 
postulated to orientate the EBD domain, allowing it to form an inhibitory interaction with the 
kinase domain. This blocks the kinase domain from dimerization-induced activation (Galisteo et 
al., 2006). The binding of the EBD domain to RTKs such as the EGFR alleviates this inhibition 
and releases the kinase domain, leading to ACK activation (Lin et al., 2012; Gajiwala et al., 2013).  
ACK has also been found to interact with and be phosphorylated at Tyr284 by Src and Hck 
(Yokoyama and Miller, 2003; Chan et al., 2011). This suggests that the activation of ACK can 
also be regulated by other kinases and is not solely induced by ACK dimerization.   
 
















Figure 1.14: Regulation of ACK activation. ACK activation is inhibited by intramolecular 
interactions. The interaction between the SH3 domain and PRR within the C-terminus of the EBD 
domain of ACK orientate the EBD, allowing it to form an inhibitory interaction with the kinase 
domain. Activation of ACK by dimerization is thought to be mediated by the SAM domain. Full 
activation of ACK might also involve Src-mediated phosphorylation at Tyr284 within the kinase 
domain of ACK. Membrane localisation of ACK could be provided by the interaction between the 
EBD and RTKs, for example the EGFR, the CRIB region and Cdc42 or the SAM domain with the 
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1.5.1.3 Roles of ACK in cytoskeletal remodeling, apoptosis 
and trafficking 
Cdc42-induced activation of ACK has been shown to be involved in cell migration by 
phosphorylating the adaptor protein, p130cas (Modzelewska et al., 2006). This promotes p130cas 
interaction with another adaptor protein, Crk, which in turn interact with a Rac1 GEF, Dock180 to 
activate Rac1 and stimulate filopodia formation (Bourdoulous et al., 1998; Albert et al., 2000; 
Gustavsson et al., 2004; Modzelewska et al., 2006). ACK has also been found to mediate the 
activation of other Rho-family proteins by phosphorylating a GEF, Dbl, which is important for 
EGF-stimulated reorganization of actin cytoskeleton (Kato et al., 2000; Kato-Stankiewicz et al., 
2001). Furthermore, ACK was shown to regulate TRAIL-induced apoptosis by promoting 
translocation of the TRAIL receptor into lipid rafts and therefore its clustering and DISC (death-
inducing signaling complex) formation (Linderoth et al., 2013). A role for ACK in regulating 
apoptosis was also shown to involve phosphorylation of Akt at Tyr176, which results in the 
translocation of the ACK-Akt complex into the nucleus to repress FoxO-responsive apoptotic gene 
expression, including p21, GADD45 and Bim-1 (Mahajan et al., 2010).  
ACK-induced actin polymerization has been shown to involve the phosphorylation of WASP at 
both Ser242 and Tyr256, which then stimulates the activation of Arp2/3 (Yokoyama et al., 2005). 
Additional regulation of Arp2/3 dynamics by ACK requires the interaction and phosphorylation 
of cortactin, an Arp2/3 regulatory protein at Tyr421, Tyr466 and Tyr482. These phosphorylation 
events are required to maintain EGFR signalling as knockdown of ACK or cortactin has been 
shown to decrease EGFR degradation (Kelley et al., 2012).  
The involvement of ACK in mediating EGFR endocytosis and trafficking was recognized due to 
several pieces of evidence showing the association between ACK, EGFR and several proteins 
involved in vesicle dynamics. ACK has been shown to interact with clathrin, adaptor protein AP-
2 and sorting nexin 9 (SNX9). ACK colocalised with clathrin in large vesicular structures and has 
been found to be involved in clathrin-coated assembly and clathrin-mediated endocytosis (Teo et 
al., 200; Shen et al., 2007; Shen et al., 2011). Following EGF stimulation, ACK was found to 
phosphorylate SNX9 at Tyr287 (Lin et al., 2002) and to promote EGFR degradation (Shen et al., 
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2007). Overall, it is postulated that ACK-mediates EGFR degradation probably by stimulating its 
endocytosis and this event requires ACK association with several vesicle-associated proteins, as 
described previously. This suggests a role for ACK in modulating EGF-mediated cell survival, 
proliferation and differentiation (Lin et al., 2002; Fox et al., 2019).   
Following activation, EGFR is endocytosed and targeted to early endosomes for either membrane 
recycling or to the endosomal pathway for lysosomal degradation (Goh et al., 2010) (Figure 1.15). 
In response to EGF stimulation, ACK interacts with the EGFR via the EBD and promotes its 
degradation (Shen et al., 2007). The interaction between ACK and EGFR was assumed to be 
indirect and to require an adaptor protein, specifically Grb2, as this has been identified in several 
studies of EGF-induced EGFR internalization (Yamazaki et al., 2002; Fox et al., 2020). Grb2 is a 
binding partner of ACK and is required for the interaction with and ACK-mediated degradation of 
several RTKs such as leukocyte tyrosine kinase (LTK), Axl family kinase and anaplastic 









Figure 1.15: The role of ACK in regulating receptor endocytosis. The diagram shows the stages 
of receptor-mediated endocytosis and EGFR internalization following EGFR stimulation. ACK: 
activated Cdc42-associated kinase, AP-2: adaptor protein 2, EGF: epidermal growth factor, EGFR: 
epidermal growth factor receptor, NEDD4-1: neural precursor cell expressed developmentally 
down-regulated protein 4, SNX9: sorting nexin 9, Ub: ubiquitin (Adapted from Fox et al., 2019). 
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ACK has also been shown to undergo ubiquitination by NEDD4-1 and is degraded together with 
the EGFR upon EGF stimulation, suggesting co-transportation of the ACK-EGFR complex during 
EGFR endocytosis (Chan et al., 2009; Lin et al., 2010). This is consistent with data from Shen et 
al. (2007) who showed co-localisation of ACK and the EGFR on EEA-1 positive vesicles in 
response to EGF stimulation and subsequently showed their co-transportation to the lysosome for 
degradation (Lin et al., 2010). ACK ubiquitination by NEDD4-1 is mediated by its SAM domain 
as lack of this domain has been shown to decrease ACK ubiquitination (Lin et al., 2010). Although 
ACK contains an UBA domain, deletion of this domain results in an increase of ACK 
ubiquitination suggesting that the UBA domain of ACK is responsible for regulating the 
interaction with NEDD4-1 and therefore is necessary to prevent excessive ubiquitination (Fox et 
al., 2019). The ACK UBA domain has also been found to regulate EGFR degradation and lack of 
this domain was shown to promote ACK and EGFR stability even after EGF stimulation (Tin et 
al., 2010). Taken together, all these studies indicated that ubiquitination of ACK serves as a sorting 
signal for trafficking the EGFR-ACK complex to the lysosome. This is consistent with a study 
by Grøvdal et al. (2008), which showed that overexpression of ACK resulted in the retention of 
the EGFR on early endosomes and prevented its translocation to multivesicular bodies (MVBs). 
Overall, the role of ACK in mediating EGFR endocytosis and degradation is important to prevent 
excessive EGF signalling and deregulation of this mechanism will promote the uncontrolled signal 
transduction that frequently occur in cancer.  
1.5.1.4 Roles of ACK in mediating cancer progression  
Several studies have shown a role for ACK as an oncogenic kinase. For instance, overexpression 
of pTyr284-ACK was found to regulate PI3-Kinase signalling in breast and prostate cancer by 
increasing the levels of pTyr176-Akt (Mahajan et al., 2010). ACK has also been shown to regulate 
the PI3-Kinase regulatory subunits by interacting and phosphorylating the p85 regulatory subunits 
at Tyr607, leading to their stabilisation. This promotes cell proliferation through an, as yet 
undiscovered, mechanism (Clayton et al., 2019). The phosphorylated p85 isoforms can form either 
homo- or heterodimers via the C-terminal regions of p85 and this was shown to occur 
predominantly in the nucleus. These nuclear dimers are predicted to drive the pro-proliferative 
functions of ACK via their free SH3 or RhoGAP domains (Clayton et al., 2019; Fox et al., 2019).  
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ACK has been found to be involved in prostate cancer progression and this was by phosphorylating 
the tumour suppressor Wwox, which results in rapid dissociation of the ACK-Wwox complex and 
subsequent Wwox poly-ubiquitination and degradation (Mahajan et al., 2005). Phosphorylation of 
the androgen receptor (AR) at Tyr267 by ACK was also shown to promote AR recruitment to 
androgen-response elements (ARE), resulting in the transcription of AR target genes in the absence 
of androgen to drive prostate cancer progression (Mahajan et al., 2007). Besides regulating the 
transcriptional activity of the AR, ACK has also been found to phosphorylate Histone H4 on 
Tyr88, upstream of the AR transcriptional start site to promote AR transcription and subsequently 
its protein levels in androgen-starved prostate cancer cell lines (Mahajan et al., 2017). This 
suggests a role for ACK as an epigenetic regulator, which has also been seen in breast cancer cell 
lines. ACK was found to phosphorylate KDM3A, a histone demethylase, on Tyr1114, which 
mediates the transactivation of the oestrogen receptor (ER) target gene, HOXA-1, an oncogene 
involved in mammary tumour progression (Mahajan et al., 2014).  
Abnormal activation or expression of ACK either through amplification or mutation has been 
shown to have a significant correlation with poor prognosis in various cancer types such as breast, 
prostate, pancreatic, hepatocellular, stomach and lung carcinoma (Van der Horst et al., 2005; 
Mahajan et al., 2010; Mahajan et al., 2012; Mahajan and Mahajan, 2013; Fox et al., 2019). 
Overexpression of ACK has been shown to stimulate EMT and therefore promote cell migration 
and invasion in gastric cancer and HCC (Xu et al., 2015; Lei et al., 2015). A study to find somatic 
mutations in genes encoding 518 protein kinases in 210 diverse human cancer identified four 
somatic mutations in ACK. These four missense mutations include R34L in SAM domain, R99Q 
in between the SAM and the kinase domains, E346K in the kinase domain and M409I in SH3 
domain. Each of these mutations was identified in a different type of cancer: R34L in lung 
adenocarcinoma, R99Q and E346K in ovarian cancer and M409I in gastric adenocarcinoma 
(Greenman et al., 2007). 
This growing evidence showing the involvement of ACK and its interacting proteins in cancer 
progression indicate that they may be good therapeutic targets and/or prognostic markers for 
certain cancer. Thus, to understand as much as possible about the role of ACK both in normal and 
in pathological conditions will be an important prelude to the development of truly effective and 
safe ACK inhibitors.  
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1.6 Aim of the study  
A Y2H screen previously undertaken by a PhD student in the lab, Dr. J. Vicenté-García, identified 
an interaction with RhoGDI-3 (Dr. J. Vicenté-García, PhD thesis, University of Cambridge, 2009). 
As described previously, RhoGDIs are one of the important regulatory proteins involved in 
controlling the activation state and accessibility of Rho-family GTPases. Furthermore, RhoGDI-3 
has also been implicated in cancer progression in its own right. Thus, it was hypothesized that 
regulation of RhoGDI-3 might underpin some aspects of ACK-driven cancer progression.  
The RhoGDI-3 interaction with ACK was validated in this study and the interactions with the other 
RhoGDIs were also identified using co-immunoprecipitation. Since ACK is a kinase, the effect of 
ACK on the phosphorylation status of the RhoGDIs was also assayed in cells and in vitro. ACK is 
also known as a nuclear-cytoplasmic shuttling kinase, therefore the site of interaction with 
RhoGDIs was also investigated through subcellular fractionation. The role of ACK in regulating 
the stability of each RhoGDIs was identified using cycloheximide chase and ubiquitination assays. 
The effect of ACK on RhoGDI target proteins was also determined in this work. To date, relatively 
few targets have been identified for the RhoGDIs and these in a sporadic manner. Thus, a 
systematic study was performed to determine all possible Rho-family GTPases that interact with 
the RhoGDIs. The effect of ACK on the binding and activation status of these targets was identified 
using co-immunoprecipitation and effector pull-down assays. In summary, all the data obtained in 
this study should help to elucidate the functional differences between the three RhoGDIs and also 



















Materials and Methods 
2.1 Molecular biology 
2.1.1 Media and reagents 
 
Table 2.1 Bacterial media and plates 
Media/plates Ingredients 
Luria Bertani (LB) Broth 
10 g/L Tryptone 
5 g/L Yeast Extract 
10 g/l NaCl 
2TY Media 
16 g/L Tryptone 
10 g/L Yeast Extract 
5 g/l NaCl 
2TY Media Plates 
16 g/L Tryptone 
10 g/L Yeast Extract 
5 g/L NaCl 
16 g/L Agar  
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Table 2.1 List of reference cDNA 
 
 




Template Accession No. 
Homo sapiens Rho GDP dissociation inhibitor (GDI) alpha (RhoGDI-1) BC106044.1 
Homo sapiens Rho GDP dissociation inhibitor (GDI) beta (RhoGDI-2) BC009200.2 
Homo sapiens Rho GDP dissociation inhibitor (GDI) gamma (RhoGDI-3) NM_001176.4 
Homo sapiens tyrosine kinase non receptor 2 (TNK2), transcript variant 1 NM_005781.4 
Synthetic yeast ubiquitin gene M15704.1 
E. coli strains Antibiotic 
resistance 
Genotype 
TOP 10 (Invitrogen) None 
F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
Δ lacX74 recA1 araD139 Δ( ara-  
leu)7697 galU galK rpsL (StrR) endA1 nupG 
TOP 10F´ (Invitrogen) Tet 
F ́{lacIq Tn10 (TetR)} mcrA ∆(mrr-hsdRMS-
mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 araD139 
∆(ara-leu)7697 galU galK rpsL endA1 nupG  
XLI MRF´ Blue Tet 
endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 






endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F ́ proAB lacIqZDM15 Tn10 (Tetr) Amy Camr]  
BL21 None F
– ompT gal dcm lon hsdSB(rB–mB–) [malB+]K-
12(λS) 
BL21 DE3 Amp 
F– ompT gal dcm lon hsdSB(rB–mB–) λ(DE3 
[lacI lacUV5-T7p07 ind1 sam7 nin5]) [malB+]K-
12(λS) 
BL21 DE3 PlysS Cam 
F– ompT gal dcm lon hsdSB(rB–mB–) λ(DE3 
[lacI lacUV5-T7p07 ind1 sam7 nin5]) [malB+]K-
12(λS) pLysS[T7p20 orip15A](CmR) 
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Table 2.4: List of DNA constructs and sources  
 
Construct Expression tag Source 
pXJ-HA-GFP HA 
Gift from Prof. Ed Manser, ICMB 
Singapore pXJ-HA-ACK HA 
pXJ-HA-dACK HA 
pGEX-2TK-PAK1 PBD (56-272) GST Gift from Dr. Heidi Welch, Babraham Institute, Cambridge  
pDESTTM 26-His-RhoGDI 1 His Previously made in the lab 
pCMV-Myc-Ub Myc Gifts from Dr. Catherine Lindon, 
Department of Pharmacology, 
University of Cambridge pCMV-Myc-Ub K48R Myc 
pDESTTM 12.2-FLAG-RhoGDI 3 FLAG Previously made in the lab 
pGEX-2T-Rhotekin (1-89) GST Previously made in the lab 
pcDNATM 3.1/nV5-DEST-RhoA V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-RhoB V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-RhoC V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Rac1 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Rac2 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Rac3 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-RhoG V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Cdc42 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-TC10 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-TCL V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Wrch1 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Wrch2 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-RhoD V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-RhoH V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-RhoF V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Rnd1 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Rnd2 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Rnd3 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Miro1 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-Miro2 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-RhoBTB1 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-RhoBTB2 V5 Previously made in the lab 
pcDNATM 3.1/nV5-DEST-RhoBTB3 V5 Previously made in the lab 
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2.1.2 Preparation of chemically competent E. coli 
1 mL of an fresh overnight culture of the desired E. coli strain was diluted into 50 mL 2TY media 
and grown at 37 °C for ~ 1 to 2 h with continuous shaking (180 rpm) until the OD600 reached 0.4 
to 0.6. Cells were then pelleted at 2000 x g for 5 min and resuspended in 25 mL ice cold 100 mM 
MgCl2. Cells were pelleted again and resuspended in 5 mL ice cold 100 mM CaCl2 before being 
left on ice for 1 h 30 min. Cells were then pelleted and resuspend in 1 mL ice cold CaCl2 (85 mM) 
containing 17% glycerol. The competent E. coli cells were stored at -80 °C for further used.  
2.1.3 Transformation of chemically competent E. coli  
Transformation of chemically competent E. coli cells was performed by mixing 50 to 100 µL of 
competent cells with 100-200 ng of DNA before incubation on ice for 5 min. Cells were then heat 
shocked at 42 °C for 45 sec, cooled on ice for another 2 min and finally resuspended in 350 µL 
2TY media. Cells were incubated at 37 °C with shaking for 1 h before being spread on selective 
agar and grown at 37 °C overnight.  
2.1.4 Small-scale purification of plasmid DNA 
Plasmid DNA was purified from 5 mL overnight bacterial culture using the GenEluteTM Plasmid 
Miniprep Kit (Sigma-Aldrich, Cat. No.	PLN350-1KT), according to manufacturer’s instructions. 
DNA was eluted with sterile Analytical Reagent Grade Water (Fisher Scientific, Cat. No. 
W/0100/21) and quantified using the A260 reading before storage at -20 °C. 
2.1.5 Digestion of plasmid DNA and TAE-agarose gel 
electrophoresis 
1 µg of plasmid DNA were digested with the relevant restriction enzymes in a total reaction 
volume of 20 µL for ~1 h at 37 °C. Following incubation, the reactions were stopped by addition 
of 5X DNA loading buffer (Table 2.5). Gels were prepared by dissolving 0.5-1 % Molecular 
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biology grade agarose (Bioline, Cat. No. BIO-41025) in 1X TAE buffer (Table 2.6). The fragments 
of interest were identified by visualizing using a UV transilluminator in comparison with a DNA 
ladder (Bioline, Cat. No. BIO-33025). The plasmid DNA was then sent for sequencing (DNA 
sequencing facility, Department of Biochemistry, University of Cambridge) if necessary.   
Table 2.5: Buffers in TAE-agarose gel electrophoresis 
 
2.1.6 GatewayÒ cloning 
Gateway entry clones for all constructs were available in the lab. Gateway entry clones were then 
purified (section 2.1.4) and recombined into Gateway expression vector using the site-specific LR 
recombination reaction. 8 μL recombination reactions were prepared containing ~150 ng of entry 
clone, ~150 ng destination vector and 2 μL of Gateway® LR Clonase® II enzyme before 
incubating at room temperature for 1 h. Next, 1 μL of the Proteinase K solution was added to the 
reaction which was incubated for another 10 min at 37 °C, before 1 μL of the reaction was 
transformed into One ShotTM TOP 10 chemically competent E. coli cells following manufacturer’s 
instructions.  
Colonies of transformed cells were patched on selective plates and their plasmid DNA analysed 
using restriction enzyme digestion (section 2.1.5). The correct size of the insert was determined 
using TAE-agarose gel electrophoresis (section 2.1.5) and validated by DNA sequencing. Table 
2.6 lists all the GatewayÒ destination vectors used in this study.  
Buffer Ingredients 
5X DNA Loading Buffer 
50 % Sucrose 
50 mM 0.2 M EDTA 
0.1 % Bromophenol Blue 
1X TAE Buffer pH 8.3 
40 mM Tris-base 
20 mM Acetic acid 
1 mM EDTA 
0.2 μM Ethidium Bromide 
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Table 2.6: GatewayÒ destination vectors 
 
2.1.7 Site- and multi site-directed mutagenesis 
Mutagenesis was performed either using a QuikChange Site-Directed Mutagenesis Kit (Cat. No. 
210518-5) or a QuikChange Multi site-Directed Mutagenesis Kit (Cat. No. 210513-5) from 
Agilent Technologies following manufacturer’s instructions. Briefly, plasmid DNA was 
denatured, mutagenic primers annealed, and extended using a Pfu-Phusion-based enzyme blend. 
This resulted in a double-stranded DNA molecule composed of a parental (wild type) strand and a 
mutagenic strand. The DNA was then treated with the restriction endonuclease DpnI, which 
cleaves the methylated, parental strand. The remaining single-stranded mutagenic DNA was then 
transformed into XL10-GoldÒ ultracompetent E. coli cells.  
The primers used in this study are detailed in Table 2.7. The cycling parameters for each single 
and multi site-directed mutagenesis reactions are described in Table 2.8 and 2.9. Transformed 







GatewayÒ destination vectors Expression Features 
pDEST26  Mammalian Encodes an N-terminus His tag 
pDEST12.2-FLAG Mammalian Encodes an N-terminus FLAGÒ tag 
pcDNA3.1/nV5-DEST Mammalian Encodes an N-terminus V5 tag 
pDEST15T Bacterial Encodes an N-terminus GST tag 
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Mutation Primer  
RhoGDI-2 (Y24F) 5¢ GGACAGCAAGCTCAATTTTAAGCCTCCACCACAG 3¢ 
RhoGDI-2 (Y48F) 5¢ GAGAGTCTAATTAAGTTCAAGAAAACGCTGCTGGG 3¢ 
RhoGDI-2 (Y107F) 5¢ GTTAAAGGAAGGTTCTGAATTTAGAGTCAAAATTCACTTC 3¢ 
RhoGDI-2 (Y125F) 5¢ GTGTCAGGCCTGAAATTCGTTCAGCACACC 3¢ 
RhoGDI-2 (Y130F) 5¢ GTTCAGCACACCTTCAGGACTGGGG 3¢ 
RhoGDI-2 (Y146F) 5¢ GGTTGGCAGCTTTGGACCTCGGCCTG 3¢ 




5¢ CTAGATCAACAAGTTTGTTCAAAAAAGCAGGCTCCGC 3¢ 
RhoGDI-3 (K73R) 5¢ CTGGCCAAGTACCGGCGGGTGCTGCTGGGG 3¢ 
RhoGDI-3 (K126R) 5¢ GACCAGGTGTTTGTCCTGCGGGAAGGTGTTGATTACAG 3¢ 
RhoGDI-3 (K134R) 5¢ GGTGTTGATTACAGAGTGCGGATCTCCTTCAAGGTCCAC 3¢ 
RhoGDI-3 (K162R) 5¢ GCCTGCGCGTGGACCGGACCGTCTACATGGTG 3¢ 
Ubiquitin (K63R) 5¢ CTGATTACAACATTCAGAGGGAGTCGACCTTACATC 3¢   
ACK (S985N) 5¢  GTGCCACGGCTGGAACGTGCAGAGGGCTG 3¢ 
DNRhoGDI-3 
(Forward) 
5¢ GCCGCCCCCTTCACCCTGGCTGACAAGGAG 3¢ 
DNRhoGDI-3 
(Reverse) 
5¢ CTCCTTGTCAGCCAGGGTGAAGGGGGCGGC 3¢ 
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Table 2.8: Cycling parameters used for site-directed mutagenesis 
 




Site-directed mutagenesis of pDEST12.2-FLAG-RhoGDI-3 (DNRhoGDI-3) 
Step Temperature Time Cycle 
Initial Denaturation 95 °C 2 min 1 
Denaturation 95 °C 20 sec 
30 Primer annealing 55 °C 30 sec 
Extension 65 °C 3 min 12 sec 
Final extension 65 °C 5 min 1 






Step Temperature Time Cycle 
Initial Denaturation 95 °C 2 min 1 
Denaturation 95 °C 20 sec 
30 
Primer annealing 55 °C 30 sec 
Extension 65 °C 
30 sec/ kb: 
A. 3 min 12 sec 
B. 3 min 12 sec 
C. 3 min 15 sec 
D. 1 min 59 sec 
E. 3 min 42 sec 
Final extension 65 °C 5 min 1 
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2.2 Expression and purification of recombinant 
proteins 
2.2.1 Small-scale expression trials in E. coli 
A single bacterial colony was inoculated into 10 mL sterile 2TY media supplemented with 
selective antibiotic and grown for ~ 16 h at 37 °C while shaking at 180 rpm. 1 mL of overnight 
culture was diluted into each of two 10 mL 2TY that were grown at 37 °C with continuous shaking 
until reaching OD600 0.8. One of the cultures was then induced with the optimised amount of IPTG, 
as described in Table 2.10. Both the induced and non-induced cultures were then incubated at 
either 37 °C for 5 h or 20 °C for ~ 16 h with continuous shaking at 180 rpm.  
After incubation, a 1 mL aliquot of non-induced and 3X 1 mL aliquots of induced culture were 
pelleted at 6000 x g for 10 min after their A600 readings were measured. The protein concentration 
of the non-induced and one induced cultures were then normalized by adding a calculated volume 
of sterile MilliQ water, before mixing with 2X SDS sample buffer (Table 2.23). The remaining 2 
mL aliquot of induced culture was also resuspended in a calculated volume of sterile MilliQ before 
being sonicated three times on ice using a 1.9 mm probe at 70% amplitude using Fisherbrand™ 
Q125 sonicator. The lysed cells were then pelleted at 6000 x g for 10 min and the supernatant was 
transferred to a new tube before being mixed with 2X SDS sample buffer at a 1:1 ratio. The 
remaining pellets representing the insoluble fraction of protein, were resuspended in MilliQ water 
and an equal volume of 2X SDS sample buffer added.  
All protein samples were then separated by SDS-PAGE (section 2.4.3) in order to determine the 
optimum conditions for production of soluble fusion protein. The optimum induction conditions 
and strain of E. coli used to express each protein is described in Table 2.10. These conditions were 
then used for large-scale expression of all proteins.  
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Table 2.10: Optimum induction conditions for soluble fusion-protein expression 
 
a Thioredoxin (Trx), an oxidoreductase 
b GroEL and GroeES (GroEL/ES), a bacterial chaperone 
 
2.2.2 Large-scale protein expression in E. coli 
2.2.2.1 Purification of GST-RhoGDIs  
A 50 mL overnight culture was transferred into 500 mL sterile 2TY media and allowed to grow at 
37 °C with continuous shaking at 180 rpm until the cells had reached late-log phase (OD600 ~0.8). 
The cells were then induced with 1mM IPTG and grown under optimum conditions that maximised 
the production of each soluble GST-RhoGDIs (Table 2.10).  
Following induction by IPTG, cells were harvested and pelleted at 8000 x g for 15 min at 4 °C. 
The cell pellets were resuspended in lysis buffer (Table 2.11) and lysed using an Emulsiflex cell 
disruptor (Avestin). 1 mM PMSF and 0.1% Triton X-100 were then added to the cell lysates which 
were cleared by centrifugation at 45000 x g for 30 min at 4 °C. The supernatant was applied to an 
MTPBS-equilibrated glutathione sepharose column. The lysates were loaded onto the column at a 
flow rate of 1 mL/min. The column was then washed with MTPBS (Table 2.11) until the A280 
returned to baseline. GST-RhoGDIs were then eluted from the column with elution buffer (Table 
Fusion protein 
construct  
E. coli strain Antibiotic 
resistance 
IPTG Temperature Duration 
pDEST15T-RhoGDI-1 BL21 (DE3) (+Trx)a Amp + Cam 1 mM 37 °C ~5 h 
pDEST15T-RhoGDI-2 BL21 (DE3) (+GroEL/ES)b Amp + Cam 1 mM 37 °C ~5 h 








pLysS Amp + Cam 1 mM 20 °C ~16 h 
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2.11). Eluted proteins were collected in 2 mL fractions and monitored at A280. Appropriate 
fractions were analysed by SDS-PAGE and Coomassie staining (section 2.4.3).  
Column fractions containing GST-RhoGDIs were collected after glutathione sepharose 
purification and concentrated to ~2 mL using an AmiconÒ Ultra 15 10K, centrifugation filter 
(Merck, Cat. No. UFC901024). The concentrated fused proteins were then applied to a HiLoadTM 
16/600 SuperdexTM 200 (S200) gel filtration column (pre-equilibrated with MTPBS) at a flow rate 
of 1 mL/min. The eluate in 2 mL fractions was monitored by A280 and collected in 2 mL fractions. 
Appropriate fractions were analysed by SDS-PAGE and Coomassie staining (section 2.4.3). The 
relevant fractions were pooled, concentrated and quantified using A280 (section 2.2.3) before 
storage at -80 °C.  
Table 2.11: Buffers used for GST-RhoGDIs purification  
 
2.2.2.2 Purification of GST-PAK1-GBD (56-272) 
A single colony of E. coli BL21 expressing GST-PAK1-GBD (56-272) (a kind gift from Dr. Heidi 
Welch, Babraham Institute, Cambridge) was inoculated into 4X 50 mL 2TY and grown for ~16 h 
at 37 °C. These cultures were used to inoculate 4X 500 mL 2TY and grown at 37 °C with 
continuous shaking at 180 rpm until reaching A600 ~0.8. The cultures were then induced with 0.1 
mM IPTG and grown for another 5 h at 37 °C. Cells were pelleted by centrifugation at 8000 x g 
Buffer Ingredient 
Lysis buffer 
50 mM Tris-HCl pH 7.5 
50 mM NaCl  
1 mM PMSF (Melford Laboratories, Cat. No. P20270) 
1X Protease Inhibitor Cocktail (Sigma-Aldrich, Cat. No. S8830) 
MTPBS pH 7.4 
16 mM Na2HPO4 
4 mM NaH2PO4 
150 mM NaCl 
0.05% Sodium Azide 
Elution buffer 
50 mM Tris-HCl pH 8.0 
150 mM NaCl 
10 mM Glutathione (Sigma-Aldrich, Cat. No. G4251) 
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for 15 min at 4 °C, resuspended in ice cold lysis buffer (Table 2.12) and lysed using an Emulsiflex. 
1 mM PMSF and 0.1% Triton X-100 were added to the lysates before pelleted at 45000 x g for 30 
min at 4 °C.  
The cleared supernatant was then applied to glutathione-agarose beads equilibrated in MTPBS and 
rotated at 4 °C for ~30 min. The beads were then washed three times with MTPBS containing 
0.1% Triton X-100 to remove any unbound proteins. Samples were collected at all stages for 
further analysis by SDS-PAGE and Coomassie staining (Section 2.4.3). The bound protein was 
then eluted from the beads by incubating the beads with elution buffer for ~30 min at 4 °C (Table 
2.12) followed by centrifugation at 1000 x g at 4 °C for 10 min. The elution process was repeated 
four times to maximize the amount of eluted protein from the beads. All the elutes samples were 
then pooled and concentrated to ~2 mL using an Amicon stirred cell centrifugation filter. The 
amount of protein was quantified using A280 (section 2.2.3) and stored at -80 °C. 
Table 2.12: Buffers used for GST-PAK1-GBD (56-272) purification  
 
2.2.2.3 Purification of GST-Rhotekin-RBD (1-89) 
GST-Rhotekin-RBD was purified according to the protocol adapted from Professor Harry Mellor, 
University of Bristol. A single colony of E. coli BL21 (DE3) pLysS expressing GST-Rhotekin-
RBD (1-89) was inoculated into 4X 50 mL 2TY and grown for ~16 h at 37 °C. The cultures were 
used to inoculate 4X 500 mL 2TY and grown at 37 °C with continuous shaking at 180 rpm. The 
cultures were then induced with 1 mM IPTG when the cells reached the late-log phase (OD600 
Buffer Ingredient 
Lysis buffer pH 7.4 
16 mM Na2HPO4 
4 mM NaH2PO4 
150 mM NaCl 
1 mM PMSF 
1X Protease Inhibitor Cocktail (Sigma-Aldrich, Cat. No. S8830) 
Elution buffer pH 
50 mM Tris-HCl pH 8.0 
10 mM Glutathione  
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~0.8) after which they were grown for another ~16 h at 20 °C. Cells were harvested and pelleted 
at 4000 x g for 30 min at 4 °C.  
Pelleted cells were resuspended in ice-cold lysis buffer (Table 2.13) and lysed using an Emusiflex. 
0.1 mM PMSF and 1 mM DTT were added to the lysates before centrifugation at 45000 x g for 30 
min at 4 °C. The cleared lysate was then applied to 400 uL glutathione-sepharose 4B beads (GE 
Healthcare, Cat. No. 17-0756-01), pre-equilibrated in lysis buffer and rotated for 5 min at 4 °C. 
After incubation, the beads were washed six times with 12 mL wash buffer (Table 2.13) and once 
with 12 mL wash buffer containing 10% glycerol by centrifuging at 1000 x g for 2 min at 4 °C. 
The beads were finally resuspended in 8 mL wash buffer containing 10% glycerol and stored at -
80 °C as 1 mL aliquots.  
Table 2.13: Buffers used for GST-Rhotekin-RBD (1-89) purification  
 
2.2.3 Quantification and storage of purified protein  
Protein was quantified using a A280 reading, measured within the linear range of 0.1 to 1, using a 
spectrophotometer (Shimadzu, Cat. No. UV-1800 UV-VIS). The concentration was then 
calculated using to the equation below, 
" = 	$%& 
Buffer Ingredient 
Lysis buffer 
50 mM Tris-HCl pH 7.5 
150 mM NaCl  
5 mM MgCl2 
1 mM DTT (Melford Laboratories, Cat. No. D11000) 
0.1 mM PMSF 
1X Protease Inhibitor Cocktail (Sigma-Aldrich, Cat. No. S8830) 
Wash buffer 
50 mM Tris-HCl pH 7.5 
150 mM NaCl  
5 mM MgCl2 
1 mM DTT  
0.5% Triton X-100  
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where " is the absorbance at 280 nm, $ is the extinction coefficient (M-1 cm-1), % is the 
concentration (M) and & is the pathlength (cm). The extinction coefficient was predicted from the 
number of tryptophan and tyrosine residues in the sequence.   
2.3 Mammalian cell culture  
2.3.1 Cell lines and reagents 
The cell line primarily used in this study was Human Embryonic Kidney, HEK293T cells. Other 
cell lines used include human pancreatic cancer (PANC-1) and prostate cancer (LNCaP) cell lines. 
All the plasticwares and reagents used in the maintenance of mammalian cell line are described in 
Tables 2.14 and 2.15.  
Table 2.14: Culture vessel and plasticware  
 
Table 2.15: Reagents for cell maintenance  
 
Culture vessel or plasticware Manufacturer Catalogue number 
10 cm Falcon 100 x 20mm Dish BD Falcon 353003 
60 mm TC easy-grip dish  BD Falcon 353004 
Corning 6 well TC plate Corning 3516 
12 Well Flat-Bottomed Tissue Culture Plate BD Falcon 353043 
CELLSTAR 25cm cell scraper  Greiner 541070 
Cryovials, 1mL Greiner 123263 
Culture vessel or plasticware Manufacturer Catalogue number 
Dulbecco’s Modified Eagle Medium (DMEM), 
High Glucose (4.5 g/L) Life Technologies 41965-062 
Antibiotic, Antimycotic (100X) Life Technologies 15240-096 
L-Glutamine (200 mM) Life Technologies 25030-081 
Fetal Bovine Serum (FBS) Life Technologies 10108-165 
Trypsin-EDTA (0.05%) Life Technologies 25300-054 
Dulbecco’s Phosphate Buffered Saline (DPBS)  Sigma-Aldrich D8537 
Dimethyl Sulphoxide (DMSO) sterile filtered Sigma-Aldrich D2650 
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2.3.2 Cell maintenance 
Cells were maintained in DMEM (High Glucose) media supplemented with 10% Fetal Bovine 
Serum (FBS), 2 mM L- Glutamine and 1% Antibiotic-Antimycotic in a 37 °C humidified incubator 
with 5% CO2. Cells were split when 80 to 90% confluence was reached. Old media was discarded, 
and the cells washed with 2 mL of Dulbecco’s phosphate buffer saline (DPBS). After DPBS was 
removed, 1 mL of 0.05% trypsin solution was added, and the cells were incubated at 37 °C for ~5 
min. The cells were then resuspended in supplemented DMEM and replated at 1:2 to 1:20 
depending on the requirement of each cell line.  
2.3.3 Cell freezing and revival 
Cells at ~80% confluency were trypsinised, resuspended in DMEM and counted using a 
hemocytometer. Cell were then pelleted at 1000 x g for 10 min and resuspended at the correct 
density in 1 mL DMEM containing 10% FBS and 10% DMSO before being transferred to cryovial. 
The vials were frozen slowly at -20 °C for 24 h, subsequently transferred to -80 °C for another 24 
h and finally transferred to liquid nitrogen for long-term storage. Frozen cells were revived by 
rapid defrosting in a 37 °C water bath. The defrosted cells aliquot was added to 10 mL 
supplemented DMEM and pelleted at 1000 x g for ~10 min. Cell pellets were then resuspended in 
10 mL supplemented DMEM and transferred to a 10 cm dish for growth at 37 °C in an humidified 
incubator with 5% CO2.  
2.3.4 Transfection of mammalian cells 
Plasmid DNA used for transfection were purified from E. coli using an Endofree Plasmid Maxi 
Kit (Qiagen, Cat. No. 12362) following manufacturer’s instructions. The DNA concentration was 
measured at A260 and calculated using the formula below, 
' = (" × 50) × -. 
where ' is the DNA concentration (µg/mL), " is the absorbance at 260 nm and -. is the dilution 
factor.  
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2.3.4.1 Transfection using LipofectamineÒ 
Cells were transfected at ~50-60% confluency using LipofectamineÒ 2000 Transfection reagent 
(Life Technologies, Cat. No. 11668-019) and Opti-Mem. A minimum of 1 μg pXJ-HA-GFP 
construct DNA was always included as a transfection control. All the volumes of transfection 
reagents described here represent the volume used for a 10 cm dishes and were adjusted as 
appropriate for other dishes according to surface area.  
Briefly, prior to transfection, 20 μL LipofectamineÒ was diluted in 1 mL Opti-Mem and left at 
room temperature for 5 min. The appropriate amount of plasmid DNA was diluted in 1 mL Opti-
Mem reagent in a separate tube. 1 mL of Lipofectamine-Opti-Mem mix was then added to the 
diluted plasmid DNA and incubated at room temperature for 20 min. The transfection solution was 
then added dropwise to the cells. The transfected cells were grown at 37 °C in an humidified 
incubator with 5% CO2 for ~40 h, before harvesting.   
2.3.4.2 Transfection using Polyethylenimine (PEI) 
Plasmid DNA was mixed with 30 μL 1 mg/mL PEI and 1 mL DMEM, and left at room temperature 
for ~10 min. The transfection solution was then added dropwise to the cells. Transfected cells were 
grown for ~40 h at 37 °C in an humidified incubator with 5% CO2, before harvesting for future 
analysis.  
2.3.5 Cell lysis and sample preparation 
Unless otherwise stated, cells were harvested and lysed at 80-90% confluency using 1 mL ice cold 
lysis buffer (Table 2.16) for each 10 cm dish. The whole cell lysates were then pelleted at 13000 
x g for 20 min. Supernatant was collected and mixed with 2X LDS sample buffer for further 
analysis (Table 2.16).  
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Table 2.16: Buffers used for cell lysis  
 
2.3.6 Cell fractionation 
Mammalian cell fractionation was performed according to a protocol adapted from Life 
Technologies. Cells were transfected with plasmid DNA before harvesting and separation into 
cytoplasmic and nuclear-enriched fractions, ~40 h post-transfection. Culture media was aspirated 
from the cells, which were then washed with 2 mL DPBS. Cells were then resuspended in 5 mL 
fresh DPBS and pelleted at 1000 x g for 15 min at 4 °C. The supernatant was discarded and the 
cell pellet was resuspended in 500 µL hypotonic buffer (Table 2.17) and incubated on ice for 15 
min. 0.5% NP40 Alternative was then added to the cells which were lysed by vortexing for 10 sec. 
Lysates were centrifuged at 1000 x g for 15 min at 4 °C and the supernatant containing the 
Buffer Ingredient 
Lysis buffer  
(Protein G 
Dynabeads) 
50 mM Tris-HCl pH 7.4  
150 mM NaCl 
1 mM EDTA 
1 mM Sodium orthovanadate (Na3VO4) (Sigma-Aldrich, Cat. No. S6508) 
1 mM β-glycerophosphate Disodium Salt Hydrate (Merck, Cat. No. 35675) 
1X Mammalian Protease Inhibitor Cocktail (Sigma-Aldrich, Cat. No. P8340) 
1% Triton X-100 
Lysis buffer  
(His-tag 
Dynabeads) 
50 mM Tris-HCl pH 7.4  
150 mM NaCl 
1 mM Sodium orthovanadate (Na3VO4)  
1 mM β-glycerophosphate Disodium Salt Hydrate  
1X Mammalian Protease Inhibitor Cocktail  
1% Triton X-100 
Lysis buffer  
(ubiquitination 
assay) 
50 mM Tris-HCl pH 7.5 
225 mM KCl 
10 mM NaF 
1% NP-40 Alternative (Calbiochem, Cat. No. 492016) 
1 mM Na3VO4  
1X Mammalian Protease Inhibitor Cocktail  
2X LDS 
sample buffer  
250 μL 4X NuPAGE® LDS Sample buffer (ThermoFisher, Cat. No. NP0007)  
170 μL sterile MilliQ 
80 μL β-mercaptoethanol (Merck, Cat. No. 805740) 
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cytoplasmic contents was collected and mixed with 2X LDS sample buffer (Table 2.16) or kept on 
ice for further analysis.   
The remaining pellet was washed with 500 µL hypotonic buffer (Table 2.17) by centrifugation at 
1000 x g for 15 min at 4 °C. The cell pellet was then resuspended in 500 µL cells extraction buffer 
(Table 2.17). The nuclear-enriched pellet was incubated on ice for 30 min with brief vortexing for 
every 10 min. Following incubation, the samples were pelleted at 13000 x g and the supernatant 
containing nuclear-enriched content was collected and mixed with 2X LDS sample buffer or kept 
on ice for further analysis.  
Both the cytoplasmic and nuclear-enriched fractions were analysed by western blotting (section 
2.4.4) or used for further analysis such as co-immunoprecipitation studies (section 2.3.9). Histone 
H3 and Heat shock protein 56 (Hsp56) or GAPDH were used as nuclear and cytoplasmic markers, 
respectively. 
Table 2.17: Buffers used for cell extraction  
 
Buffer Ingredient 
Hypotonic buffer  
20 mM Tris-HCl pH 7.4 
10 mM NaCl 
3 mM MgCl2  
Cells extraction buffer  
100 mM Tris-HCl pH 7.4 
100 mM NaCl 
1 mM EDTA 
1 mM EGTA 
0.1% SDS 
1 mM NaF 
2 mM Na3VO4 
1% Triton X-100 
10% Glycerol 
0.5% Sodium deoxycholate 
20 mM Na4P2O7 
1 mM PMSF 
1X Mammalian Protease Inhibitor Cocktail 
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2.3.7 Inhibition of mammalian protein synthesis 
~24 h post-transfection, cells were serum-starved overnight with DMEM containing 0.5% FBS. 
~40 h post-transfection, cells were treated with 25 µg/mL cycloheximide (CHX) (Sigma-Aldrich, 
Cat. No. C4859) or DMSO for 2 to 8 h. At various time points, cells were harvested and lysed with 
lysis buffer (Table 2.16). The cell lysate was centrifuged at 13000 x g for 20 min at 4 °C. The 
supernatant was collected and mixed in a 1:1 ratio with 2X LDS sample buffer (Table 2.16).  
2.3.8 Inhibition of mammalian protein degradation 
Protein degradation was inhibited either using MG132 (Sigma-Aldrich, Cat. No. M7449) or 
Bafilomycin A1 (Baf) (Sigma-Aldrich, Cat. No. B1793). 10 µM MG132, 1 µM Baf or DMSO 
were added to transfected cells, ~40 h post-transfection. Treated cells were then incubated for ~6 
h at 37 °C before being harvested and lysed in lysis buffer (Table 2.16). The cell lysate was 
centrifuged at 13000 x g for 20 min at 4 °C. The supernatant was collected and mixed with 2X 
LDS sample buffer (Table 2.16).  
2.3.9 Co-immunoprecipitation 
2.3.9.1 Co-immunoprecipitation using Protein G Dynabeads 
Transfected cells were harvested and lysed in lysis buffer (Table 2.16), ~40 h post-transfection. 
Cell lysates were centrifuged at 13000 x g for 20 min at 4 °C. Supernatants were then transferred 
to tube containing 30 µL Protein G DynabeadsTM (ThermoFisher, Cat. No. 10004D) that were pre-
washed once with 1X PBS-tween 20 (1X PBST) (Table 2.18). Tubes were rotated for ~1 h at 4 °C 
to remove any non-specific binding proteins. 
Whilst the samples were pre-clearing, another 30 µL of Protein G DynabeadsTM were aliquoted 
into tubes and washed with 1X PBST. 1 mg/mL of the selected antibody (Table 2.19) were diluted 
in 200 μL 1X PBST and added to each tube before rotation for 30 min at room temperature to 
allow for antibody-Protein G binding. All excessive antibody was removed by washing the beads 
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three times with 500 μL 1X PBST. The beads were either incubated directly with lysates or were 
cross-linked with DMP (dimethyl pimelimidate) (ThermoFisher, 21666) before incubation with 
lysates. For cross-linking, the beads were washed twice with 500 μL 0.2 M Triethanolamine pH 
8.2, resuspended in 500 μL 200 mM DMP in 0.2 M Triethanolamine pH 8.2 and rotated at room 
temperature for another 20 min. Following the 20 min incubation, the cross-linked antibody-bead 
complex was rotated with 50 mM Tris-HCl pH 7.4 for another 15 min and subsequently washed 
three times with 500 μL 1X PBST.  
1 mL of pre-cleared cell lysate was then added to the beads and incubated for at least 1 h at 4 °C. 
All unbound proteins were removed, and the beads were washed three times with 500 μL cold lysis 
buffer (Table 2.16). Lastly, the beads were resuspended in 20 μL 1X PBS (Table 2.18) and mixed 
with 2X LDS sample buffer (Table 2.16) at a 1:1 ratio for future analysis by western blotting 
(section 2.4.4).  
Table 2.18: Buffers used for co-immunoprecipitation  
 
Table 2.19: Antibodies used for co-immunoprecipitation  
Buffer Ingredient 
1X PBS  
150 mM NaCl 
16 mM Na2HPO4 
4 mM NaH2PO4 pH 7.4 
1X PBST 
150 mM NaCl 
16 mM Na2HPO4 
4 mM NaH2PO4 pH 7.4 
0.1% Tween-20 (Sigma-Aldrich, Cat. No. P1379) 
Antibody Manufacturer Catalogue number 
Anti-FLAG Sigma-Aldrich F3165 
Anti-ACK Santa Cruz Biotechnology sc-28336 
Anti-HA Santa Cruz Biotechnology Sc-7392 
Anti-RhoGDI-1 Santa Cruz Biotechnology sc-373724 
Anti-Myc Santa Cruz Biotechnology sc-40 
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2.3.9.2 Co-immunoprecipitation with His-tag Dynabeads 
His-tagged proteins were co-immunoprecipitated using His-tag DynabeadsTM (ThermoFisher, Cat. 
No. 10103D), a cobalt-coated magnetic bead. ~40 h post-transfection, transfected cells were 
harvested and lysed with ice cold lysis buffer (Table 2.16). Cell lysates were centrifuged at 13000 
x g for 20 min at 4 °C and supernatants were transferred to tubes containing 30 μL pre-washed 
His-tag DynabeadsTM (pre-washed with 1X PBST). Tubes were rotated at 4 °C for ~1 h and 
subsequently washed three times with 500 μL cold lysis buffer. Lastly, the beads were resuspended 
in 30 μL 1X PBS (Table 2.18) and mixed with 2X LDS sample buffer (Table 2.16) at 1:1 ratio for 
future analysis by western blotting (section 2.4.4).  
2.3.10 Effector pull-down 
2.3.10.1 GST-Rhotekin-RBD pull-down  
Transfected cells were grown for ~24 h before being serum-starved with DMEM supplemented 
with 0.5% FBS overnight. ~40 h post-transfection, cells were washed once with 2 mL DPBS before 
resuspended in 5 mL DPBS. The cells were pelleted at 1000 x g for 5 min at 4 °C. 100 µL (~10 
µg) GST-Rhotekin-bead suspension were equilibrated with ice cold lysis buffer (Table 2.20). The 
cell pellets were resuspended in 600 µL lysis buffer and incubated on ice for 2 min before 
centrifugation at 13000 x g for 5 min at 4 °C. The cleared supernatant was transferred to the pre-
equilibrated GST-Rhotekin-RBD-bead suspension and rotated at 4 °C for 45 min. Following 
incubation, the beads were washed 2X with lysis buffer before centrifugation at 1000 x g at 4 °C. 
The GTP-bound Rho-family proteins were eluted from the beads with 2X LDS sample buffer 
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Table 2.20: Buffer used for effector pull-down  
 
2.3.10.2 GST-PAK1-GBD pull-down  
~24 h post-transfection, transfected cells were serum-starved overnight. Cells were then washed 
once with 2 mL DPBS and resuspended in 5 mL DPBS. The cells were then centrifuged at 1000 x 
g for 5 min at 4 °C. Pelleted cells were then lysed with 600 µL ice cold lysis buffer (Table 2.20) 
containing 10 µg GST-PAK1-GBD. The lysates were incubated on ice for 2 min before being 
pelleted at 13000 x g for 5 min at 4 °C. 10 µL glutathione sepharose 4B beads (GE Healthcare, 
Cat. No. 17-0756-01) were equilibrated with lysis buffer before incubation with the cleared 
supernatant for 45 min at 4 °C. Following incubation, the beads were washed twice with ice cold 
lysis buffer by centrifugation at 1000 x g for 2 min at 4 °C. The presence of GTP-bound Rho-
family proteins were identified by western blotting (section 2.4.4).  
 
2.3.11 Cell fractionation and effector pull-down  
Transfected cells were serum-starved overnight in 0.5% FBS before harvesting, ~40 h post-
transfection. Cells were resuspended in 5 mL DPBS and pelleted at 1000 x g for 5 min at 4 °C. 
The supernatant was discarded, and the cell pellets were resuspended in 300 µL ice cold hypotonic 
buffer (Table 2.17) alone for GST-Rhotekin-RBD pull-down assays or with buffer containing 10 
µg GST-PAK1-GBD for GST-PAK1-GBD pull-down assays. Cells were then incubated on ice for 
10 min. 0.5% NP40 Alternative was added to the cells, which were lysed by vortexing for 10 sec. 
The lysates were centrifuged at 1000 x g for 5 min at 4 °C. The pellets were kept on ice for nuclear-
Buffer Ingredient 
Lysis buffer pH 7.5 
20 mM Tris pH 7.5 
150 mM NaCl 
5 mM MgCl2 
0.5% NP40 Alternative 
5 mM β-glycerophosphate  
1 mM DTT 
1X Mammalian Protease Inhibitor Cocktail 
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enriched extraction, whereas the supernatants were transferred to tubes containing pre-equilibrated 
GST-Rhotekin-RBD-bead suspension or glutathione sepharose 4B beads (pre-equilibrated with 
lysis buffer) The tubes were rotated at 4 °C for 45 min. Following incubation, the beads were 
washed twice with lysis buffer and mixed with 2X LDS sample buffer (Table 2.16).  
The remaining pellets retained for nuclear extraction were washed with 300 µL hypotonic buffer 
and resuspended in 300 µL ice cold lysis buffer (Table 2.20) alone for GST-Rhotekin-RBD pull-
down or with buffer containing 10 µg GST-PAK1-GBD for GST-PAK1-GBD pull-down. The 
nuclear-enriched pellets were incubated on ice for 30 min with brief vortexing every 10 min. 
Following incubation, the samples were pelleted at 13000 x g and the supernatants, containing 
nuclear-enriched contents, were collected and transferred to tubes containing pre-equilibrated 
GST-Rhotekin-RBD-bead suspension or glutathione sepharose 4B beads. The tubes were rotated 
at 4 °C for 45 min before being washed twice with lysis buffer (Table 2.20) and mixed with 2X 
LDS sample buffer. Gel samples from the whole cell lysate and both the cytoplasmic and nuclear-
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2.4 Protein techniques 
2.4.1 Reagents used for protein techniques  
 Table 2.21: Reagents for western blotting 
 
2.4.2 Determination of protein concentration  
Protein concentration was estimated using a Bradford assays, a colorimetric protein assay. 1 µL 
sample was added to 1 mL mixture solution containing 800 µL MilliQ water and 200 µL protein 
assay dye reagent concentrate (Bio-Rad, Cat. No. 500-0006) in a 1 mL cuvette. The solution was 
left at room temperature for ~5 min before measuring the A595. Protein concentrations were 
estimated using a standard straight-line equation derived from Bovine serum albumin (BSA) 
standards.  
Reagent Manufacturer Catalogue number 
NuPAGE Novex 4-12% Bis-Tris Gel ThermoFisher NP0323 
PageRuler Prestain Protein ladder ThermoFisher 26616 
Immobilon-P Transfer PVDF membranes Millipore IPVH00010 
BF2 Chromatography paper Sartorius FT-2-519-460507N 
Skimmed milk powder Marvel 7888067 
Luminol Sodium salt Sigma-Aldrich A4685 
Para-hydroxy coumaric acid Sigma-Aldrich C9008 
Acrylamide: Bis-Acrylamide solution Biorad 20260005 
Fuji X-ray film Fuji XRY001 
RestoreTM Western Blot Stripping Buffer ThermoFisher 21059 
Ammonium Persulphate Melford Laboratories A1512 
TEMED Sigma-Aldrich T22500 
InstantBlueTM stain Expedeon ISB1L 
Ponceau- S Sigma-Aldrich P7170 
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2.4.3 SDS-PAGE and Coomassie staining 
All purified proteins were resolved using Tris-glycine gels. Gels were prepared using the recipes 
in Table 2.22 into Novex® Mini 1.0 mm gel cassettes (Life Technologies, Cat. No. NC2010). 10 
μL of protein samples were mixed with 2X SDS sample buffer (Table 2.23) at a 1:1 ratio. Gels 
were run in 1X SDS-PAGE running buffer (Table 2.23) in an XCell SureLockTM Mini-Cell 
Electrophoresis System (Life Technologies) at 200 volts for 55 min and stained using the 
InstantBlueTM stain (Table 2.21) for 1 h. 
 Table 2.22: Recipe for Tris-glycine gels 
 
a 29:1 Acrylamide:Bis-Acrylamide solution  
 
 
Table 2.23: Buffers used for SDS-PAGE 
 
Ingredient Resolving gel (12%) Stacking gel (5%) 
1.5 M Tris-HCL pH 8.8 1500 µL - 
0.5 M Tris-HCL pH 6.8 - 500 µL 
30% Acrylamidea 2400 µL 250 µL 
Sterile MilliQ 2000 µL 1200 µL 
10% SDS 60 µL 20 µL 
10% Ammonium Persulphate 48 µL 40 µL 
TEMED 6 µL 2 µL 
Buffer Ingredient 
2X SDS sample buffer 
 
33.3 mM Tris-HCl pH 7.4 
6 M Urea 
3.3% SDS 
66.7 mM 2-Mercaptethanol 0.1% (w/v) 
Bromophenol Blue 
SDS-PAGE running buffer pH 8.3 
 
25 mM Tris Base  
192 mM Glycine  
0.1% SDS 
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2.4.4 Western blotting  
Proteins were resolved using SDS-PAGE either using precast NuPAGE® Novex® 4-12% gels at 
200 volts for 35 min according to manufacturer’s protocol or Tris-glycine gels (Table 2.22) run at 
200 volts for 55 min. The PageRuler Prestained Protein ladder (ThermoFisher, Cat. No. 26616) 
was used as a marker. The proteins were then transferred to Immobilon®-P PVDF membrane 
either using an XCell IITM Blot Module (Invitrogen, Cat No. EI9051) or Semi-PhorTM Blotter 
(Hoefer Scientific Instrument, Cat. No. TE70), according to manufacturer’s instruction.  
After transfer, membranes were stained with Ponceau-S (Table 2.21) for 1 min to check the 
efficiency of protein transfer before blocking with 10% skimmed milk (Table 2.24) at 4 °C for a 
minimum of 1 h. Next, the membrane was incubated with specific antibodies towards the protein 
of interest for a specific period of time (Table 2.25) before being washed three times with 1X 
PBST (Table 2.18) for 20 min each. Proteins were visualized by treating with enhanced 
chemiluminescence solution (ECL) (Table 2.24) for 2 min and exposing the membrane to medical 
X-ray film.  
Table 2.24: Buffers used for western blotting 
Buffer Ingredient 
 
NuPAGE® running Buffer 
   
 
50 mM Tris-HCl pH 7.3  
50 mM MES 
0.1% SDS 
1 mM EDTA 
1X Transfer buffer 
 
26 mM Tris-HCl pH 7.2  
149 mM Glycine 
20% Methanol 
Blocking solution 50 mL 1X PBS-Tween 5 g skimmed milk powder 
Luminol solution 100 mM Tris-HCl pH 8.6 1.25 mM Sodium Luminol Salt 
Enhancer solution 11 mg para-hydroxy coumaric acid  10 mL DMSO 
Enhanced Chemiluminescence 
solution 
5 mL Luminol Solution  
50 μL Enhancer Solution  
1.5 μL 30% H2O2 (Fisher Scientific, Cat. No. H/1800/15) 
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Table 2.25: Antibodies used in western blotting 
 
 
2.4.5 In vitro kinase assays 
0.3 µM GST-ACK (1-489) was allowed to auto-phosphorylate by incubating with 0.5 mM ATP in 
1X Kinase Buffer (Table 2.26) for 10 min at 30 °C. Following incubation, auto-phosphorylated 
ACK was added to 1X Kinase buffer containing 10 µM GST-RhoGDI-1 or GST-RhoGDI-2 and 
Antibody Manufacturer Catalogue number Dilution 
Anti-FLAG-HRP Sigma-Aldrich A8592 1:5000 
Anti-His-HRP Santa Cruz Biotechnology sc-8036 HRP 1:2500 
Anti-V5-HRP ThermoFisher R961-25 1:5000 
Anti-HA-HRP Santa Cruz Biotechnology sc-7392 HRP 1:500 
Anti-pTyr-HRP Santa Cruz Biotechnology sc-7020 HRP 1:500 
Donkey anti-Goat-HRP Abcam Ab6885 1:5000 
Goat anti-Rabbit-HRP Newmarket Scientific GTXRB-DHRPX 1:5000 
Goat anti-Mouse-HRP Newmarket Scientific GTXMU-DHRPX 1:5000 
Anti-HA Santa Cruz Biotechnology Sc-7392 1:500 
Anti-ACK Santa Cruz Biotechnology sc-28336 1:2500 
Anti-RhoGDI-1 Sigma-Aldrich 06730 1:5000 
Anti-RhoGDI-1 Santa Cruz Biotechnology sc-373724 1:5000 
Anti-RhoGDI-2 Proteintech 16122-1-AP 1:5000 
Anti-RhoGDI-3 Santa Cruz Biotechnology sc-393690 1 :100 
Anti-RhoGDI-3 Aviva System Biology ARP33854 1:1000 
Anti-GAPDH Santa Cruz Biotechnology sc-47724 1:2500 
Anti-GST GE Healthcare 27-4577-01 1:50000 
Anti-pTyr 284 Merck 09-142 1:2500 
Anti-pTyr 607 Abnova PAB24722 1:1000 
Anti-Histone H3 Abcam Ab1791 1:10000 
Anti-Hsp56 Santa Cruz Biotechnology sc-100758 1:1250 
Anti-p53 Cell Signalling Technology 2524 1:1250 
Anti-RhoA Santa Cruz Biotechnology Sc-418 1:500 
Anti-RhoB Proteintech 14326-1-AP 1:3000 
Anti-RhoC Cell Signalling Technology 3430 1:1000 
Anti-Rac1 Merck 05-389 1:1250 
Anti-Myc Santa Cruz Biotechnology sc-40 1:500 
Anti-pSTAT3 Cell Signalling Technology 9145 1:5000 
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0.5 mM ATP, in a total reaction volume of 50 µL. Reactions were incubated at 30 °C for 1 h before 
mixing with 2X LDS sample buffer (Table 2.16) at a 1:1 ratio. Gel samples from each reaction 
were collected and analysed by western blotting (section 2.4.4).  
 

















1X Kinase Buffer 
 
20 mM Tris-HCl pH 7.5 
10 mM MgCl2 
0.5 mM DTT 
0.1 mM Na3VO4 










Chapter 3  
The interaction of ACK with the RhoGDIs 
 
A previous PhD student in the lab, Dr. J. Vicenté-García, performed a Y2H screen to identify novel 
ACK-interacting proteins (Clayton et al., 2019). Using a construct spanning the N-terminal half of 
ACK as shown in Figure 3.1A, 14 novel interacting partners including RhoGDI-3 were identified. 
A construct spanning amino acids 73-225 of RhoGDI-3 (Figure 3.1B) was found to interact with 
the N-terminal half of ACK. This chapter describes the subsequent validation of the ACK-
RhoGDI-3 interaction and the interactions found between ACK and all three RhoGDI family 
members through co-expression in mammalian cells and co-immunoprecipitation.      
 











Figure 3.1: Regions of ACK and RhoGDI-3 involved in the interaction as identified by Y2H 
screening. (A) The N-terminal half of ACK (red box) (A) was found to interact with (B) the C-
terminal of RhoGDI-3 (72-225 amino acids) as indicated by the blue box. SAM: sterile a motif, 
NES: nuclear export signal, Kinase: tyrosine kinase domain, SH3: Src Homology 3 domain, CRIB: 
Cdc42/Rac interacting binding region, CL: Clathrin-interacting region, EBD: EGFR binding 
domain and UBA: ubiquitin-association domain. 
 
Generally, even though Y2H screening is known for its rapid identification of interacting proteins 
in a eukaryotic system, it also has some drawbacks such as high rates of false negative or positive 
result. These can be due to a potential decrease in the stability of proteins of interest in a non-
native environment and the possibility that a lack of native post-translational modifications will 
affect binding between proteins (Brückner et al., 2009). Thus, it is important for any interaction 
identified by Y2H to be validated by an orthogonal method, for example co-immunoprecipitation, 
which is a widely accepted method used to detect physiological interactions between proteins. 
However, low affinity and transient protein-protein interaction can also be difficult to detect 
through co-immunoprecipitation.  
A 
B 
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Co-immunoprecipitation utilizes immunoaffinity between the primary protein (bait) and the 
support reagent to detect secondary protein(s) (targets) bound to the primary. For instance, in this 
work, for immuno-based detection of an interaction, Protein G coated DynabeadsTM were used as 
a support to immobilise antibodies specific for the bait. Protein G is a bacterial cell wall protein 
that has the ability to recognize and bind to the Fc region of mammalian immunoglobulin G (IgG) 
antibodies. It also possible to utilize innate affinity where the highly selective affinity between, for 
example, poly-histidine (6X His) and beads coated with cobalt can be used to separate His-tagged 
proteins. The latter method is especially good for removing non-specific background caused, for 
example, by antibody heavy and light chains, which is especially important when analysing 
proteins that run at ~55 and ~25 kDa. Since all three RhoGDI family members are ~25 kDa, their 
detection can be masked by the presence of these chains, thus the latter method was more suitable 
in some cases. His-tagged proteins and cobalt-coated Dynabeads were therefore used to analyse 
the interactions between ACK and Rho-GDI-1 or -2. Attempts were made to identify the 
interaction between His-tagged RhoGDI-3 and ACK using the same method, however His-
RhoGDI-3 expression could not be detected using anti-His antibody. Therefore, the interaction 
between ACK and RhoGDI-3 was validated using FLAG-RhoGDI-3 and Protein G coated 
DynabeadsTM. 
 
3.1 Validation of the ACK-RhoGDI-3 interaction 
The interactions between exogenously transfected full-length Homo sapiens RhoGDI-3 and ACK 
together with a kinase dead form of ACK (K158R), dACK, were analysed in HEK293T cell by 
co-immunoprecipitation. An expression construct for HA-tagged ACK was a kind gift from Prof. 
Ed Manser (Institute of Molecular and Cell Biology, Singapore). Both of the mammalian 
constructs encoding FLAG-tagged RhoGDI-3 and HA-tagged dACK were already available in the 
lab.  
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3.1.1 Expression trials of FLAG-RhoGDI-3, HA-ACK 
and HA-dACK  
Prior to co-immunoprecipitation, expression trials of all constructs were performed. 5 µg each of 
HA-ACK, HA-dACK and FLAG-RhoGDI-3 were transfected, either alone or together, into 
HEK293T cells and allowed to express for ~40 h as described in section (section 2.3.4). Protein 
levels were analysed by western blotting using anti-HA antibody for ACK and dACK and anti-
FLAG antibody for RhoGDI-3. 
Figure 3.2 shows that expression levels of HA-dACK were generally lower than HA-ACK and 
this has been observed previously in the lab. FLAG-RhoGDI-3 was detected under all three 
condition but decreased in the presence of dACK and decreased even more substantially in the 
presence of ACK. These transfections conditions were therefore used for co-immunoprecipitation 








Figure 3.2: Expression of FLAG-RhoGDI-3, HA-ACK and HA-dACK in HEK293T cell. 5 
μg each of FLAG-RhoGDI-3, HA-ACK and HA-dACK were transfected either alone or in 
combination into HEK293T cells and harvested after ~40 h. The expression of the recombinant 
proteins was assessed using western blot analysis. GAPDH was used as a marker to indicate even 
loading of samples.  
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3.1.2 The interaction of RhoGDI-3 with ACK and 
dACK  
Following expression trials, the interactions between RhoGDI-3 and ACK or dACK were analysed 
by co-immunoprecipitation using anti-FLAG antibody to pull-down FLAG-RhoGDI-3 or anti-
ACK antibody to precipitate HA-ACK or HA-dACK. Briefly, FLAG-RhoGDI-3, HA-ACK and 
HA-dACK were transfected into HEK293T cells alone or in combinations and allowed to express 
for ~40 h before harvesting and lysis. Pre-cleared supernatant samples were immunoprecipitated 
with anti-FLAG or anti-ACK antibodies that was cross-linked to a set of pre-washed Protein G 
Dynabeads. Bound proteins were then detected using anti-ACK antibody for ACK and dACK or 
anti-FLAG antibody for RhoGDI-3. 
As shown in Figure 3.3, RhoGDI-3 was seen to interact with both ACK or dACK when lysates 
were immunoprecipitated with either FLAG (RhoGDI-3) or ACK. These data also suggest that the 
interaction is independent of ACK kinase activity. These data therefore validated the interaction 
found through Y2H and hence suggested a possible new role for ACK in regulating Rho-family 






















Figure 3.3: Co-immunoprecipitation of RhoGDI-3 with ACK and dACK. FLAG-RhoGDI-3, 
HA-ACK and HA-dACK were transfected either alone or in combination into HEK293T cells and 
harvested after ~40 h. Cells were then lysed and immunoprecipitated with anti-FLAG or anti-ACK 
antibodies. Co-immunoprecipitated protein were assessed using anti-FLAG antibody for FLAG-
RhoGDI-3 or anti-ACK antibody for HA-ACK and HA-dACK. The expression of the recombinant 
protein in the whole cell lysate (WCL) is shown in the bottom 3 panels, while the co-
immunoprecipitated (IP) samples are shown in the top 4 panels. In whole cell lysates, analysis of 
GAPDH was used to assess equal loading of samples across the wells. The western blot shown is 
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3.2 The interaction of ACK with other RhoGDI 
family members 
The Y2H data indicated that residues 73-225 of RhoGDI-3 mediates the interaction with ACK 
(Figure 3.1). As all three human RhoGDI proteins share more than 50% similarity at their C-
termini (Figure 1.12) (Olofsson, 1999), it was postulated that RhoGDI-1 and 2 could also interact 
with ACK. His-tagged RhoGDI-1 and His-tagged RhoGDI-2 constructs were therefore used to 
analyse any possible interactions with HA-ACK and HA-dACK.   
3.2.1 Cloning of full-length RhoGDI-2 into the 
mammalian expression vector, pDEST26 
A His-tagged full length RhoGDI-1 mammalian expression vector, a Gateway entry clone for His-
RhoGDI-2 and a Gateway mammalian expression vector, pDEST26, were already available in the 
lab. Full length Homo sapiens RhoGDI-2 was transferred from the Gateway entry clone into the 
Gateway expression vector, pDEST26 by LR recombination. The LR reaction utilises the Lambda 
recombination system to facilitate the transfer of DNA surrounded by att sites, a site-specific 
attachment sequences, from entry clones into appropriate destination vectors. RhoGDI-2 was 
recombined into pDEST26 and the resultant DNA was transformed into chemically competent E. 
coli TOP10 cells. DNA from individual colonies was analysed using BsrG1 restriction analysis. 
The correct size of the insert was determined by gel electrophoresis and confirmed by DNA 
sequencing. 
As shown in Figure 3.4, clone 1 showed the correct size of insert at ~605 bp. This expression clone 
was then used for mammalian trial expressions and co-immunoprecipitation. 
 











3.2.2 Expression of RhoGDI-1 and -2 in mammalian cell 
lines 
The expression of His-RhoGDI-1 and His-RhoGDI-2 constructs was analysed in HEK293T cells. 
A range of DNA concentrations from 1 µg to 5 µg was transfected into HEK293T cells. A 
minimum of 0.5 μg of GFP expression construct was used as a transfection control. The expression 
level for each protein, under each condition was determined by western blotting with an anti-His 
antibody.  
Figure 3.5A shows the expression level of His-RhoGDI-1 and His-RhoGDI-2 increased with the 
increasing amount of DNA in each transfection. Conditions were chosen where the band intensity 
for RhoGDI-1 and -2 expression were similar to each other and to that of RhoGDI-3 to allow all 
the interactions to be easily viewed in the same experiments. 2 µg of RhoGDI-1 and 4.5 µg of 
RhoGDI-2 showed similar expression levels as 5 µg of FLAG-RhoGDI-3 (Figure 3.5B). 
Figure 3.4: BsrGI digestion of a full length 
RhoGDI-2 mammalian expression clone. 
A selected colony from Gateway cloning of 
pDEST26-RhoGDI-2 was digested with 
BsrGI and the digested products were 
separated by agarose gel electrophoresis. M: 
Marker 
















Figure 3.5: Expression of full length His-RhoGDI-1 and His-RhoGDI-2 in HEK293T cells. 
(A) Transfection trials of His-RhoGDI-1 and His-RhoGDI-2 using DNA between 1 µg to 5 µg. 
Cells were harvested after ~40 h transfection and subjected to western blotting analysis. Red boxes 
indicate similar levels of RhoGDI-1 and -2. (B) Transfection trials of 2 µg of His-RhoGDI-1, 4.5 
µg of His-RhoGDI-2 and 5 µg of FLAG-RhoGDI-3. Analysis of GAPDH was used to asses equal 
loading of samples across the wells.  
 
These optimised conditions were then used to analyse expression levels with ACK and dACK 
(Figure 3.6). Both His-RhoGDI-1 and His-RhoGDI-2 showed similar pattern of expression to 
FLAG-RhoGDI-3, with a noticeable decrease in expression when co-expressed with HA-ACK and 
a smaller decrease with HA-dACK. The levels of ACK increased in cells co-expressing RhoGDI-
A 
B 
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Figure 3.6: Co-expression of full length RhoGDI-1, RhoGDI-2, ACK and dACK in 
HEK293T cells. (A) Co-expression of His-RhoGDI-1, HA-ACK and HA-dACK. (B) Co-
expression of His-RhoGDI-2, HA-ACK and HA-dACK. Cells were harvested after ~40 h 
transfection and subjected to western blotting analysis. Analysis of GAPDH was used to asses 
equal loading of samples across the wells. 
A 
B 
Chapter 3  The interaction of ACK with the RhoGDIs 
 92 
3.2.3 The interactions of RhoGDI-1 and -2 with ACK 
and dACK 
The interactions of RhoGDI-1 or -2 with ACK or dACK were analysed using cobalt-coated 
magnetic beads. Briefly, His-RhoGDI-1 and -2 were co-expressed with HA-ACK or HA-dACK 
for ~40 h. The lysates were then incubated with cobalt-coated magnetic beads at 4 °C and the 
precipitated proteins were analysed by western blotting with anti-His and anti-ACK antibodies. 
RhoGDI-1 (Figure 3.7) and RhoGDI-2 (Figure 3.8) were shown to interact with ACK. This work 
therefore identified a further two new binding targets of ACK in addition to RhoGDI-3 and 









Figure 3.7: Co-immunoprecipitation of RhoGDI-1 with ACK and dACK. His-RhoGDI-1 was 
transfected alone or together with HA-ACK or HA-dACK into HEK293T cells. Constructs were 
allowed to express for ~40 h before harvested and lysed. The lysates were then precipitated with 
cobalt-coated magnetic beads for ~1 h. The precipitated proteins were assessed using anti-His or 
anti-ACK antibodies. The expression of the recombinant protein in the whole cell lysate (WCL) is 
shown in the bottom 3 panels, while the co-immunoprecipitated (IP) samples are shown in the top 
two panels. In whole cell lysate, GAPDH was used to assess equal loading of samples across the 
wells. The western blot shown is representative of at least two independent experiments. WCL: 
whole cell lysate; IP: immunoprecipitation.  










Figure 3.8: Co-immunoprecipitation of RhoGDI-2 with ACK and dACK. His-RhoGDI-2 was 
transfected alone or together with HA-ACK or HA-dACK into HEK293T cells. Constructs were 
allowed to express for ~40 h before harvested and lysed. The lysates were then precipitated with 
cobalt-coated magnetic beads for ~1 h. The precipitated proteins were assessed using anti-His or 
anti-ACK antibodies. The expression of the recombinant protein in the whole cell lysate (WCL) is 
shown in the bottom 3 panels, while the co-immunoprecipitated (IP) samples are shown in the top 
two panels. In whole cell lysate, GAPDH was used to assess equal loading of samples across the 
wells. The western blot shown is representative of at least three independent experiments. WCL: 
whole cell lysate; IP: immunoprecipitation.   
 
3.3 The interaction between endogenous ACK and 
RhoGDI-1 
3.3.1 Antibody selection for RhoGDI 
All the interactions shown so far relied on exogenous expression of all proteins. Thus, attempts 
were made to show the interaction between endogenous ACK and RhoGDIs. A selection of 
commercially available RhoGDI antibodies were tested for specificity. Five antibodies were 
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available which were suggested to be specific for certain RhoGDI family members (Table 3.1). 
These antibodies were tested with exogenously expressed RhoGDIs in HEK293T cells.  
Table 3.1 Commercial antibodies for RhoGDI proteins 
 
His-RhoGDI-1 was predicted to have a MW of ~27 kDa, while His-RhoGDI-2 was ~26 kDa. 
Endogenous RhoGDI-1 and -2 were expected to be 24 and 23 kDa, respectively. Figure 3.9A 
shows that the commercially available antibody for RhoGDI-1, 06730, cross-reacts with RhoGDI-
2. However, the second antibody for RhoGDI-1, sc-373724, is specific for RhoGDI-1. The 
RhoGDI-2 antibody, 16122-1-AP, recognises both RhoGDI-1 and RhoGDI-2 but not RhoGDI-3 
(Figure 3.9B). 
FLAG-RhoGDI-3 was anticipated to be at ~28 kDa and the endogenous RhoGDI-3 would be at 
~25 kDa. Unfortunately, neither of the antibodies for RhoGDI-3 were specific, as they also 
detected RhoGDI-1 (Figure 3.10). The epitope used to raise the antibody sc393690 is confined 
within amino acids 1-95 of mouse RhoGDI-3, however human RhoGDI-3 is ~80% similarity in 
this region. Since the other RhoGDIs also share ~40% sequence similarity in this particular region, 
this may contribute to the non-specificity of the antibody. The second RhoGDI-3 antibody, 
ARP33854, is raised against a synthetic peptide from N-terminal region of human RhoGDI-3, 
nevertheless, this antibody also detects RhoGDI-1.  
As only one specific antibody was identified and this recognized endogenous RhoGDI-1, this work 
was taken forward to investigate the interaction between endogenous RhoGDI-1 and ACK.  
 
 
RhoGDI Manufacturer Catalogue number 
RhoGDI-1 
Sigma-Aldrich 06730 
Santa Cruz Biotechnology sc-373724 
RhoGDI-2 Proteintech 16122-1-AP 
RhoGDI-3 
Santa Cruz Biotechnology sc393690 
Aviva System Biology ARP33854 



















Figure 3.9: The specificity profiles of commercially available antibodies for RhoGDI-1 and -
2. Commercially available antibodies for both RhoGDI-1 and -2 were tested using exogenously 
expressed RhoGDIs by western blot analysis. HEK293T cells were transfected with His-RhoGDI-
1, -2 and FLAG-RhoGDI-3. Constructs were allowed to express for ~ 40 h before being harvested 
and lysed. The specificity of the antibodies was assessed by western blotting with (A) RhoGDI-1 




His-RhoGDI-1 ＋ ⎯ ⎯
His-RhoGDI-2 ⎯ ＋ ⎯



















Endogenous RhoGDI-1 (~24 kDa) 
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Figure 3.10: The specificity profiles of commercially available antibodies for RhoGDI-3. 
Commercially available antibodies for RhoGDI-3 were tested using exogenously expressed 
RhoGDIs by western blot analysis. HEK293T cells were transfected with His-RhoGDI-1, -2 and 
FLAG-RhoGDI-3. Constructs were allowed to express for ~ 40 h before being harvested and lysed. 
The specificity of the antibodies was assessed by western blotting.  
 
3.3.2 Visualization of endogenous ACK and RhoGDI-1 
Amongst the three RhoGDIs, RhoGDI-1 is ubiquitously expressed (Olofsson, 1999). Endogenous 
levels of ACK have also been visualized in several cancer cell lines such as pancreatic cancer 
(PANC-1, CD18), prostate cancer (LAPC-4 and LNCaP), breast cancer (MCF7), lung cancer 
(H292) and ovarian cancer (A2780-CP) (Mahajan et al., 2012). Since PANC-1 and LNCaP cells 
were available in the lab, they were tested for detection of endogenous ACK and RhoGDI-1 by 
western blotting with specific antibodies for ACK and RhoGDI-1.  
His-RhoGDI-1 ＋ ⎯ ⎯
His-RhoGDI-2 ⎯ ＋ ⎯























Endogenous RhoGDI-1 (~24 kDa)
His-RhoGDI-1
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As shown in Figure 3.11, endogenous levels of both ACK and RhoGDI-1 were identified in both 
PANC-1 and LNCaP cells. These cell lines were therefore used to determine if there was an 







Figure 3.11: Endogenous levels of ACK and RhoGDI-1 in PANC-1 and LNCaP cells. PANC-
1 and LNCaP cells were allowed to grow to 80% confluency before being harvested and lysed. 
The endogenous protein levels of ACK and RhoGDI-1 were identified by western blotting. 
GAPDH was used to assess equal loading of samples across the wells. 
 
3.3.3 The interaction between endogenous ACK and 
RhoGDI-1  
The interaction between endogenous ACK and RhoGDI-1 was investigated by co-
immunoprecipitation. Briefly, the cells were allowed to grow to 80% confluency before being 
harvested and lysed. The lysates were then immunoprecipitated with either anti-IgG (mouse or 
rabbit) as a control, anti-ACK or anti-RhoGDI-1 antibodies for ~1 h at 4°C. The precipitated 
proteins were assessed by western blotting. 
Endogenous RhoGDI-1 was seen to interact with ACK in LNCaP cells (Figure 3.12A). RhoGDI-
1 appears to be in all precipitated PANC-1 samples (Figure 3.12B) making the interaction between 
ACK and RhoGDI-1 in PANC-1 cells inconclusive. 















Figure 3.12: The interaction between endogenous ACK and RhoGDI-1 in LNCaP and 
PANC-1 cells. LnCaP and PANC-1 cells were allowed to grow to 80% confluency before being 
harvested and lysed. The lysates were then immunoprecipitated with anti-IgG, anti-ACK or anti-
RhoGDI-1 antibodies. The precipitated proteins were determined by western blotting. The 
endogenous expression of each protein in the whole cell lysate (WCL) is shown on the left, while 
the co-immunoprecipitated (IP) samples are shown on the right. In whole cell lysates, GAPDH 
was used to assess equal loading of samples across the wells. WCL: whole cell lysate; IP: 
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3.4 Summary  
The data presented in this chapter show that all three RhoGDIs are binding partners of ACK.  
Attempts were made to validate the interaction between ACK and all three RhoGDIs with 
endogenous proteins. However, since commercially available antibodies were only specific for 
RhoGDI-1 and not for RhoGDI-2 and RhoGDI-3, the interaction with endogenous ACK was only 
validated for RhoGDI-1. ACK was also shown to interact with RhoGDI-1 only in the prostate 
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Chapter 4  
The effect of ACK on the phosphorylation 
status of RhoGDI proteins 
 
This chapter will discuss all the efforts undertaken to determine whether the RhoGDIs are 
substrates for ACK. The initial findings showed ACK might phosphorylate the RhoGDIs. 
Unfortunately, as the work continue to identify the phosphorylation sites on RhoGDI-2, it become 
apparent that the observed phosphorylation was on a tyrosine present within the attB1 site on the 
Gateway expression vector used to express the protein.   
4.1 Initial analysis of the phosphorylation status of 
the RhoGDI proteins 
ACK was shown to interact with all three RhoGDIs in the previous chapter. Thus, it was 
hypothesized that these proteins could be substrates for ACK, so their phosphorylation status was 
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analysed using co-immunoprecipitation and western blotting with a pan anti-pTyr antibody. The 
phosphorylation status of RhoGDIs was only determined for RhoGDI-1 and -2 but not RhoGDI-3 
as the His-tagged version of RhoGDI-3 did not express in HEK293T cells. Attempts were made 
to use different expression constructs of RhoGDI-3 but these gave a high background that made 
the analysis difficult.  
Briefly, full-length His-RhoGDI-1 and -2 expression constructs were transfected into HEK293T 
cells alone or co-transfected with HA-ACK or dACK. ~40 h post-transfection, cells were harvested 
and lysed. The lysates were then precipitated with cobalt-coated magnetic beads for ~1 h at 4°C. 
Following incubation, the beads were washed and eluted with sample buffer and analysed by 
western blotting with a pan anti-pTyr antibody.   
As shown in Figure 4.1A, phospho-ACK, (pACK, ~120 kDa) was detected in the cells transfected 
with ACK alone, while no pACK was detected in cells transfected with dACK. These expression 
patterns for ACK and dACK were expected and useful as an antibody control as ACK undergoes 
autophosphorylation at Tyr284 and dACK, the kinase-dead form of ACK does not 
autophosphorylate. The data in Figure 4.1B show that both RhoGDI-1 and -2 were phosphorylated 
with the phospho-RhoGDI (pRhoGDI) bands only appearing in cells expressing ACK, and not in 
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Figure 4.1: The phosphorylation status of RhoGDI-1 and -2 in the presence of ACK. His-
tagged RhoGDIs, HA-ACK and HA-dACK were transfected alone or in combination into 
HEK293T cells. Constructs were allowed to express for ~40 h before being harvested and lysed. 
The lysates were then precipitated with anti-HA antibody or cobalt-coated magnetic beads before 
elution with sample buffer. The presence of pACK and pRhoGDIs were identified by western 
blotting with a pan anti-pTyr antibody. The expression of the recombinant protein in the whole 
cell lysate (WCL) is shown in the bottom two or 3 panels, while the co-immunoprecipitated (IP) 
samples are shown in the top one or two panels. GAPDH was used to assess the equal loading of 
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4.2 Identification of the primary ACK 
phosphorylation sites on RhoGDI-2   
ACK has been shown to phosphorylate multiple substrates on tyrosine and in one case on serine 
residues (Yokoyama et al., 2005). For instance, ACK was found to phosphorylate cortactin, an 
Arp2/3 regulatory protein on Tyr421, Tyr466 and Tyr482 (Kelley et al., 2012). Since ACK has 
been shown to interact with all three RhoGDIs, it was assumed that ACK would phosphorylate 








Figure 4.2: Conserved tyrosine sites between the three RhoGDIs. The sequence of all three 
RhoGDIs was aligned using multiple sequence alignment programme, Clustal Omega. Conserved 
tyrosine sites between all three RhoGDIs are highlighted in yellow, with RhoGDI-2 numbering. A 
tyrosine sites not fully conserved but shared between RhoGDI-1 and -2 (RhoGDI-2 numbering) is 
highlighted in red, while one shared between RhoGDI-1 and -3 is blue (RhoGDI-1 numbering).  
Asterisk (*) single, fully conserved residue, colon (:) conservation between groups of strongly 
similar properties and period (.) conservation between groups of weakly similar properties.  
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RhoGDI-1 and -2 have been shown to be phosphorylated at a conserved Tyr156 and Tyr153, 
respectively, by several kinases such as Src, Syk, c-Abl (DerMardirossian et al., 2006; Wu et al., 
2009; Liu et al., 2019; Luo et al., 2013). This tyrosine is also conserved in RhoGDI-3, suggesting 
that ACK might also phosphorylate the RhoGDIs at this residue. To test this, Tyr153 of RhoGDI-
2 was mutated to phenylalanine (His-Y153F-RhoGDI-2) and its phosphorylation by ACK was re-
examined.  
Figure 4.3 shows that the Y153F-RhoGDI-2 mutant retained its ability both to interact with and 
be phosphorylated by ACK, indicating that Tyr153 was not the target phosphorylation site for 









Figure 4.3: Phosphorylation at Y153F-RhoGDI-2 by ACK. His-Y153F-RhoGDI-2 and His-wt-
RhoGDI-2 was transfected into HEK293T cells either alone or together with HA-ACK. Constructs 
were allowed to express for ~40 h before harvested and lysed. The lysates were then precipitated 
with cobalt-coated magnetic beads before eluted with sample buffer. The interaction and 
phosphorylation levels of Y153F-RhoGDI-2 mutant were determined by western blotting with an 
anti-ACK and a pan anti-pTyr antibody, respectively. The expression of the recombinant protein 
in the whole cell lysate is shown in the bottom 3 panels, while the co-immunoprecipitated (IP) 
samples are shown in the top 3 panels. GAPDH was used to assess the equal loading of samples. 
WCL: whole cell lysate; IP: immunoprecipitation.  
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As Tyr153 was not the target phosphorylation site for ACK on RhoGDI-2, all 6 remaining 
conserved tyrosine residues (Figure 4.2) were mutated individually to phenylalanine and then 
assessed for their binding and phosphorylation status when expressed with ACK in HEK293T 
cells. RhoGDI-2 wt was used as a control.  
Firstly, the ability for each of the mutant to bind to ACK was assessed. The data in Figure 4.4 








Figure 4.4: Co-immunoprecipitation of RhoGDI-2 mutants with ACK. His-tagged RhoGDI-2 
mutants and wt were co-transfected with ACK into HEK293T cells. Constructs were allowed to 
express for ~40 h before harvested and lysed. The lysates were then precipitated with cobalt-coated 
magnetic beads for ~1 h. The precipitated proteins were assessed using anti-His or anti-ACK 
antibodies. The expression of the recombinant protein in the whole cell lysate (WCL) is shown in 
the bottom 3 panels, while the co-immunoprecipitated (IP) samples are shown in the top two 
panels. In whole cell lysate, GAPDH was used to assess equal loading of samples. WCL: whole 
cell lysate; IP: immunoprecipitation. 
 
Next, the phosphorylation status of each mutant was identified in cells expressing ACK and 
compared to wt. As shown in Figure 4.5, all the mutants were phosphorylated by ACK. These data 
suggested that indicating that ACK might phosphorylate the final tyrosine present in RhoGDI-2, 













HA-ACK ⎯ ＋ ⎯ ⎯ ＋ ⎯ ＋ ＋ ＋ ＋ ＋ ＋
HA-dACK ⎯ ⎯ ＋ ⎯ ⎯ ＋ ⎯ ⎯ ⎯ ⎯ ⎯ ⎯
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Figure 4.5: Identification of ACK phosphorylation sites on RhoGDI-2. His-tagged RhoGDI-2 
mutants and wt were co-transfected with ACK into HEK293T cells. Constructs were allowed to 
express for ~40 h before harvested and lysed. The lysates were then precipitated with cobalt-coated 
magnetic beads for ~1 h at 4°C. The phosphorylated RhoGDI-2 proteins were determined using a 
pan anti-pTyr antibody. The expression of the recombinant protein in the whole cell lysate (WCL) 
is shown in the bottom 3 panels, while the co-immunoprecipitated (IP) samples are shown in the 
top two panels. In whole cell lysate, GAPDH was used to assess equal loading of samples. WCL: 

















HA-ACK ＋ ⎯ ⎯ ＋ ⎯ ＋ ＋ ＋ ＋ ＋
HA-dACK ⎯ ＋ ⎯ ⎯ ＋ ⎯ ⎯ ⎯ ⎯ ⎯
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Since mutation of all the conserved tyrosine residues in RhoGDI-2 did not prevent the 
phosphorylation by ACK, the remaining tyrosine residue in RhoGDI-2, Tyr125, which is not 
conserved between the three RhoGDIs was postulated to be the target phosphorylation site for 
ACK. To test this, all the tyrosine residues present in RhoGDI-2, including Tyr125 were mutated 
to phenylalanine (His-DYRhoGDI-2) and its phosphorylation levels were compared to wt 








Figure 4.6: Identification of ACK phosphorylation sites on Tyr125 of RhoGDI-2. His-wt 
RhoGDI-2 and His-DYRhoGDI-2 were co-transfected with ACK into HEK293T cells. Constructs 
were allowed to express for ~40 h before harvested and lysed. The lysates were then precipitated 
with cobalt-coated magnetic beads for ~1 h at 4°C. Following incubation, the phosphorylation 
status of His-DYRhoGDI-2 was determined by western blotting with a pan anti-pTyr antibody. 
The expression of the recombinant protein in the whole cell lysate (WCL) is shown in the bottom 
3 panels, while the co-immunoprecipitated (IP) samples are shown in the top two panels. In whole 
cell lysate, GAPDH was used to assess equal loading of samples. WCL: whole cell lysate; IP: 
immunoprecipitation.  
 
Surprisingly, (His-DYRhoGDI-2) was still phosphorylated by ACK, suggesting that ACK might 
phosphorylate tyrosine which is not on RhoGDI-2 but potentially in the construct.   
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4.2.1 ACK phosphorylates the tyrosine present within 
the attB1 site of pDEST26 
ACK was still able to phosphorylate His-DYRhoGDI-2, which indicated that ACK might 
phosphorylate the last tyrosine left in the construct, which resides within the attB1 site of pDEST26 
(Figure 4.7). To evaluate this, the tyrosine within the attB1 site was mutated to phenylalanine 





Figure 4.7: The position of a tyrosine within the attB1 in pDEST26-RhoGDI-2. Tyrosine 
present within the attB1 site in pDEST26-RhoGDI-2 was indicated by red arrow.  
Firstly, the ability for the mutant to interact with ACK was identified. Figure 4.8 shows that the 
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Figure 4.8: The interaction between the attB1 mutant and ACK. His-DYattB1-RhoGDI-2, His-
DYRhoGDI-2 and His-wtRhoGDI-2 were transfected into HEK293T cells alone or together with 
ACK. Constructs were allowed to express for ~40 h before precipitated with cobalt-coated 
magnetic beads for ~1 h at 4 °C. The presence of ACK in immunoprecipitated sample was 
identified by western blotting with anti-HA antibody. The expression of the recombinant protein 
in the whole cell lysate (WCL) is shown in the bottom 3 panels, while the co-immunoprecipitated 
(IP) samples are shown in the top two panels. In whole cell lysate, GAPDH was used to assess 
equal loading of samples across the wells. WCL: whole cell lysate; IP: immunoprecipitation. 
 
Next, the phosphorylation levels of DYattB1-RhoGDI-2 were compared to wt RhoGDI-2 and 
DYRhoGDI-2 in the presence of ACK. The data in Figure 4.9 shows that the wt and DYRhoGDI-
2 mutants were both phosphorylated by ACK but not the DYattB1-RhoGDI-2 mutant.  
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Figure 4.9: The phosphorylation levels of the attB1 mutants by ACK. HEK293T cells were 
transfected with His-DYattB1-RhoGDI-2, His-DYRhoGDI-2 and His-wtRhoGDI-2 either alone or 
together with ACK. Constructs were allowed to express for ~40 h before harvested, pelleted and 
lysed. The lysates were precipitated with cobalt-coated magnetic beads for ~1 h at 4 °C. The 
phosphorylation levels were identified by western blotting with a pan anti-pTyr antibody. The 
expression of the recombinant protein in the whole cell lysate (WCL) is shown in the bottom 3 
panels, while the co-immunoprecipitated (IP) samples are shown in the top two panels. In whole 
cell lysate, GAPDH was used to assess equal loading of samples. WCL: whole cell lysate; IP: 
immunoprecipitation. 
 
To confirm that the tyrosine within the attB1 site was the phosphorylation site by ACK, a final 
mutant was made where the tyrosine within the attB1 site was mutated to phenylalanine in wt 
RhoGDI-2 (His-attB1wt-RhoGDI-2). The ability of the mutant to interact with and phosphorylated 
by ACK was analysed and compared to wt RhoGDI-2.  
As shown in Figure 4.10, the His-attB1wt-RhoGDI-2 mutant still bound to ACK but its 
phosphorylation levels decreased significantly compared to the wt. This suggests that TyrattB1 is a 
major and probably the only phosphorylation site for ACK in RhoGDI-2 construct.  
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Figure 4.10: The interaction and phosphorylation levels of RhoGDI-2 wt and the attB1 
mutants by ACK. HEK293T cells were transfected with His-DYattB1wt-RhoGDI-2 and His-
wtRhoGDI-2 either alone or together with ACK. Constructs were allowed to express for ~40 h 
before harvested, pelleted and lysed. The lysates were precipitated with cobalt-coated magnetic 
beads for ~1 h at 4 °C. Following incubation, their ability to interact and their phosphorylation 
levels were analysed by western blotting with anti-HA and a pan anti-pTyr antibodies, 
respectively. The expression of the recombinant protein in the whole cell lysate (WCL) is shown 
in the bottom 3 panels, while the co-immunoprecipitated (IP) samples are shown in the top 3 
panels. In whole cell lysate, GAPDH was used to assess equal loading of samples. WCL: whole 
cell lysate; IP: immunoprecipitation. 
 
4.3 The effect of ACK interaction on the 
phosphorylation of RhoGDI-1 and -2 in vitro 
Whilst the analysis in cells utilising mutants, presented in the previous section was underway, an 
in vitro kinase assay was performed in parallel to investigate the ability of ACK to phosphorylate 
RhoGDI-1 and -2. The in vitro kinase assay was performed using purified ACK, RhoGDI-1 and -
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2. Attempts were also made to purify RhoGDI-3 in E. coli but these were unsuccessful, possibly 
because of the N-terminal extension that is highly hydrophobic.  
Figure 4.11 shows the fragment of ACK (1-489) used in this assay. The purified protein was a kind 




Figure 4.11: Schematic of the GST-tagged ACK construct purified from E. coli. An ACK 
construct spanning amino acids 1-489 (red box) was used to assess the effect of ACK on RhoGDI 
phosphorylation in vitro. SAM: sterile a motif, NES: nuclear export signal, Kinase: tyrosine kinase 
domain, SH3: Src Homology 3 domain, CRIB: Cdc42/Rac interacting binding motif, CL: Clathrin-
interacting region, EBD: EGFR binding domain and UBA: ubiquitin-association domain. 
 
4.3.1 Purification of full-length RhoGDI proteins from 
E. coli 
4.3.1.1 Generation of RhoGDI bacterial expression constructs 
In order to express full-length GST-tagged RhoGDI proteins in E. coli, the Gateway entry clone 
containing each RhoGDIs were recombined with a bacterial expression vector, pDEST15T using 
the LR recombination reaction, according to the manufacturer’s protocol (section 2.1.6). This 
vector is a modified version of pDEST15T available in the lab, where a thrombin protease site has 
been inserted between the GST tag and the fusion protein. The resultant DNA was transformed 
into chemically competent E. coli TOP10 cells. Individual colonies were analysed using BsrG1 
restriction analysis. The correct size of the inserts was determined by gel electrophoresis and 
confirmed by DNA sequencing.  
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As shown in Figure 4.12, all three RhoGDIs were successfully transferred into pDEST15T with 
recombinant plasmids identified that carried the correctly sized inserts of 614, 605, and 675 bp 
respectively.  















4.3.1.2 Small-scale expression trials of GST-RhoGDI in E. coli 
The expression of all three RhoGDIs was initially trialled in E. coli BL21 (DE3). The DE3 lysogen 
encodes T7 polymerase and allows expression of the full-length RhoGDIs, which are under the 
A B 
C 
Figure 4.12: BsrGI digestion of full-length 
RhoGDI bacterial expression clones. A 
selected colony from Gateway cloning of 
pDEST15T-RhoGDIs was digested with 
BsrGI and digested products were separated 
by agarose gel electrophoresis. M: Markers. 
(A) RhoGDI-1, (B) RhoGDI-2 and (C) 
RhoGDI-3. 
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control of the T7 promoter in pDEST15T. The cells were induced with IPTG and grown for either 
5 h at 37 °C or overnight at 20 °C. The soluble and insoluble fractions were collected and analysed 
by SDS-PAGE and Coomassie staining (section 2.4.3).  
Although all three RhoGDIs were found to express well in both the conditions following IPTG 
induction, they were not soluble (Figure 4.13). Thus, additional efforts were trialled to improve 
the solubility of these RhoGDIs by transforming them in E. coli BL21 (DE3) strains that expressed 
either the bacterial chaperone proteins, GroEL and GroeES (GroEL/ES) or thioredoxin (Trx). Both 
of these proteins are known to prevent the aggregation and precipitation of fused proteins by aiding 
their correct folding and hence can improve their solubility (Laminet et al., 1990; LaVallie et al., 
1993).  
RhoGDI-1 (Figure 4.14A) and -3 (Figure 4.15) are shown to be most soluble when co-expressed 
with Trx at 37 °C or 20 °C, while the best soluble expression of RhoGDI-2 (Figure 4.14B) was 
achieved with GroEL/ES at 37 °C. These E. coli strains and induction condition were then used 
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Figure 4.13: Small-scale expression trial of GST-RhoGDI proteins in E. coli BL21 (DE3). E. 
coli BL21 (DE3) cells transformed with GST-RhoGDIs and induced with IPTG for either ~5 h at 
37 °C or ~16 h at 20 °C. Cells were then harvested, pelleted and lysed using a sonicator. Gel 
samples were collected from non-induced (NI), induced (I), insoluble (P) and soluble (S) fractions 
of induced cells. The level of expression of the GST-RhoGDIs and their solubility under each 
condition was assessed by SDS-PAGE and Coomassie staining. M: MW markers.  (A) RhoGDI-
1, (B) RhoGDI-2 and (C) RhoGDI-3.  
C 
A B 
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Figure 4.14: Small-scale expression trials of GST-RhoGDI-1 and -2 proteins in E. coli BL21 
(DE3) expressing bacterial chaperone proteins, GroEL/ES or Trx. E. coli BL21 (DE3) 
expressing either GroEL and GroeES (GroEL/ES) or thioredoxin (Trx) were transformed with 
GST-RhoGDIs and induced with IPTG for either ~5 h at 37 °C or ~16 h at 20 °C. Cells were then 
harvested, pelleted and lysed using a sonicator. Gel samples were collected from non-induced (NI), 
induced (I), insoluble (P) and soluble (S) fractions of induced cells. The level of GST-RhoGDIs 
and their solubility under each condition was assessed by SDS-PAGE and Coomassie staining. M: 
MW markers. (A) RhoGDI-1 and (B) RhoGDI-2  
B 
A 
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Figure 4.15: Small-scale expression trials of GST-RhoGDI-3 protein in E. coli BL21 (DE3) 
expressing bacterial chaperone proteins, GroEL/ES or Trx. E. coli BL21 (DE3) expressing 
either GroEL and GroeES (GroEL/ES) or thioredoxin (Trx) were transformed with GST-RhoGDI-
3, and induced with IPTG for either ~5 h at 37 °C or ~16 h at 20 °C. Cells were then harvested, 
pelleted and lysed using a sonicator. Gel samples were collected from non-induced (NI), induced 
(I), insoluble (P) and soluble (S) fractions of induced cells. The level of GST-RhoGDI-3 and its 
solubility under each condition was assessed by SDS-PAGE and Coomassie staining. M: MW 
markers.   
 
4.3.1.3 Large-scale expression and purification of GST-
RhoGDI proteins in E. coli 
All three GST-fusion RhoGDIs were expressed in 3 L E. coli cultures under optimised conditions 
and purified as described in section 2.2.21. Briefly, following induction by IPTG, cells were 
harvested, pelleted and lysed using an Emulsiflex in lysis buffer (Table 2.11). The lysates were 
cleared by centrifugation and the supernatant applied to a glutathione sepharose column at a flow 
rate of 1 mL/min. The glutathione sepharose column was then washed with MTPBS (Table 2.11) 
to remove unbound proteins. GST-tagged RhoGDIs were then eluted from the glutathione 
sepharose column with 10 mM reduced glutathione. Eluate was collected in 2 mL fractions and 
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the absorbance monitored at 280 nm. Appropriate fractions were analysed by SDS-PAGE and 
Coomassie staining, together with samples from the column flow-through and the MTPBS wash. 
Purifications using the glutathione sepharose column was not sufficient to remove all 
contaminating proteins. Hence, an additional size exclusion column was used to further purify the 
proteins.  
4.3.1.3.1 Purification of GST-tagged RhoGDI-1  
Figure 4.16A shows the present of 4 major peaks following glutathione sepharose purification of 
RhoGDI-1. Fractions 2 to 11 from peaks 1 to 3 and fractions 18 and 19 from peak 4 were collected 
and analysed by SDS-PAGE and Coomassie staining.  
As shown in Figure 4.16B, GST-RhoGDI-1 with a MW ~50 kDa can be observed in all the 
collected fractions. However, the GST-RhoGDI-1 present in peaks 1 to 3 bound less tightly to 
glutathione sepharose, being eluted at ~1.5 mM glutathione, compared to peak 4 that was eluted 
at ~3 mM glutathione. This could potentially be because the GST-RhoGDI-1 in peaks 1 to 3 has 
an altered conformation of GST, thereby reducing the affinity of GST-RhoGDI-1 for glutathione 
sepharose column. Thus, it was decided to proceed with the tighter bound GST-RhoGDI-1 species 
in peak 4. Fractions 13 to 25 were pooled and concentrated to ~2 mL in an Amicon stirred cell and 
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Figure 4.16: Purification of full-length GST-RhoGDI-1 protein from E. coli using affinity 
chromatography. E. coli BL21 (DE3) cells expressing Trx were transformed with an expression 
construct for GST-RhoGDI-1 and induced with IPTG for ~5 h at 37 °C before being harvested, 
pelleted and lysed using an Emulsiflex. The cleared lysates were then (A) applied to glutathione 
sepharose column. (B) Fractions 2 to 11 from peak 1 to 3 and fractions 18 and 19 from peak 4 
were collected together with samples from each stages and analysed by SDS-PAGE and 
Coomassie staining. M: MW markers.  
A 
B 
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Purified GST-RhoGDI-1 from the glutathione sepharose purification was applied to a HiLoadTM 
16/600 SuperdexTM 200 pg gel filtration column. As shown in the elution chromatogram (Figure 
4.17), two peaks were obtained and gel samples from both of the peaks together with samples from 
each stages were collected and analysed by SDS-PAGE and Coomassie staining. The first peak 
covering fractions 23 to 30, represented the void volume of the column and so contains proteins 
too large to enter the column. These fractions were also seen to contain GST-RhoGDI-1 (Figure 
4.17-gel on the right) but this protein was likely large, insoluble or aggregated material. Fractions 
31 to 37 (peak 2) also contained GST-RhoGDI-1 and this was likely to be well-folded protein of 
the correct MW and was largely free from contaminants. These fractions were pooled and 
concentrated to ~0.5 mL. The protein was quantified using A280 and store at -80 °C. 
 
Figure 4.17: Additional purification of full-length GST-RhoGDI-1 from E. coli by size 
exclusion chromatography. The eluted fractions 13 to 25 obtained from affinity chromatography 
were pooled, concentrated and passed over a HiLoadTM 16/600 SuperdexTM 200 pg gel filtration 
column. Gel samples collected from fractions 23 to 28 from peak 1 and 31 to 37 from peak 2 were 
analysed by SDS-PAGE and Coomassie staining. Load sample obtained from affinity purification 
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4.3.1.3.2 Purification of GST-tagged RhoGDI-2 
The purification of GST-RhoGDI-2 by affinity chromatography is shown in Figure 4.18. In this 
case GST-RhoGDI-2 was eluted with a 10 mM glutathione step. In the elution chromatogram, 
there were two peaks observed following glutathione sepharose purification of RhoGDI-2. 
Fractions 3 to 6 from peak 1 and fractions 7 to 13 from peak 2 were pooled and concentrated 
separately before being applied to size exclusion column to further purified the protein.  
 
Figure 4.18: Purification of full-length GST-RhoGDI-2 protein from E. coli using affinity 
chromatography. E. coli BL21 (DE3) cells expressing GroEL/ES were transformed with GST-
RhoGDI-2 and induced with IPTG for ~5 h at 37 °C before harvested, pelleted and lysed using an 
Emulsiflex. The cleared lysates were then applied to glutathione sepharose column and bound 
GST-RhoGDI-2 was eluted from the column with steep gradient of elution buffer, up to 10 mM 
reduced glutathione. Gel samples were collected from each stage of purification and analysed by 
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Figure 4.19 shows the separation by gel filtration for both peaks obtained from the previous affinity 
purification; peak 1 containing fractions 3 to 6 (Figure 4.19A) and peak 2 comprising fractions 7 
to 13 (Figure 4.19B). Following gel filtration, there were five peaks observed and gel samples 
from peaks 1 to 4 were collected and analysed by SDS-PAGE and Coomassie staining.  
The first peak from both gel filtrations column which covered fraction 23 to 27 (Figure 4.19A) and 
fractions 23 to 29 (Figure 4.19B) represented the void volume of the column. These fractions were 
shown to contain GST-RhoGDI-2 but as for RhoGDI-1, these fractions were not considered useful. 
The later peaks from both gel filtration column, containing fractions 33 to 41 (Figure 4.19A) and 
fractions 33 to 42 (Figure 4.19B) were also seen to contain GST-RhoGDI-2 together with several 
low MW proteins. This suggests that separation by gel filtration did not fully separate the low MW 
contaminants from GST-RhoGDI-2 or that degradation was continuing to occur during the 
purification. However, fractions 31 to 33 (Figure 4.19A) and 30 to 33 (Figure 4.19B) that showed 
the fewest contaminants were pooled together and concentrated to ~0.5 mL. The amount of GST-
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Figure 4.19: Additional purification of full-length GST-RhoGDI-2 protein from E. coli by 
size exclusion chromatography. (A) The eluted fractions 3 to 6 and (B) 7 to 13 obtained from the 
previous affinity purification were pooled, concentrated and passed over a HiLoadTM 16/600 
SuperdexTM 200 pg gel filtration column. Gel samples collected from respective fractions, as 
shown in elution chromatogram were analysed by SDS-PAGE and Coomassie staining. The load 
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4.3.1.3.3 Purification of GST-tagged RhoGDI-3 
RhoGDI-3 was purified in the same way as RhoGDI-1 and -2 with a combination of affinity and 
size exclusion chromatography.  
There were two peaks observed from glutathione sepharose chromatography that included fraction 
2 to 5 (peak 1) and 6 to 13 (peak 2) (Figure 4.20A). Gel samples from both the peaks were collected 
and analysed by SDS-PAGE and Coomassie staining. As shown in Figure 4.20B, GST-RhoGDI-
3 were present in all the fractions and its was seen to be relatively pure. However, these fractions 
were pooled and applied to a HiLoadTM 16/600 SuperdexTM 200 pg gel filtration column for further 
purification.  
As shown in Figure 4.21A, following separation by gel filtration, although 5 peaks were obtained, 
all the GST-RhoGDI-3 was eluted in peak 1 (fractions 23 to 26), the void volume of the column, 
suggesting it was in a higher molecular weight complex containing aggregated proteins. This may 
be due to the N-terminal extension of RhoGDI-3 that contains two cysteines, which could drive 
protein aggregation. Thus, 5 mM DTT was included in a second attempt of purification.  
However, the additional DTT did not reduce the aggregation of GST-tagged RhoGDI-3 (Figure 
4.21B) and all the protein remained in fractions 23 to 28, corresponding to the void volume of the 
column. There was also potential that GST-tagged RhoGDI-3 was aggregating with other 
contaminants such as DNA. However, the lysis buffer used in these purifications contained 500 
mM NaCl, which should eliminate interactions with DNA. Similar problems were encountered 
previously by Adra et al. (1997) who showed full-length RhoGDI-3 was in inclusion bodies in E. 
coli, making purification difficult. No additional attempts were made to overcome these issues and 
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Figure 4.20: Purification of full-length GST-RhoGDI-3 protein from E. coli using affinity 
chromatography. E. coli BL21 (DE3) expressing Trx was transformed with GST-RhoGDI-3 and 
induced with IPTG overnight at 20 °C. Cells were harvested, pelleted and lysed using an 
Emulsiflex. The cleared lysates were then applied to glutathione sepharose column and bound 
GST-RhoGDI-3 was eluted from the column with a gradient of elution buffer, up to 10 mM 
reduced glutathione. (A) The absorbance at 280 nm. (B) Gel samples were collected from each 
stage of glutathione sepharose purification and analysed by SDS-PAGE and Coomassie staining. 
M: MW markers. 
B 
A 
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Figure 4.21: Additional purification of full-length GST-RhoGDI-3 from E. coli by size 
exclusion chromatography. The eluted fractions 2 to 13 from affinity were pooled, concentrated 
and passed over a HiLoadTM 16/600 SuperdexTM 200 pg gel filtration column. Gel samples 
collected from respective fractions, as shown in the chromatogram were analysed by SDS-PAGE 
and Coomassie staining. Load sample obtained from affinity purification was also included in the 
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4.3.2 ACK does not phosphorylate RhoGDI-1 and -2 in 
vitro 
The effect of ACK on RhoGDI-1 and -2 phosphorylation in vitro was assessed using an in vitro 
kinase assay. Briefly, 0.3 µM ACK was allowed to undergo autophosphorylation to ensure full 
activity before incubating with 10 µM GST-RhoGDI-1 or RhoGDI-2 for ~1 h at 30 °C. Samples 
from each reaction were collected and analysed by SDS-PAGE and western blotting with a pan 
anti-pTyr antibody.  
Figure 4.22 shows the presence of GST control proteins, GST-RhoGDI-1 and -2. GST-ACK was 
not detected when blotting with the anti-GST antibody as the levels of enzyme were very low in 
the reactions. However, the presence of GST-ACK was identified by western blotting with anti-
pY284. No phosphorylated RhoGDI-1 and -2 were detected when blotting with a pan anti-pTyr 











Figure 4.22: Phosphorylation 
status of RhoGDI-1 and -2 by 
ACK in vitro. 10 µM GST 
control proteins, GST- RhoGDI-
1 and -2 were incubated with 0.5 
mM ATP only or together with 
0.3 µM autophosphorylated 
GST-ACK at 30 °C for ~1 h. 
Samples from each reaction 
were collected and analysed by 
SDS-PAGE and western 
blotting with anti-GST, anti-










GST ＋ ＋ ＋ ⎯ ⎯ ⎯ ⎯ ⎯ ⎯
ATP ⎯ ＋ ＋ ⎯ ＋ ＋ ⎯ ＋ ＋
GST-ACK ⎯ ⎯ ＋ ⎯ ⎯ ＋ ⎯ ⎯ ＋
GST-RhoGDI-1 ⎯ ⎯ ⎯ ＋ ＋ ＋ ⎯ ⎯ ⎯
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4.4 Summary 
Initial findings indicated that ACK potentially phosphorylated both RhoGDI-1 and -2 in cells, 
however, as work continued to identify the specific ACK phosphorylation site on RhoGDI-2, ACK 
was found to phosphorylate the tyrosine present within the attB1 site of the expression construct 
rather than any residue within RhoGDI-2 itself. In parallel with the cellular analysis, an in vitro 
kinase assay was performed using GST-tagged RhoGDI-1 and -2. Again, no phosphorylation by 
ACK was observed. All the data described in this chapter indicate that ACK binds to but does not 
phosphorylate the RhoGDI proteins, at least RhoGDI-1 and -2. It remains to be formally 
demonstrated whether RhoGDI-3 is a substrate for ACK, however this appears to be unlikely.  
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Subcellular localization of the RhoGDIs, 
ACK and the ACK-RhoGDI complexes 
 
5.1 Subcellular localization of the RhoGDIs 
All three RhoGDIs have been previously documented to localize in both the nucleus and cytoplasm 
(Marzouk et al., 2007; Krieser and Eastman, 1999). However, their functional roles are more 
defined in the cytoplasm. For instance, cytoplasmic RhoGDIs are known to form complexes with 
small GTPases and maintain them in their inactive state (Dovas and Couchman, 2005). As for their 
nuclear functions, RhoGDI-1 has been found to bind and regulate oestrogen receptor a (ERa) in 
MCF-7 cells (Marzouk et al., 2007). N-terminally truncated RhoGDI-2 has also been found to 
accumulate in the nucleus following Caspase 3-induced cleavage during apoptosis (Krieser and 
Eastman, 1999). Interestingly, RhoGDI-3 has been found to cluster around the nucleus (Adra et 
al., 1997) and to localize in both the cytoplasm and the nucleus of normal pancreatic cells but only 
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in the cytoplasm of cancerous cells (de León-Bautista et al., 2016). This suggests nuclear roles for 
all three RhoGDI proteins and a potential role for RhoGDI-3 in cancer.  
In this work, RhoGDI localization was analysed using subcellular fractionation as described in 
section 2.3.6. Briefly, His-RhoGDI-1, His-RhoGDI-2 and FLAG-RhoGDI-3 were transfected into 
50% confluent HEK293T cells. Constructs were allowed to express for ~24 h before incubation in 
0.5% serum, overnight. Cells were fractionated into cytoplasmic and nuclear-enriched fractions 
~40 h post-transfection. To isolate the cytoplasmic compartment, the cells were incubated with 
hypotonic buffer (Table 2.17) to induce cell swelling and then lysed with the addition of 0.5% 
NP40 Alternative. Cells were then centrifuged at low speed and the supernatant containing the 
cytoplasmic contents were collected. The remaining pellets were washed with hypotonic buffer 
before lysed with cell extraction buffer (Table 2.17) to rupture the nuclear membrane. The samples 
were pelleted at high speed and supernatants containing nuclear-enriched contents were collected. 
The presence of proteins in each compartment was identified by western blotting. Histone H3 and 
Heat shock protein 56 (Hsp56) or GAPDH were used as nuclear and cytoplasmic markers, 
respectively.  
Figure 5.1 shows the nuclear and cytoplasmic distribution of the RhoGDIs. RhoGDI-1 and -2 were 
only found in the cytoplasm (Figure 5.1A). This data contradicts previous findings that show 
nuclear localization for both RhoGDIs (Marzouk et al., 2007; Krieser and Eastman, 1999). This 
could be due to the difference in the types of cells used in the different studies. Also, for RhoGDI-
2, only the N-terminally truncated version of RhoGDI-2 has been found in the nucleus previously 
(Krieser and Eastman, 1999), whereas in this study, full-length RhoGDI-2 was analysed and 
detected only in the cytoplasm. Interestingly, RhoGDI-3 was observed in both the cytoplasmic and 
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Figure 5.1: Subcellular localization of the RhoGDIs. HEK293T cells were transfected with His-
RhoGDI-1, His-RhoGDI-2 or FLAG-RhoGDI-3. Constructs were allowed to express for ~24 h 
before serum starvation overnight. Cells were then harvested and fractionated into cytoplasmic 
and nuclear-enriched compartments. (A) The levels of RhoGDI-1, RhoGDI-2 and (B) RhoGDI-3 
in the whole cell lysates (WCL) is shown on the left, while their levels in each subcellular 
compartment is shown on the right. Hsp56 or GAPDH and Histone H3 were used as cytoplasmic 
and nuclear markers, respectively. GAPDH was used to assess equal loading of samples across the 
wells in the whole cell lysates. The western blot shown is representative of at least three 
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5.2 The N-terminus of RhoGDI-3 is essential in 
regulating RhoGDI-3 subcellular localization  
All three RhoGDIs share two homologous structural domains: An N-terminal regulatory arm 
domain (residues 1–69) and a C-terminal immunoglobulin-like domain (residues 70-225) (Figures 
1.11 and 1.12). Both domains contribute significantly to the binding and inhibitory actions of the 
RhoGDI proteins towards Rho-family proteins. However, RhoGDI-3 has an additional 26 amino 
acids at its N-terminus. This unique extension is predicted to contain a small additional 
amphipathic helix, which extends from residue 5 to 28 and has been shown to play an important 
role in Golgi targeting and stabilizing the cytoplasmic RhoG-RhoGDI-3 complex (Brunet et al., 
2002). RhoGDI-3 has been found to associate with membranous and cytoskeletal fractions 
(Zalcman et al., 1996). This unique subcellular localization among the RhoGDIs has been assumed 
to involve the unique hydrophobic N-terminus of RhoGDI-3. Thus, to investigate the function of 
the N-terminal 26 amino acids of RhoGDI-3, a deletion mutant was created.  
An N-terminal deletion mutant of RhoGDI-3 (FLAG-DNRhoGDI-3) was generated using 
QuikChange Site-Directed Mutagenesis Kit (section 2.1.7) according to the manufacturer’s 
protocol. A selected clone was sent for DNA sequencing for validation before further used. 
In order to assess the contribution of RhoGDI-3 residues, 1 to 26, to the nuclear localization of 
RhoGDI-3, FLAG-DNRhoGDI-3 was transfected into HEK293T cells and the cells were 
fractionated into the cytoplasmic and nuclear-enriched fraction ~40 h post-transfection. The levels 
of FLAG-DNRhoGDI-3 in each fraction were determined by western blotting and quantified by 
ImageJ. The nuclear-cytoplasmic ratio of the FLAG-DNRhoGDI-3 mutant was then compared to 
wt RhoGDI-3.  
As shown in Figure 5.2, the N-terminally truncated mutant of RhoGDI-3 was expressed at higher 
levels than wt RhoGDI-3, indicating it might be more stable. The mutant was still able to localize 
to both the cytoplasm and the nucleus of HEK293T cells. Interestingly, however, the nuclear-
cytoplasmic ratio of FLAG-DNRhoGDI-3 mutant was significantly higher compared to wt, 
Chapter 5            Subcellular localization of the RhoGDIs, 
       ACK and the ACK-RhoGDI complexes 
      
 133 














Figure 5.2: The role of the N-terminus of RhoGDI-3 in regulating RhoGDI-3 subcellular 
localization. FLAG-DNRhoGDI-3 and FLAG-wtRhoGDI-3 were transfected into HEK293T cells. 
Constructs were allowed to express for ~24 h before serum starvation overnight. Cells were then 
harvested and fractionated into cytoplasmic and nuclear-enriched ~40 h post-transfection. (A) The 
levels of FLAG-DNRhoGDI-3 and FLAG-wtRhoGDI-3 in each fraction were determined by 
western blotting and quantified by ImageJ. The expression of recombinant proteins in the whole 
cell lysate (WCL) is shown in the left, while their expression in each fraction is shown in the right 
hand panels. Hsp56 and Histone H3 were used as cytoplasmic and nuclear markers, respectively. 
GAPDH was used to assess equal loading of samples across the wells in the total whole cell lysate. 
(B) The nuclear-cytoplasmic ratio of each protein was then plotted. The relative amounts are 
shown as average values ± SEM of three experiments **p£ 0.005. WCL: whole cell lysate; C: 
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This is consistent with data obtained from the nuclear prediction tool, NetNES1.1 (La Cour et al., 
2004) that suggest the N-terminus of RhoGDI-3 could contain an NES. The NES motif is predicted 
to be the leucine-rich sequence spanning amino acids 14 to 21 (LELLRLAL) because the 




Figure 5.3: Nuclear export signal (NES) prediction for RhoGDI-3. The likelihood of an NES 
sequence occurring in RhoGDI-3 was predicted using NetNES1.1 prediction tool. An NES motif 
is predicted to be the leucine-rich sequence spanning amino acids Leu14 to Leu21. HMM: Hidden 
Markov Model and NN: Neural Network. The table on the right describes the calculated NES score 
for each residue predicted to be involved in the NES signal.  
 
5.3 Subcellular localization of ACK  
ACK can shuttle between the cytosol and the nucleus to rapidly transduce extracellular signals 
from the RTKs to intracellular effectors in both the cytosol and nucleus (Mahajan and Mahajan, 
2015). ACK localization can also be affected by the confluency state the cells. ACK mainly resides 
in the nucleus of semi-confluent glioblastoma cells but is found in the cytoplasm of confluent cells. 
Furthermore, the interaction with Cdc42 was found to drive the nuclear localization of ACK 
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(Ahmed et al., 2004). Hence, the localization of ACK was analysed in this study using subcellular 
fractionation.  
HA-ACK and HA-dACK were transfected into 50% confluent HEK293T cells. Constructs were 
allowed to express for ~24 h before serum starvation overnight. Cells were then harvested ~40 h 
post-transfection (80-90% confluency) and fractionated into cytoplasmic and nuclear-enriched 
fractions as described previously. 
Figure 5.4 shows that both ACK and dACK localize to both the cytoplasm and nuclear-enriched 
fractions, suggesting that ACK localization is not dependent on the kinase activity of ACK. 







Figure 5.4: Subcellular localization of ACK and dACK in HEK293T cells. HA-ACK and HA-
dACK were transfected into HEK293T cells. Constructs were allowed to express for ~24 h before 
serum starvation overnight. Cells were then harvested and fractionated into cytoplasmic and 
nuclear-enriched compartments before being subjected to western blotting. The expression of 
ACK and dACK in the whole cell lysate (WCL) is shown on the left, while their levels in each 
subcellular compartment is shown on the right. Histone H3 and Hsp56 were used as nuclear and 
cytoplasmic markers, respectively. GAPDH was used to assess equal loading of samples across 
the wells in the total whole cell lysate. The western blot shown is representative of at least three 
independent experiments. WCL: whole cell lysate; C: cytoplasmic fraction; N: nuclear-enriched 
fraction.  
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5.4 The effect of co-expression on ACK or RhoGDI 
subcellular localization 
5.4.1 The effect of RhoGDI on ACK subcellular 
localization 
Since ACK has been shown to shuttle between the nucleus and cytoplasm, it was important to 
investigate whether co-expression with the RhoGDIs would affect its localization.  
To investigate this, HA-ACK was transfected alone or together with either His-RhoGDI-1, His-
RhoGDI-2 or FLAG-RhoGDI-3 into HEK293T cells. Constructs were allowed to express for ~24 
h before serum starvation overnight. ~40 h post-transfection, cells were harvested and separated 
into cytoplasmic and nuclear-enriched compartments. The proteins levels in each fraction were 
determined by western blotting.  
The subcellular localization of ACK was not affected by co-expression with any of the RhoGDIs, 








Chapter 5            Subcellular localization of the RhoGDIs, 
       ACK and the ACK-RhoGDI complexes 












Figure 5.5: Subcellular localization of ACK following co-expression with the RhoGDIs. 
HEK293T cells were transfected with HA-ACK alone or together with His-RhoGDI-1, His-
RhoGDI-2 or FLAG-RhoGDI-3. Constructs were allowed to express for ~24 h before serum 
starvation overnight. Cells were then harvested and fractionated into cytoplasmic and nuclear-
enriched compartments ~40 h post-transfection. The levels of ACK in each fraction were 
determined by western blotting. The expression of recombinant proteins in whole cell lysate 
(WCL) is shown in the left, while their expression in each subcellular compartment is shown in 
the right hand panels. Histone H3 and GAPDH were used as nuclear and cytoplasmic markers, 
respectively. GAPDH was used to assess equal loading of samples across the wells in the total 
whole cell lysates. The western blot shown is representative of at least three independent 
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5.4.2 The effect of ACK on RhoGDI subcellular 
localization 
Both RhoGDI-1 and -2 were only found in the cytoplasm in this study and it was possible that the 
cytoplasmic localization of both RhoGDI-1 and -2 could be altered when co-expressed with ACK. 
Furthermore, it was postulated that ACK might also altered the subcellular localization of 
RhoGDI-3 as it was found to reside in both the cytoplasmic and nucleoplasmic compartments, in 
a similar manner to ACK.  
To test this, all three RhoGDIs were transfected alone or in combination with ACK into HEK293T 
cells. Following subcellular fractionation, the presence of each RhoGDI in both the cytoplasmic 
and nuclear-enriched fractions was identified by western blotting.  
Figure 5.6 shows that both RhoGDI-1 and -2 maintained their cytoplasmic localization, even when 
co-expressed with ACK.  
The same experiment was performed for RhoGDI-3. Interestingly, RhoGDI-3 was still able to 
maintain its cytoplasmic and nuclear localization but the overall levels and the nuclear levels of 
RhoGDI-3 decreased when co-expressed with ACK (Figure 5.7A), suggesting ACK plays a role 
in controlling the levels of RhoGDI-3 in the cell. The nuclear-cytoplasmic ratio of RhoGDI-3 
(Figure 5.7B) also decreased significantly in the presence of ACK, suggesting that ACK could 
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Figure 5.6: Subcellular localization of RhoGDI-1 and -2 in HEK293T cells following co-
expression with ACK. HEK293T cells were transfected with His-RhoGDI-1 and His-RhoGDI-2 
either alone or together HA-ACK. Constructs were allowed to express for ~24 h before serum 
starvation overnight. Cells were then harvested and fractionated into cytoplasmic and nuclear-
enriched compartments ~40 h post-transfection. The levels of both RhoGDIs in each fraction were 
determined by western blotting. The expression of recombinant proteins in whole cell lysates 
(WCL) is shown in the left, while their expression in each subcellular compartment is shown in 
the right hand panels. Histone H3 and Hsp56 were used as nuclear and cytoplasmic markers, 
respectively. GAPDH was used to assess equal loading of samples across the wells in the total 
whole cell lysate. The western blot shown is representative of at least three independent 
experiments. WCL: whole cell lysate; C: cytoplasmic fraction; N: nuclear-enriched fraction.  
A 
B 
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Figure 5.7: Subcellular localization of FLAG-RhoGDI-3 in HEK293T cells following co-
expression with ACK. FLAG-RhoGDI-3 was transfected alone or in combination with HA-ACK 
into HEK293T cells. Constructs were allowed to express for ~24 h before serum starvation 
overnight. Cells were then harvested ~40 h post-transfection and fractionated into cytoplasmic and 
nuclear-enriched extracts. (A) The levels of RhoGDI-3 in each fraction were determined by 
western blotting and quantified by ImageJ. The expression of recombinant proteins in whole cell 
lysate (WCL) is shown in the left, while their expression in each subcellular compartment is shown 
in the right hand panels. Histone H3 and GAPDH were used as nuclear and cytoplasmic markers, 
respectively. GAPDH was also used to assess equal loading of samples across the wells in the total 
whole cell lysate. (B) The nuclear-cytoplasmic ratio of RhoGDI-3 was then plotted. The relative 
amounts are shown as average values ± SEM of three experiments *p£ 0.05. WCL: whole cell 
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5.5 Subcellular localization of the ACK-RhoGDI-
3 complex 
Subcellular localisation of the ACK-RhoGDI-1 or -2 complexes were not tested due to time 
constraint but it is likely that they form in the cytoplasm. This is mainly because both RhoGDIs 
were found to localise exclusively in the cytoplasm and co-expression with ACK does not alters 
their localisation. However, both RhoGDI-3 and ACK were demonstrated to be present in both the 
cytoplasm and in nuclear-enriched fractions. Co-expression with ACK did not alter RhoGDI-3 
localization but decreased RhoGDI-3 protein levels, predominantly in the nuclear-enriched 
fraction. These data suggest that ACK might interact with and mediate RhoGDI-3 degradation in 
the nucleus. ACK could also promote the export of RhoGDI-3 out of the nucleus and its subsequent 
degradation in the cytoplasm. Both possibilities are consistent with decreased total levels of 
RhoGDI-3 in cells expressing ACK. To investigate this, the subcellular localization of the ACK-
RhoGDI-3 complex was determined through fractionation and co-immunoprecipitation using an 
anti-FLAG antibody to pull-down FLAG-RhoGDI-3-HA-ACK complex.  
Briefly, FLAG-RhoGDI-3 and HA-ACK were transfected into HEK293T cells alone or in 
combination and allowed to express for ~24 h before serum starvation overnight. ~40 h post-
transfection, cells were harvested and fractionated into cytoplasmic and nuclear-enriched fractions. 
An anti-FLAG antibody was then added to both the pre-cleared fractions and incubated at 4 °C for 
45 min. FLAG-RhoGDI-3 was immunoprecipitated using pre-washed Protein G Dynabeads for 30 
min and eluted with sample buffer. The presence of bound ACK in each fraction was determined 
by western blotting with an anti-ACK antibody.  
Interestingly, data shown in Figure 5.8 shows that RhoGDI-3 binds to ACK almost exclusively in 
the nucleus. This suggests that ACK potentially mediates RhoGDI-3 degradation in the nucleus or 
export RhoGDI-3 out of the nucleus and promotes its degradation in the cytoplasm. These data 
also imply that ACK has a role in regulating RhoGDI-3 nuclear function, which is presently 
unknown.  
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Figure 5.8: The subcellular localization of the FLAG-RhoGDI-3-HA-ACK complex in 
HEK293T cells. FLAG-RhoGDI-3 was transfected alone or in combination with HA-ACK into 
HEK293T cells. ~24 h post-transfection, cells were serum-starved overnight. Cells were then 
harvested and fractionated into cytoplasmic and nuclear-enriched compartments. Each of the 
fractions was incubated with anti-FLAG antibody before immunoprecipitation with Protein G 
Dynabeads. Co-immunoprecipitated ACK in each fraction was assessed by blotting with anti-ACK 
antibody, as shown in the top 2 panels on the right. The expression of recombinant proteins in the 
whole cell lysate (WCL) is shown in the left hand panel, while their expression in each fraction is 
shown in the bottom 4 panels, in the right hand panel. Histone H3 and Hsp56 were used as nuclear 
and cytoplasmic markers, respectively. GAPDH was used to assess equal loading of samples 
across the wells in the total whole cell lysate. WCL: whole cell lysate; C: cytoplasmic fraction; 
N: nuclear-enriched fraction.  
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5.6 Summary  
Data presented in this chapter demonstrated that both RhoGDI-1 and -2 are located in the 
cytoplasm, whereas RhoGDI-3 can be in both cytoplasmic and nuclear-enriched fractions. 
Interestingly, the nuclear targeting of RhoGDI-3 was not regulated by its first 26 amino acids, 
contrary to previous finding (Brunet et al., 2002). Conversely, we found that these extra 26 amino 
acids are predicted to contain an NES motif and are therefore potentially involved in mediating 
nuclear export of RhoGDI-3.   
ACK was found to be in both the cytoplasm and nuclear-enriched fractions and this localization 
was shown to be kinase-independent. RhoGDI-1 and -2 localization was not affected by ACK 
under the conditions tested. Since both of the RhoGDIs can interact with ACK and localize 
exclusively in the cytoplasm, it is assumed that the ACK-RhoGDI-1 and -2 complexes must form 
in the cytoplasm.   
In a similar manner to other RhoGDIs, RhoGDI-3 localization was not affected by the presence of 
ACK. However, its nuclear levels and nuclear-cytoplasmic ratio were seen to decrease 
significantly when co-expressed with ACK. Interestingly, ACK was also found to interact with 
RhoGDI-3 exclusively in the nuclear-enriched fraction. Collectively, these data suggest that 
binding of ACK and RhoGDI-3 in the nucleus might either mediate RhoGDI-3 degradation in the 
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It was observed that co-expression with ACK resulted in decreased protein levels of RhoGDI-3. 
Since the activation of Rho-family GTPases activation is tightly regulated by the RhoGDIs, 
aberrant levels of these regulators have been found to associate with the deregulation of Rho-
family GTPases activity, which can contribute to cancer progression (Cho et al., 2019). For 
instance, low levels of RhoGDI-1 have been found to promote breast cancer development (Bozza 
et al., 2015), while high levels of RhoGDI-1 are shown to be associated with hepatocellular 
carcinoma (Wang et al., 2014). Loss of RhoGDI-2 protein levels have been shown to be highly 
associated with invasive and metastatic phenotypes in both bladder cancer and leukaemia 
(Theodorescu, 2004; Nakata et al., 2008), while increased RhoGDI-2 protein levels are found in 
breast and gastric cancer (Moon et al., 2010; Cho et al., 2014). Low levels of RhoGDI-3 have been 
observed in late stages of pancreatic cancer (de León-Bautista et al., 2016).  
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6.1 The effect of ACK on RhoGDI-1 and -2 
stability 
To investigate the effect of ACK on RhoGDIs protein levels, a stability assay was performed. This 
assay utilises cycloheximide (CHX), a protein synthesis inhibitor. Briefly, His-RhoGDI-1 and His-
RhoGDI-2 were transfected into HEK293T cells alone or in combination with ACK. Constructs 
were allowed to express for ~24 h before serum starvation overnight. Cells were then treated with 
25 µg/mL CHX, or DMSO as a control, for 2, 5 and 8 h. At various time points, cells were 
harvested and lysed. The levels of both RhoGDIs were analysed by western blotting, quantified 
with ImageJ and the relative amounts were plotted.  
As shown in Figure 6.1 and 6.2, RhoGDI-1 and -2 were relatively stable alone for up to 8 h. 
RhoGDI-1 protein levels was not affected by the presence of ACK (Figure 6.1B), while RhoGDI-
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Figure 6.1: RhoGDI-1 protein stability assay. HEK293T cells were transfected with His-
RhoGDI-1 alone or in combination with HA-ACK. Constructs were allowed to express for ~24 h 
before serum starvation overnight. Cell were then treated with DMSO or 25 µg/mL CHX for 2, 5 
and 8 h. At each time point, cells were harvested and lysed. (A) The level of RhoGDI-1 at each 
time point was identified by western blotting. (B) RhoGDI-1 protein levels in CHX-treated cells 
were quantified with ImageJ and normalised to levels in DMSO-treated cells. The protein levels, 
relative to levels at 2 h are plotted. Results are shown as average values ± SEM of three 
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Figure 6.2: RhoGDI-2 protein stability assay. HEK293T cells were transfected with His-
RhoGDI-2 alone or in combination with HA-ACK. Constructs were allowed to express for ~24 h 
before serum starvation overnight. Cells were then treated with DMSO or 25 µg/mL CHX for 2, 5 
and 8 h. At each time point, cells were harvested and lysed. (A) The level of RhoGDI-2 at each 
time point was identified by western blotting. (B) RhoGDI-2 protein levels in CHX-treated cells 
were quantified with ImageJ and normalised to the levels in DMSO-treated cells. The protein 
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6.2 The effect of ACK on RhoGDI-3 stability  
Data presented in previous chapters demonstrate that RhoGDI-3 protein levels decrease in cells 
expressing ACK. Thus, the effect of ACK on RhoGDI-3 stability was analysed. As shown in 
Figure 6.3, RhoGDI-3 protein levels were relatively stable over time but co-expression with ACK 
decreased the levels of RhoGDI-3 significantly, suggesting a role for ACK in mediating RhoGDI-











Figure 6.3: RhoGDI-3 protein stability assay. HEK293T cells were transfected with FLAG-
RhoGDI-3 alone or in combination with HA-ACK. Constructs were allowed to express for ~24 h 
before serum starvation overnight. Cells were treated with DMSO or 25 µg/mL CHX for up to 8 
h. At each time point, cells were harvested and lysed. (A) The level of RhoGDI-3 at each time 
point was identified by western blotting. (B) RhoGDI-3 protein levels in CHX-treated cells were 
quantified with ImageJ and normalised to levels in DMSO-treated cells. The protein levels, relative 
to levels at 2 h are plotted. (C) The relative levels of RhoGDI-3 at 2 and 8 h. Results are shown as 
average values ± SEM of three independent experiments, ****p<0.0001. 
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6.3 ACK mediates RhoGDI-3 degradation 
through the proteasome  
Among RhoGDI family members, ACK exclusively acts to lower the levels of RhoGDI-3. This 
could be achieved by increasing the degradation of RhoGDI-3, which could be mediated by either 
the proteasome or the lysosome. Proteasomal degradation, usually referred to as the ubiquitin-
proteasome system (UPS) involves the covalent attachment of four or more Ubiquitin (Ub) 
molecules to lysine residues on targeted proteins. These poly-ubiquitinated proteins are then 
recognised and cleaved by the 26S proteasome into small peptides, which are later digested into 
single amino acids by cytosolic proteases.  
The UPS also exists in the nucleus (nUPS) and targets misfolded nuclear proteins in order to 
maintain nuclear quality control (Mikecz, 2006). Some substrates of nUPS have been identified, 
for examples Jun, Myc, Fos, p53, STAT1, Far1 and MyoD (Ciechanover et al., 1991; Kim and 
Maniatis, 1996; Blondel et al., 2000; Floyd et al., 2001). Protein degradation through the lysosome, 
also known as autophagy, involves the sequestration of proteins directly by the lysosome, a 
membrane-bound intracellular compartment with a concentration of proteases (Mizushima et al., 
2008).  
In order to distinguish between proteasomal and lysosomal degradation, an inhibitor specific for 
each pathway was used. MG132 blocks the proteolytic activity of 26S proteasome complex, while 
Bafilomycin A1 (Baf), blocks autophagic flux by inhibiting autolysosome acidification.  
Briefly, HEK293T cells were transfected with FLAG-RhoGDI-3 alone or together with HA-ACK. 
Constructs were allowed to express for ~40 h before being treated with DMSO, 10 µM MG132 or 
1 µM Baf, individually for 6 h. Cells were then harvested, lysed and RhoGDI-3 protein levels were 
identified by western blotting. Cyclin B1 and RhoB were used as positive control for MG132 and 
Baf, respectively. The levels of RhoGDI-3 in MG132 or Baf-treated cells were quantified with 
ImageJ and normalised to levels in DMSO-treated cells.  
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As shown in Figure 6.4A, Cyclin B1 levels increase following treatment with MG132, consistent 
with previous reports that show it is degraded by the UPS (Potapova et al., 2009). The levels of 
RhoB in non-transfected cells also increased after treatment with Baf (Figure 6.4B), consistent 
with Pérez-Sala et al. (2009). RhoGDI-3 levels were seen to increased marginally in both MG132- 
and Baf-treated cell, suggesting that RhoGDI-3 can be regulated by the proteasome as well as the 
lysosome. Interestingly, however, ACK-mediated degradation of RhoGDI-3 was inhibited 
prominently by MG132 (Figure 6.4A) and not by Baf (Figure 6.4B), indicating that ACK 
stimulated the degradation of RhoGDI-3 is through the proteasome and not the lysosome. RhoB 
protein levels also increased in cells expressing RhoGDI-3 alone or when co-expressed with ACK, 









Figure 6.4: Proteasome inhibition blocks RhoGDI-3 degradation following co-expression 
with ACK. FLAG-RhoGDI-3 was transfected into HEK293T cells alone or together with HA-
ACK. Constructs were allowed to express for ~40 h. DMSO, 10 µM MG132 or 1 µM Baf were 
then added for the last 6 h before cells were harvested and lysed. The levels of RhoGDI-3 were 
identified by western blotting. Cyclin B1 and RhoB were used as positive controls for MG132 and 
Baf treatments, respectively. RhoGDI-3 protein levels in treated cells were quantified with ImageJ 
and normalised to levels in DMSO-treated cells. Relative values are shown below the blot.  
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6.4 ACK mediates degradation of RhoGDI-3 in the 
nucleus  
Data presented in section 5.5 showed that ACK interacts with RhoGDI-3 in the nuclear-enriched 
fraction and this interaction was linked to a decrease in RhoGDI-3 protein levels, especially in the 
nuclear-enriched fraction. Thus, it was hypothesized that ACK might either mediate RhoGDI-3 
degradation in the nucleus or regulate export of RhoGDI-3 out from the nucleus and stimulate its 
degradation in the cytoplasm. 
To investigate this, HEK293T cells were transfected with RhoGDI-3 either alone or in 
combination with ACK. Constructs were allowed to express for ~24 h before serum starvation 
overnight. Cells were then treated with DMSO or 25 µg/mL CHX for a further 2 and 5 h. At each 
time point, cells were fractionated into cytoplasmic and nuclear-enriched extracts. RhoGDI-3 
protein levels in each fraction were identified by western blotting, quantified with ImageJ and the 
relative amounts were plotted.  
Figure 6.5 show RhoGDI-3 protein levels are relatively stable when expressed alone, in both the 
cytoplasmic and nuclear-enriched fractions. However, the levels of RhoGDI-3 in each fraction 
decrease in cells expressing ACK, but this loss was more significant in the nuclear-enriched 
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Figure 6.5: RhoGDI-3 protein stability upon ACK co-expression in cytoplasmic and nuclear-
enriched fractions. HEK293T cells were transfected with FLAG-RhoGDI-3 alone or together 
with HA-ACK. Constructs were allowed to express for ~24 h before serum starvation overnight. 
DMSO and 25 µg/mL CHX were then added to control and treated cells, respectively. Cells were 
fractionated into cytoplasmic and nuclear-enriched compartments, 2 and 5 h post-treatments. (A) 
The levels of RhoGDI-3 in each fraction, at each time point were identified by western blotting. 
Histone H3 and GAPDH were used as nuclear and cytoplasmic markers, respectively. GAPDH 
was also used to assess equal loading of samples across the wells in the total whole cell lysate. (B) 
RhoGDI-3 protein levels in CHX-treated cells were quantified with ImageJ and normalised to 
levels in DMSO-treated cells. The protein levels at 5 h, relative to levels at 2 h are plotted. Results 
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6.5 The role of the N-terminus of RhoGDI-3 in 
regulating RhoGDI-3 stability 
6.5.1 The N-terminus of RhoGDI-3 is not necessary for 
the interaction with ACK 
Previous data presented in this work (section 6.2) show that RhoGDI-3 stability is affected when 
co-expressed with ACK and that this is not the case for both RhoGDI-1 and -2. An N-terminally 
truncated mutant of RhoGDI-3 was also shown to be more stable than the wt RhoGDI-3 (section 
5.2). Thus, it was postulated that the N-terminal extension of RhoGDI-3 is important for ACK to 
regulate RhoGDI-3 degradation. 
First, the role of the N-terminus of RhoGDI-3 in regulating the interaction between ACK and 
RhoGDI-3 was investigated by co-immunoprecipitation. Interestingly, the original construct of 
RhoGDI-3 identified by the Y2H screen contained only residues 73 to 225 of RhoGDI-3, thus it 
was likely that an N-terminal deleted mutant of RhoGDI-3 would still be able to bind to ACK.  
Data in Figure 6.6 shows that the N-terminally truncated mutant of RhoGDI-3 does indeed retain 
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Figure 6.6: The role of the N-terminus of RhoGDI-3 in regulating the interaction between 
RhoGDI-3 and ACK. HEK293T cells were transfected with FLAG-DNRhoGDI-3 alone or in 
combination with HA-ACK. Constructs were allowed to express for ~40 h before being harvested 
and lysed. Anti-FLAG antibody was then added to pre-cleared cell lysates and incubated for 45 
min. FLAG-DNRhoGDI-3 was immunoprecipitated with pre-washed Protein G Dynabeads and 
bound ACK was identified by western blot analysis. The expression of the recombinant protein in 
the whole cell lysate (WCL) is shown in the bottom 3 panels, while the co-immunoprecipitated 
(IP) samples are shown in the top two panels. In the whole cell lysate, GAPDH was used to assess 
equal loading of samples across the wells. WCL: whole cell lysate; IP: immunoprecipitation. 
 
6.5.2 ACK regulates RhoGDI-3 stability through the N-
terminus  
To further investigate the function of the N-terminus in regulating RhoGDI-3 stability especially 
in cells expressing ACK, a CHX stability assay was performed by transfecting HEK293T cells 
with either DNRhoGDI-3 or wt RhoGDI-3 alone or together with ACK.  
As shown in Figure 6.7, the DNRhoGDI-3 mutant is relatively stable alone, similar to wt RhoGDI-
3. Co-expression with ACK did not decrease DNRhoGDI-3 protein levels compared to its effect 
on wt RhoGDI-3. These data suggest that the N-terminus of RhoGDI-3 is important in regulating 
RhoGDI-3 stability in the presence of ACK. 
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Figure 6.7: The role of the N-terminus of RhoGDI-3 in regulating RhoGDI-3 stability in the 
presence of ACK. FLAG-RhoGDI-3 and FLAG-DNRhoGDI-3 were transfected into HEK293T 
cells alone or together with ACK. Constructs were allowed to express for ~24 h before serum 
starvation overnight. Cells were then treated with DMSO or 25 µg/mL CHX for 2, 5 and 8 h. At 
each time point, cells were harvested and lysed. (A) The levels of wtRhoGDI-3 and DNRhoGDI-
3 were identified by western blotting. (B) RhoGDIs protein levels in CHX-treated cells were 
quantified with ImageJ and normalised to levels in DMSO-treated cells. The protein levels, relative 
to levels at 2 h are plotted. Results are shown as average values ± SEM from three independence 
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6.6 The effect of RhoGDI interaction on ACK 
stability 
Previous data presented in this work demonstrate that ACK decreases RhoGDI-3 stability but not 
RhoGDI-1 or -2. The effect of all three RhoGDI on ACK stability was also investigated in similar 
stability assays.  
As shown in Figure 6.8, ACK is stable in the absence of exogenous RhoGDIs for over 8 h. 
However, ACK levels decreased when co-expressed with all three RhoGDIs, suggesting a role for 













Chapter 6            The effect of ACK on RhoGDI  
  protein stability 


















Figure 6.8: ACK protein stability assay. HEK293T cells were transfected with ACK alone or in 
combination with His-RhoGDI-1, His-RhoGDI-2 or FLAG-RhoGDI-3. Constructs were allowed 
to express for ~24 h before serum starvation overnight. Cells were then treated with DMSO or 25 
µg/mL CHX for 2, 5 and 8 h. At each time point, cells were harvested and lysed. The levels of 
ACK at each time point either alone or when co-expressed with (A) RhoGDI-1 or -2 and (B) 
RhoGDI-3 were identified by western blotting and quantified with ImageJ. (C) ACK protein levels 
in CHX-treated cells were quantified with ImageJ and normalised to levels in DMSO-treated cells. 
The protein levels, relative to levels at 2 h are plotted. Results are shown as average values ± SEM 
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6.7 Summary  
The data presented in this chapter show that RhoGDI-1 stability was not affected by ACK, while 
levels of RhoGDI-2 slightly increased in the presence of exogenous ACK. Cellular levels of 
RhoGDI-3, however substantially decreased in the presence of exogenous ACK. ACK was shown 
to mediate RhoGDI-3 degradation via the proteasome and this degradation occurred mainly in the 
nucleus. Furthermore, the N-terminus of RhoGDI-3 seems to be necessary for ACK-mediated 
degradation of RhoGDI-3 as an N-terminally truncated mutant of RhoGDI-3 was more stable when 
co-expressed with ACK, compared to wt RhoGDI-3.  
Interestingly, ACK was also shown to be less stable when co-expressed with any of the RhoGDIs, 
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Chapter 7  
The effect of ACK on RhoGDI-3 
ubiquitination  
 
Previous data described in Chapter 6 shows lower levels of RhoGDI-3 in the presence of ACK and 
indicated that regulation of ubiquitin-proteasome degradation could be the mechanism behind this. 
Thus, further studies to investigate the effect of ubiquitination on RhoGDI-3 stability and 
localization were undertaken and especially the role of ACK in this process. 
Ubiquitination is known to affect protein function by regulating activity, stability, localization and 
the ability to bind to partners (Jaffrey and Xu, 2011). This PTM involves the covalent attachment 
of the last amino acid of a Ub, Gly76, to one or more lysines of a target protein, through a cascade 
of three classes of enzymes: E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme 
and E3 ubiquitin ligase (Figure 7.1). An E1 activates Ub by forming a thioester-linked E1-Ub 
intermediate through the catalytic cysteine of the E1. The activated Ub is then transferred to the 
catalytic residues of an E2. The E3 is important in catalysing the transfer of Ub either directly from 
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the E2-Ub intermediate or after thioester linkage of Ub with the E3 itself, to specific protein 
substrates (Sardowski and Sarcevic, 2010).  
Unconventional substrate recognition and targeting can involve the conjugation of Ub at the free 
N-terminus of a substrate. For instance, a transcriptional activator, MyoD, has been shown to be 
ubiquitinated at its N-terminus, which then leads to its degradation (Breitschopf et al., 1998). Other 
examples of proteins modulated in this way include cell-cycle-dependent kinase inhibitor p21 
(Bloom et al., 2003), human papillomavirus 16 oncoprotein E7 (Reinstein et al., 2000), 
extracellular signal-regulated kinase 3 (ERK3) (Coulombe et al., 2004) and latent membrane 
protein 1 (LMP1) of Epstein Barr virus (Aviel et al., 2000). Interestingly, the substitution of 
internal lysine residues in some of these proteins was also shown to decrease ubiquitination and 
degradation events, suggesting that both the N-terminus and internal lysine residues might serve 






























Figure 7.1: A schematic diagram of the 
ubiquitination system. The E1 activates 
the C-terminal residue of a Ub molecule. 
The activated Ub is then attached to a 
cysteine residue in the E1 active site. The 
Ub is then transferred to the catalytic 
residue of E2. E3 facilitates the transfer of 
Ub from the E2-Ub intermediate to the 
substrate protein, resulting in poly-
ubiquitination, multi-ubiquitination or 
mono-ubiquitination. 
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Ubiquitin modifications can occur in many formats: as a single Ub attached to a single lysine 
(mono-ubiquitination, Mono-Ub), a single Ub unit on multiple lysines in the same protein (multi-
ubiquitination, Multi-Ub) or multiple Ub on the same lysine, forming ubiquitin chains (poly-
ubiquitination, poly-Ub) (Figure 7.1). This structural diversity is highly dependent on the lysine 
residues of the target proteins and the Ub itself.  
The simplest form of ubiquitination, mono-ubiquitination, is known to regulate both proteasome-
dependent (Isasa et al., 2010) and independent functions (Trotman et al., 2008). In a poly-Ub 
chain, ubiquitin chains that consist of only a single linkage, are called homotypic (Figure 7.2) and 
the most prevalent linkages are found through Lys48 or Lys63 of Ub. Different types of linkages 
confer different fates on the substrates (Sadowski and Sarcevic, 2010). For instance, a poly-Ub 
linkage through Lys48 is known to induce proteasomal degradation, whereas linkage via Lys63 
may lead to proteasome-independent fates, such as altering the subcellular localization of target 
proteins (Glickman and Ciechanover, 2002; Wang et al., 2018) or kinase activation (Deng et al., 
2000). Recently, different types of poly-Ub linkage known as heterotypic poly-Ub have also been 
found to promote both proteasome-depended and independent functions of the modified substrate 
(Meyer and Rape, 2014; Ohtake and Tsuchiya, 2016; Ohtake et al., 2018; Stolz and Dikic, 2018). 
This poly-Ub linkage can occurred through mixed linkages occurring within the same polymer 
(non-branched), or one ubiquitin molecule is modified by two or more subsequent ubiquitin 
molecule (branched).  
There is also another atypical poly-Ub linkage, which occurs through the ubiquitination of the N-
terminal methionine, commonly known as Met1-Ub or linear ubiquitination (Kirisako et al., 2006). 
The addition of Met1-Ub is catalysed by linear ubiquitin chain assembly complex (LUBAC) E3 
ligase, which is composed of three subunits; HOIL-1L, HOIP, and SHARPIN (Kirisako et al., 
2006; Gerlach et al., 2011; Tokunaga et al., 2011) to promote proteasomal degradation of the 
modified substrate. For instance, LUBAC-mediated ubiquitination of cellular FLICE-like 
inhibitory protein (cFLIP), an anti-apoptotic molecule, has been shown to stimulate TNF-induced 
cell death and inflammation (Tang et al., 2018). 
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Figure 7.2: Different types of poly-Ub linkage. Poly-Ub chains linkage can occur through the 
linear ubiquitination, a single lysine residue (homotypic) or a multiple lysine residue on a single 
Ub unit (heterotypic).  
 
RhoGDI-1 has been shown to undergo ubiquitination upon interaction with an E3 ligase known as 
GRAIL. GRAIL-mediated polyubiquitination of RhoGDI-1 has been shown to occur through a 
Lys63 linkage and this does not lead to RhoGDI-1 degradation. The potential ubiquitination site 
on RhoGDI-1 is still unknown but RhoGDI-1 ubiquitination was found to inhibit RhoA activation 
(Su et al., 2006). To date, no study has investigated RhoGDI-3 ubiquitination but there are several 
potential ubiquitination sites on RhoGDI-3, as predicted by UbiSite (Table 7.1).  





This prediction software relies on a pool of known substrate motifs for ubiquitin conjugation. The 
reliability prediction is based on the score calculated, which are categorised into 0.5 £ s ³ 1.0 
(high), 0.25 £ s ³ 0.5 (medium) and 0.125 £ s ³ 0.25 (low).   
 
Amino acid Putative ubiquitination sites Score 
73 RSLAKY K RVLLGP 0.533472 
126 DQVFVL K EGVDYR 0.530605 
134 GVDYRV K ISFKVH 0.572311 
162 RGLRVD K TVYMVG 0.580189 
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7.1 RhoGDI-3 undergoes ubiquitination  
As described in Table 7.1, there are several predicted ubiquitination sites on RhoGDI-3, suggesting 
a possibility that RhoGDI-3 undergoes ubiquitination. To test this, FLAG-RhoGDI-3 was 
transfected alone or in combination with Myc-Ub (a kind gift from Dr. Catherine Lindon, 
Department of Pharmacology, University of Cambridge) into HEK293T cells. Constructs were 
allowed to express for ~24 h before serum starvation. ~40 h post-transfection, cells were treated 
with 10 µM of MG132 or DMSO for ~6 h and then harvested. The pre-cleared lysates were 
immunoprecipitated with anti-FLAG antibody that was cross-linked to pre-washed protein G 
Dynabeads. The ubiquitination level of RhoGDI-3 was then analysed by western blotting with an 
anti-Myc antibody.  
In both the WCL and IP samples, there were “laddering” pattern of RhoGDI-3 in lanes showing 
RhoGDI-3 with Myc-Ub (lanes 2, 4, 6 and 8) compared to RhoGDI-3 alone (lanes 1, 3, 5 and 7) 
and these ubiquitin “smears” increased with MG132 treatment (lanes 4 and 8) (Figure 7.3). These 
data suggest RhoGDI-3 undergoes ubiquitination which is affected by MG132 treatment.  
There was a ~55 kDa band observed in all lanes. However, this band was thought not to be a 
ubiquitinated form of RhoGDI-3 but potentially a non-specific protein detected by the anti-Myc 
antibody. An ~43 kDa protein was also detected in the WCL samples, only when treated with 
MG132 (lanes 3 and 4) but this band was also assumed not to be a ubiquitinated form of RhoGDI-
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Figure 7.3: Ubiquitination of RhoGDI-3. FLAG-RhoGDI-3 and Myc-Ub were transfected alone 
or together, into HEK293T cells and allowed to express for ~24 h. Cells were serum-starved 
overnight before being treated with MG132 or DMSO for ~6 h. Cells were then harvested, lysed 
and immunoprecipitated using anti-FLAG antibody, ~40 h post-transfection. The ubiquitination 
level of RhoGDI-3 was assessed by western blotting using anti-Myc and anti-FLAG antibodies. 
The expression of the recombinant protein in the whole cell lysates (WCL) is shown on the left, 
while the co-immunoprecipitated (IP) samples are shown in the right hand panels. In whole cell 
lysates, GAPDH was used to assess equal loading of samples across the wells. The western blot 
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7.2 Types of RhoGDI-3 ubiquitination  
Previous data showed that RhoGDI-3 undergoes ubiquitination. The presence of high MW 
ubiquitinated species suggests that multiple ubiquitin molecules have been added to RhoGDI-3 
and this is potentially due to progressive poly-ubiquitination. Poly-Ub can occur through several 
linkages but the most prevalent linkages are found through Lys48 or Lys63. To investigate the 
type of poly-Ub linkages on RhoGDI-3, Myc-K48R and Myc-K63R Ub mutants were utilized. 
These Ub mutants prevent poly-Ub linkage via Lys48 or Lys63, respectively. The Myc-K48R-Ub 
construct was a kind gift from Dr. Catherine Lindon (Department of Pharmacology, University of 
Cambridge), while Myc-K63R-Ub was generated in this work.  
Each of the mutants was transfected alone or together with RhoGDI-3 into HEK293T cells and 
allowed to express for ~24 h before serum-starved overnight. ~40 h post-transfection, cells were 
harvested, lysed and immunoprecipitated with an anti-FLAG antibody. The ubiquitinated 
RhoGDI-3 was analysed by western blotting and the pattern observed with both K48R and K63R 
Ub mutants were compared to wt Ub. 
As shown in Figure 7.4, wt and both the Ub mutants expressed at similar levels. When co-
expressed with RhoGDI-3, the ubiquitin smears in the WCL decreased with wt Ub and K63R Ub 
but not with K48R Ub, suggesting that both wt Ub and K63R Ub molecules were incorporated 
into RhoGDI-3 but K48R Ub was not. In the IP samples, cells expressing RhoGDI-3 and wt Ub 
(lane 4) show a smear starting from ~55 and reaching to >130 kDa, suggesting that RhoGDI-3 
undergoes poly-Ub. However, the smear slightly decreased with K63R Ub (lane 6), while it 
increased substantially with K48R Ub (lane 5). Correspondingly, in the WCL, the levels of Ub 
monomer increase in cells co-expressing RhoGDI-3 and K48R Ub but not with wt Ub and K63R 
Ub. These data suggest that addition of the K48R Ub mutant to RhoGDI-3 may terminate different 
stages of poly-Ub chain formation, resulting in multiple bands that appears as a smear. Hence, 
these data suggest that RhoGDI-3 undergoes poly-ubiquitination which contain K48 linkages. 
However, the multiple bands observed in cells co-expressing RhoGDI-3 and K48R Ub could also 
suggest that RhoGDI-3 undergoes poly-Ub following multi-Ub at different lysine residues, linear 
ubiquitination, linear-Lys48 mixed poly-Ub or other heterotypic poly-Ub linkage that are highly 
dependent on Lys48.  
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Figure 7.4: Potential poly-ubiquitin-linkage of RhoGDI-3. FLAG-RhoGDI-3 was transfected 
alone or together with Myc-wt-Ub, Myc-K48R-Ub or Myc-K63R-Ub into HEK293T cells. 
Constructs were allowed to express for ~24 h before serum-starved overnight. Cells were then 
harvested, lysed and immunoprecipitated using anti-FLAG antibody, ~40 h post-transfection. The 
ubiquitination level of RhoGDI-3 was assessed by western blotting using anti-Myc antibody. The 
expression of the recombinant protein in the whole cell lysate (WCL) is shown in the left hand 
panel, while the co-immunoprecipitated (IP) samples are shown in the right hand panel. In whole 
cell lysate, GAPDH was used to assess equal loading of samples across the wells. The western blot 
shown is representative of at least three independent experiments. WCL: whole cell lysate; IP: 
immunoprecipitation. 
 
To investigate the possibility that RhoGDI-3 undergoes multi-Ub prior to Lys48 poly-Ub, a KO 
Ub mutant (Addgene plasmid # 17603, a gift from Prof. Ted Dawson) was used in which all 7 
lysine residues have been mutated to arginines. This KO Ub mutant retains the ability to bind to a 
substrate through Gly76 and can be incorporated as a single or multiple-mono-Ub molecules onto 
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a targeted protein. However, unlike wt Ub, it cannot form the homotypic and heterotypic poly-Ub 
chain (Figure 7.2). This KO mutant would not prevent the possibility of RhoGDI-3 undergoing 
atypical linear poly-ubiquitination (Figure 7.2).  
Briefly, HEK293T cells were transfected with FLAG-RhoGDI-3, HA-wt-Ub and HA-KO-Ub 
either alone or in combination. ~24 h post-transfection, cells were serum-starved overnight. Cells 
were then harvested, lysed and immunoprecipitated with anti-FLAG antibody. Any differences in 
RhoGDI-3 ubiquitination with wt and the KO Ub mutant were identified by western blotting with 
an anti-Myc antibody.  
As shown in Figure 7.5, cells expressing KO Ub alone seem to have slightly less KO Ub 
incorporated into the ubiquitin smear in the WCL (lane 3) compared to the wt Ub (lane 2). 
Consistent with this, free KO Ub was also visible, suggesting that this mutant was linked to 
substrate less often as expected. The same pattern is seen in the WCL samples when RhoGDI-3 is 
present. In the IP samples, the same pattern of ubiquitin smears can be observed either with wt 
(lane 5) or KO Ub (lane 6), implying that both wt and KO Ub can still be added to RhoGDI-3. 
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Figure 7.5: The ubiquitination structures on RhoGDI-3. FLAG-RhoGDI-3 was transfected 
alone or together with HA-wt-Ub or HA-KO-Ub into HEK293T cells. Constructs were allowed to 
express for ~24 h before serum-starved overnight. Cells were then harvested, lysed and 
immunoprecipitated using anti-FLAG antibody, ~40 h post-transfection. The ubiquitination level 
of RhoGDI-3 was assessed by western blotting using anti-HA antibody. The expression of the 
recombinant protein in the whole cell lysate (WCL) is shown on the left panel, while the co-
immunoprecipitated (IP) samples are shown on the right. In whole cell lysate, GAPDH was used 
to assess equal loading of samples across the wells. The western blot shown is representative of at 
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7.3 Ubiquitination promote RhoGDI-3 
degradation 
The previous data shows that RhoGDI-3 potentially undergoes poly-Ub via Lys48 linkages or 
linear ubiquitination. A poly-Ub linkage through Lys48 has been shown to induce proteasomal 
degradation of target proteins (Glickman and Ciechanover, 2002). Thus, to further characterize 
any role for ubiquitination in RhoGDI-3 stability, HEK293T cells were transfected with FLAG-
RhoGDI-3 alone or in combination with either Myc-wt-Ub or Myc-K48R-Ub before being 
subjected to a CHX stability assay. Constructs were allowed to express for ~24 h prior to serum 
starvation overnight. ~40 h post-transfection, cells were treated with 25 µg/mL CHX or DMSO 
for 2, 5 and 8 h. At various time points, cells were harvested, lysed and analysed by western 
blotting. The levels of RhoGDI-3 in CHX-treated cells were quantified with ImageJ and 
normalised to levels in DMSO-treated cells. Relative values for RhoGDI-3 protein levels were 
then plotted in a graph.  
Figure 7.6 shows that RhoGDI-3 undergoes K48-poly-Ub-mediated degradation as RhoGDI-3 
protein levels significantly decreased in cells expressing wt Ub but not in the presence of K48R 
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Figure 7.6: The role of ubiquitination in promoting RhoGDI-3 degradation. FLAG-RhoGDI-
3 was transfected alone or together with Myc-wt-Ub or Myc-K48R-Ub in HEK293T cells. ~24 h 
post-transfection, cells were serum-starved overnight. ~40 h post-transfection, cells were treated 
with DMSO or 25 µg/mL CHX for 2, 5 and 8 h. At each time point, cells were harvested and lysed. 
(A) The level of RhoGDI-3 at each time point was identified by western blotting. (B) RhoGDI-3 
protein levels in CHX-treated cells were quantified with ImageJ and normalised to levels in 
DMSO-treated cells. The protein levels, relative to levels at 2 h are plotted. Results are shown as 




RhoGDI-3 + wt Ub 
RhoGDI-3 + K48R Ub 
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7.4 The effect of ACK on RhoGDI-3 
ubiquitination  
7.4.1 ACK decreases the levels of RhoGDI-3 
ubiquitination  
Phosphorylation of the tumour suppressor Wwox by ACK results in rapid dissociation of the ACK-
Wwox complex and the subsequent induction of Wwox poly-ubiquitination and degradation 
(Mahajan et al., 2005). ACK has also been shown to promote EGFR ubiquitination and 
degradation and this is mediated by its UBA domain (Shen et al., 2006). Although in this case, 
ACK does not phosphorylate RhoGDI proteins, it was speculated that ACK could play a role in 
changing the ubiquitination modification of RhoGDI-3 and therefore regulate RhoGDI-3 
degradation.  
To identify the effect of ACK on RhoGDI-3 ubiquitination, HEK293T cells were transfected with 
FLAG-RhoGDI-3, Myc-Ub and HA-ACK alone or in combination. Constructs were allowed to 
express for ~24 h before serum starvation overnight. Cells were harvested and lysed, ~40 h post-
transfection. The pre-cleared lysates were then immunoprecipitated with anti-FLAG antibody. The 
ubiquitination level of RhoGDI-3 was identified by western blotting with an anti-Myc antibody.  
Figure 7.7 shows that co-expression of RhoGDI-3 with ACK ablates RhoGDI-3 ubiquitination. 
Levels of ubiquitination are undetectable, although there are significantly lower levels of RhoGDI-
3 as well. This suggests that ACK promotes RhoGDI-3 degradation either by interfering with 
ubiquitin attachment to RhoGDI-3 or by binding to the Ub-RhoGDI-3 complex and promoting its 
recognition by the UPS.  
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Figure 7.7: The effect of ACK on RhoGDI-3 ubiquitination. HEK293T cells were transfected 
with FLAG-RhoGDI-3, Myc-Ub and HA-ACK either alone or in combination. Constructs were 
allowed to express for ~24 h before serum starvation overnight. Cells were then harvested and 
lysed, ~40 h post-transfection. The pre-cleared supernatant was immunoprecipitated with anti-
FLAG antibody. The ubiquitination level of RhoGDI-3 was identified by western blotting with an 
anti-Myc antibody. The expression of the recombinant protein in the whole cell lysate (WCL) is 
shown on the left panel, while the co-immunoprecipitated (IP) samples are shown on the right. In 
whole cell lysate, GAPDH was used to assess equal loading of samples. The western blot shown 
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7.4.2 The effect of ACK on the subcellular distribution 
of ubiquitinated RhoGDI-3 
Previous data described in sections 5.5 and 6.4 show ACK interacts with and mediates RhoGDI-
3 degradation predominantly in the nucleus. Since ACK has been shown to decrease the 
ubiquitination of RhoGDI-3, it is possible that this event occurs in the nucleus. 
 
To test this, HEK293T cells were transfected with FLAG-RhoGDI-3, Myc-Ub and HA-ACK 
alone or together. Constructs were allowed to express for ~24 h before serum starvation 
overnight. Cells were then harvested and fractionated into cytoplasmic and nuclear-enriched 
fractions. Each of the pre-cleared fractions were immunoprecipitated with an anti-FLAG 
antibody. The presence of ubiquitinated RhoGDI-3 in each fraction was identified by western 
blotting with anti-Myc and anti-FLAG antibodies. 
 
Figure 7.8 shows the ubiquitinated forms of RhoGDI-3 were found in both the fractions, 
but predominantly in the cytoplasm. The levels of ubiquitinated proteins in general (Figure 
7.8A) significantly decreased in cells co-expressing RhoGDI-3, Ub and ACK compared to 
previous data and this was probably because the proportion of exogenous Ub relative to 
endogenous Ub varied between experiments. The levels of ubiquitinated proteins were shown 
to decrease most significantly in the nucleus (Figure 7.8B) compared to the cytoplasm. 
Interestingly, the level of ubiquitinated RhoGDI-3 in the immunoprecipitated samples was 
almost completely absent in both the fractions when co-expressed with ACK, suggesting that 
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Figure 7.8: The effect of ACK on RhoGDI-3 ubiquitination in the cytoplasmic and nuclear- 
enriched fractions. FLAG-RhoGDI-3 and Myc-Ub were transfected alone or in combination 
with HA-ACK into HEK293T. Constructs were allowed to express for ~24 h before serum 
starvation overnight. ~40 h post-transfection, cells were harvested and fractionated into 
cytoplasmic and nuclear-enriched fractions. Each of the extracts were immunoprecipitated with 
anti-FLAG antibody. The presence of ubiquitinated RhoGDI-3 in each of the fraction was 
identified by western blotting. (A) Protein levels in the whole cell lysate (WCL). GAPDH was 
used to assess the equal loading of samples. (B) Protein levels in each fraction are shown on the 
left panel with GAPDH and Histone H3 were used as cytoplasmic and nuclear markers, 
respectively. The ubiquitination levels of RhoGDI-3 in immunoprecipitated samples are shown 
on the right panel. The western blot shown is representative of at least three independent 
experiments. WCL: whole cell lysate; IP: immunoprecipitation. 
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7.4.3 The role of the UBA domain of ACK in regulating 
RhoGDI-3 ubiquitination  
ACK has been shown to decrease the overall levels of RhoGDI-3 protein and its ubiquitination. 
This could be achieved potentially by ACK binding to Ub-RhoGDI-3 via is UBA domain and 
enhancing RhoGDI-3 proteasomal degradation. The UBA domain of ACK has been found to 
facilitate the interaction with ubiquitinated proteins and regulates EGFR ubiquitination and 
degradation (Shen et al., 2007). Hence, ACK may regulate RhoGDI-3 degradation through 
modulation of its ubiquitination via the UBA domain. To determine the function of the UBA 
domain of ACK in regulating RhoGDI-3 degradation, a point mutation, S985N, was introduced 
into the UBA domain of ACK (HA-S985N-ACK), which has been shown previously to prevent 
ACK binding to ubiquitin-conjugated proteins (Tin et al., 2010).  
Firstly, the efficacy of the ACK S985N mutation was assessed by investigating Ub binding ability 
compared to wt ACK. Briefly, Myc-Ub was transfected alone or in combination with HA-wt-ACK 
or HA-S985N-ACK. Constructs were allowed to express for ~40 h before being harvested and 
lysed. The pre-cleared lysates were then immunoprecipitated with anti-Myc antibody and co-
immunoprecipitated ACK detected by western blotting with anti-HA antibody.  
Data shown in Figure 7.9 shows that the ACK S985N mutant was unable to interact with 
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Figure 7.9: Co-immunoprecipitation of Ub with ACK wt and ACK S985N. Myc-Ub was 
transfected alone or together with HA-wt-ACK or HA-S985N-ACK into HEK293T cells. 
Constructs were allowed to express for ~40 h before being harvested and lysed. The pre-cleared 
lysates were then immunoprecipitated with anti-Myc antibody. Bound ACK was detected by 
western blotting with an anti-HA antibody. The expression of the recombinant protein in the whole 
cell lysate (WCL) is shown on the left panel, while the co-immunoprecipitated (IP) samples are 
shown on the right. In whole cell lysate, GAPDH was used to assess equal loading of samples 
across the wells. WCL: whole cell lysate; IP: immunoprecipitation. 
 
The ability of ACK S985N to interact with RhoGDI-3 was investigated by co-expressing FLAG-
RhoGDI-3 alone or together with the HA-wt-ACK or HA- S985N-ACK in HEK293T cells. Cells 
were harvested and lysed ~40 h post-transfection. FLAG-RhoGDI-3 was then immunoprecipitated 
with an anti-FLAG antibody and bound ACK was identified by western blotting with an anti-HA 
antibody.  
Data shown in Figure 7.10 demonstrates that ACK S985N was still able to interact with RhoGDI-
3. However, the levels of RhoGDI-3 also increased when co-transfected with ACK S985N 
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compared to wt ACK, suggesting that the UBA domain of ACK might be involved in regulating 









Figure 7.10: Co-immunoprecipitation ACK S985N with RhoGDI-3. FLAG-RhoGDI-3, HA-
wt-ACK or HA-S985N-ACK were transfected alone or together into HEK293T cells. Constructs 
were allowed to express for ~40 h before being harvested and lysed. Anti-FLAG antibody was 
then added to the pre-cleared supernatant and FLAG-RhoGDI-3 was immunoprecipitated with a 
set of pre-washed Protein G Dynabeads. Bound ACK S985N was detected by western blotting 
with an anti-HA antibody. The expression of the recombinant protein in the whole cell lysate 
(WCL) is shown in the bottom 3 panels, while the co-immunoprecipitated (IP) samples are shown 
in the top 2 panels. In the whole cell lysate, GAPDH was used to assess the equal loading of 
samples. WCL: whole cell lysate; IP: immunoprecipitation. 
 
Next, the effect of the S985N mutation on RhoGDI-3 ubiquitination was investigated by co-
expressing FLAG-RhoGDI-3, Myc-Ub and HA-S985N-ACK in HEK293T cells. ~40 h post-
transfection, FLAG-RhoGDI-3 was immunoprecipitated with anti-FLAG antibody and the levels 
of ubiquitinated RhoGDI-3 was identified by western blotting with an anti-Myc antibody. 
Co-expression with ACK S985N did not rescue RhoGDI-3 ubiquitination, on the contrary Ub-
RhoGDI-3 levels were very similar to co-expression with wt ACK (Figure 7.11), suggesting that 
although ACK S895N can sustain RhoGDI-3 protein levels, this is not through regulating levels 
of RhoGDI-3 ubiquitination.   
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Figure 7.11: The effect of ACK S985N on RhoGDI-3 ubiquitination. HEK293T cells were 
transfected with FLAG-RhoGDI-3, Myc-Ub, HA-wt-ACK and HA-S985N-ACK. Constructs were 
allowed to express for ~24 h before serum starvation overnight. Cells were harvested and lysed, 
~40 h post-transfection. The pre-cleared supernatant was immunoprecipitated with anti-FLAG 
antibody. The ubiquitination level of RhoGDI-3 was identified by western blotting with an anti-
Myc antibody. The expression of the recombinant protein in the whole cell lysate (WCL) is shown 
on the left panel, while the co-immunoprecipitated (IP) samples are shown on the right. In whole 
cell lysate, GAPDH was used to assess equal loading of samples. The western blot shown is 










FLAG-RhoGDI-3 ⎯ ＋ ＋ ＋ ＋ ＋ ＋
HA-wt-ACK ⎯ ⎯ ⎯ ＋ ＋ ⎯ ⎯
HA-S985N-ACK ⎯ ⎯ ⎯ ⎯ ⎯ ＋ ＋




















FLAG-RhoGDI-3 ⎯ ＋ ＋ ＋ ＋ ＋ ＋
HA-wt-ACK ⎯ ⎯ ⎯ ＋ ＋ ⎯ ⎯
HA-S985N-ACK ⎯ ⎯ ⎯ ⎯ ⎯ ＋ ＋
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7.5 Summary  
RhoGDI-3 has been shown to undergo ubiquitination but the type of Ub conjugation is still 
undefined due to inconsistency of the data obtained. Analysis in cells utilising several Ub mutants 
suggest that RhoGDI-3 undergoes Lys48 poly-Ub, linear ubiquitination or linear-Lys48 mixed 
poly-Ub. A poly-Ub linkage through Lys48 has been shown to promote RhoGDI-3 degradation.  
Co-expression with ACK completely abolished RhoGDI-3 ubiquitination. This was very clear 
even though there were lower levels of RhoGDI-3. Co-expression with ACK S985N, a UBA 
domain mutant, did not rescue RhoGDI-3 ubiquitination but the UBA domain of ACK is still 
potentially involved in regulating RhoGDI-3 stability.  
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The effect of RhoGDIs on their target  
 
8.1 Identification of RhoGDIs target 
There is a total of ~145 RhoGEFS and RhoGAPs in mammalian cells but only three RhoGDIs and 
their role is still not fully understood (Rocks et al., 2018). There is growing evidence showing the 
functions of the RhoGDIs not only as negative regulators of Rho GTPases but also as chaperones 
to target the Rho GTPases to specific subcellular compartments such as the Golgi (Brunet et al., 
2002). The RhoGDI-Rho protein complex also helps to stabilize the Rho proteins and prevents 
them from being targeted for proteasomal degradation (Ho et al., 2008). RhoGDI-1 depletion has 
been found to increase the accumulation of newly synthesized Rho-family proteins in the 
endoplasmic reticulum, where post-translational modification occurs, again indicating a role for 
RhoGDI-1 as a chaperone (Boulter et al., 2010). Besides functioning to stabilize the inactive GDP-
bound form of the small GTPases, RhoGDIs have also been shown to be necessary for maintaining 
the GTP-bound state of certain small GTPases. For instance, RhoGDI-1 needs to bind to active 
Cdc42 to allow for Cdc42-induced cell proliferation and transformation (Lin et al., 2003). The 
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RhoGDI-1-Rac1 interaction is also crucial for stimulating NADPH oxidase system in neutrophils 
(Abo et al., 1991). In contrast, the RhoGDI-1-Rac2 complex was found to abrogate the activation 
of NADPH oxidase (Abo et al., 1994), suggesting that RhoGDI-1 target specific Rho-family 
proteins for specific functions.  
Studies to date with RhoGDIs usually focus on the interaction between the ‘typical’ or ‘classical’ 
small GTPases such as RhoA, Rac1 and Cdc42 with RhoGDI-1 or RhoGDI-2. Less is known about 
the third member of the family, RhoGDI-3, and its interacting partners, although RhoGDI-3 has 
been shown to target RhoB and RhoG to endomembranes (Zalcman et al., 1996). To allow a more 
thorough understanding of RhoGDI function, a systematic study has been undertaken here to 
determine all possible Rho-family GTPases that interact with the RhoGDIs. These data should 
help to elucidate any functional differences between the three RhoGDIs.   
A panel of expression constructs encoding all V5-tagged Rho-family GTPases (Table 8.1) was 
already available in the lab. Through co-immunoprecipitation, the interaction between each of the 
RhoGDIs and Rho-family GTPases were determined.  
Co-immunoprecipitations were performed to verify known interactions and also determine any 
new targets of the RhoGDIs. Analysis of most of the interactions between RhoGDI-1 or -2 and the 
Rho-family GTPases were performed using His-tagged RhoGDI-1 or -2 and cobalt-coated 
magnetic beads while RhoGDI-3 interactions were analysed with FLAG-tagged RhoGDI-3 and 
Protein G-coated magnetic beads. However, FLAG-tagged RhoGDI-1 and -2 were used to identify 
any interactions with RhoD, RhoF, Wrch2, Miro1, Miro2, RhoH and Rnd2 due to non-specific 
interaction between these Rho-family GTPases and the cobalt-coated magnetic beads.  
Briefly, His-tagged or FLAG-tagged RhoGDIs were co-expressed with V5-tagged versions of all 
Rho-family GTPases in HEK293T cells. Constructs were allowed to express for ~40 h before being 
harvested and lysed with mammalian lysis buffer (Table 2.16). The lysates were then incubated 
with cobalt-coated magnetic beads or anti-FLAG-coated Protein G Dynabeads for ~1 h. The 
precipitated proteins were eluted from the beads with sample buffer (Table 2.16) and analysed by 
western blotting. RalB was included as a negative control.  
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Table 8.1: List of Rho-family small GTPases used in the screening 
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8.1.1 Expression trials of Rho-family GTPases 
Expression and co-expression trials were carried out to determine the appropriate conditions to co-
express all combination of proteins. This was achieved for all combinations (data not shown) 
except for the RhoBTB subfamily (Figure 8.1A) and Rnd3 (Figure 8.2) where expression could 
not be achieved in the presence of any of the RhoGDIs. Additionally, RhoGDI-2 could not be co-
expressed with Miro2 (Figure 8.1B), while Rnd1 are not expressed when co-transfected with 
















Figure 8.1: The expression trials of the RhoBTB 
subfamily and Miro2 with all three RhoGDIs. (A) 
Each of the V5-tagged RhoBTB subfamily members 
and (B) V5-tagged Miro2 and were transfected 
alone or together with His- or FLAG-RhoGDI-1, 
His- or FLAG-RhoGDI-2 or FLAG-RhoGDI-3 into 
HEK293T cells. Constructs were allowed to express 
for ~40 h before being harvested and lysed. The 
expression of recombinant proteins was identified 
by western blotting. 
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Figure 8.2: The expression trials of the Rnd subfamily with all three RhoGDIs. Each of the 
V5-tagged Rnd subfamily members were transfected alone or together with His-RhoGDI-1, His-
RhoGDI-2 or FLAG-RhoGDI-3 into HEK293T cells. Constructs were allowed to express for ~40 
h before being harvested and lysed. The expression of recombinant proteins was identified by 
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8.1.2 RhoGDI-1 targets 
8.1.2.1 RhoGDI-1 binding to classical Rho-family members 
RhoGDI-1 is ubiquitously expressed and has been shown previously to form complexes with 
RhoA, RhoC, Rac1, Rac2, Cdc42 and RhoG (Olofsson, 1999; Elfenbein et al., 2009). All of the 
Rho-family GTPases identified as RhoGDI-1 targets to date are known regulators of actin 
cytoskeletal reorganization and play crucial roles in controlling cell proliferation and migration 
(Gómez Del Pulgar et al., 2008).  
Co-immunoprecipitations were performed to verify the known interactions and also identify any 
new targets for RhoGDI-1. Briefly, His-RhoGDI-1 were co-expressed with V5-tagged versions of 
all 10 classical members of the Rho-family GTPases. Constructs were allowed to express for ~40 
h before being harvested and incubated with cobalt-coated magnetic beads. The precipitated 
proteins were analysed by western blotting.  
As shown in Figure 8.3, RhoGDI-1 can be seen to interact with every member of the Rac and Rho 
subfamilies except for RhoB. These data confirmed the interaction profile for RhoGDI-1 that was 
already known and validated Rac3 as a RhoGDI-1 partner for the first time. Despite binding to 
Cdc42, RhoGDI-1 failed to interact with the other classical members of the Cdc42 subfamily; 
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Figure 8.3: The interaction of RhoGDI-1 with the typical Rho-family GTPases. HEK293T 
cells were transfected with His-RhoGDI-1 alone or together with V5-tagged (A) RhoA, RhoB, 
RhoC, (B) Rac1, Rac2, Rac3, RhoG, (C) Cdc42, TC10 and (D) TCL. Constructs were allowed to 
express for ~40 h. Cells were then harvested, lysed and precipitated with cobalt-coated magnetic 
beads. The precipitated proteins were eluted from the beads and identified by western blotting. 
RalB and Rac3 (only for TCL interaction) were used as negative and positive controls, 
respectively. The expression of the recombinant protein in the whole cell lysate (WCL) is shown 
in the bottom 3 panels, while the co-immunoprecipitated (IP) samples are shown in the top two 
panels. GAPDH was used to assess the equal loading of samples across the wells. Results are 
representative of at least two independent experiments. WCL: whole cell lysate; IP: 
immunoprecipitation. (A) the Rho subfamily, (B) the Rac subfamily, (C and D) the Cdc42 
subfamily (Cdc42, TC10 and TCL). 
A B 
C D 
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8.1.2.2 RhoGDI-1 binding to non-classical Rho-family 
members 
Very few studies have been undertaken to identify any interactions between RhoGDI-1 and the 
atypical Rho-family GTPases. Here, co-immunoprecipitation was performed by transfecting 
HEK293T cells with the 9 non-classical Rho-family GTPases for which co-expression was 
achieved alone or together with His- or FLAG-RhoGDI-1. The lysates were precipitated with 
cobalt-coated magnetic beads or anti-FLAG antibody coupled to Protein G Dynabeads. Bound 
Rho-family GTPases were determined by western blotting with anti-V5 antibody.  
The remaining members of the Cdc42 subfamily, Wrch1 (Figure 8.4A) and Wrch2 (Figure 8.4B) 
failed to interact with RhoGDI-1. This result shows that Cdc42 is the sole target for RhoGDI-1 
within Cdc42 subfamily.  
RhoGDI-1 also did not bind to RhoD (Figure 8.4C). RhoGDI-1 potentially bound to RhoF 
although a low level of precipitated RhoF was seen in the absence of RhoGDI-1 (Figure 8.4D).  
There was no interaction detected between RhoGDI-1 and RhoH (Figure 8.4G), despite being 
observed in a previous study (Li et al., 2002). No interactions were identified for Rnd1 and 2 
(Figures 8.4E and G) and the Miro subfamilies (Figures 8.4F and G), suggesting that other 
RhoGDIs or alternative mechanisms are involved in mediating the activity of these non-classical 
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Figure 8.4: The interaction of RhoGDI-1 with the atypical Rho-family GTPases. HEK293T 
cells were transfected with His- or FLAG-RhoGDI-1 alone or together with V5-tagged (A) Wrch1, 
(B) Wrch2, (C) RhoD, (D) RhoF, (E) Rnd1, (F) Miro1, (G) Rnd2, Miro2 and RhoH. Constructs 
were allowed to express for ~40 h before being harvested, lysed and precipitated with cobalt-
coated beads or anti-FLAG antibody coupled to Protein G Dynabeads. The precipitated proteins 
were identified by western blotting. RalB and Rac3 or RhoC were used as negative and positive 
controls, respectively. The expression of the recombinant protein in the whole cell lysate (WCL) 
is shown in the bottom 3 or 4 panels, while the co-immunoprecipitated (IP) samples are shown in 
the top two or 3 panels. GAPDH was used to assess the equal loading of samples across the wells. 
Results are representative of at least two independent experiments. WCL: whole cell lysate; IP: 
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8.1.3 RhoGDI-2 targets 
8.1.3.1 RhoGDI-2 binding to classical Rho-family GTPases 
The second member of the RhoGDI family is RhoGDI-2 (also known as D4/Ly-GDI). RhoGDI-2 
is selectively expressed in hematopoietic cells such as B and T lymphocytes (Scherle et al., 1993). 
Although the full target profile for RhoGDI-2 still remains unclear, it has been shown to bind to 
Rac2, RhoA, RhoC and, to a lesser extent, Rac1, Rac3, Cdc42 and RhoG (Scheffzek et al., 
2000; Moissoglu et al., 2009; Griner et al., 2015). 
All potential interactions for RhoGDI-2 were analysed by co-immunoprecipitation and the 
precipitated proteins were analysed by western blotting. RalB was included as negative control. 
Figure 8.5 shows Rac1, Rac3 and RhoC are targets of RhoGDI-2. No binding was seen with RhoB, 
Rac2, TC10 and TCL. No binding was also observed with RhoA, Cdc42 or RhoG in this system, 
despite being reported in previous studies (Scherle et al., 1993; Platko et al., 1995; Adra et al., 
1993). This maybe because RhoGDI-2 is reported to have a lower affinity than RhoGDI-1 for Rho-
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Figure 8.5: The interaction of RhoGDI-2 with the typical Rho-family GTPases. His-RhoGDI-
2 was transfected alone into HEK293T cells or together with V5-tagged (A) RhoA, RhoB, RhoC, 
(B) Rac1, Rac2, Rac3, RhoG, (C) Cdc42, TC10 and TCL. Constructs were allowed to express for 
~40 h before being harvested and lysed. The pre-cleared cell lysates were then precipitated with 
cobalt-coated magnetic beads. The precipitated Rho proteins were then eluted from the beads and 
identified by western blotting. RalB and Rac3 were used as negative and positive controls, 
respectively. The expression of the recombinant protein in the whole cell lysate (WCL) is shown 
in the bottom 3 panels, while the co-immunoprecipitated (IP) samples are shown in the top two 
panels. GAPDH was used to assess the equal loading of samples across the wells. Results are 
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8.1.3.2 RhoGDI-2 binding to non-classical Rho-family 
GTPases 
Similarly to RhoGDI-1, fewer studies have been reported which analyse the interaction between 
RhoGDI-2 and the atypical Rho-family GTPases.  
Thus, all possible interactions were analysed by co-immunoprecipitation with either cobalt-coated 
magnetic beads or anti-FLAG antibody coupled to Protein G Dynabeads. Any co-precipitated Rho-
family GTPases were identified by western blotting.  
Figure 8.6 shows that RhoGDI-2 failed to interact with any of the atypical Rho-family GTPases, 
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Figure 8.6: The interaction of RhoGDI-2 with the atypical Rho-family GTPases. HEK293T 
cells were transfected with His- or FLAG-RhoGDI-2 alone or in combination with V5- tagged (A) 
Wrch1 (B) Wrch2, Rnd2, RhoH, (C) RhoD (D) RhoF, (E) Rnd1 and (F) Miro1. Constructs were 
allowed to express for ~40 h before harvested and lysed. The cell lysates were then precipitated 
with cobalt-coated magnetic beads or anti-FLAG antibody cross-linked to pre-washed protein G 
Dynabeads. The precipitated proteins were then identified by western blotting. RalB and Rac3 or 
RhoC were used as negative or positive controls. The expression of the recombinant protein in the 
whole cell lysate (WCL) is shown in the bottom 3 or 4 panels, while the co-immunoprecipitated 
(IP) samples are shown in the top two or 3 panels. GAPDH was used to assess the equal loading 
of samples across the wells. Results are representative of at least two independent experiments. 
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8.1.4 RhoGDI-3 targets 
8.1.4.1 RhoGDI-3 binding to classical Rho-family GTPases 
The final member of the RhoGDI family proteins is RhoGDI-3, which is widely expressed but is 
found at particularly high levels in brain, lung, kidney and testis (Zalcman et al., 1996). Although 
less well studied than the other two members of the family, some RhoGDI-3 interacting Rho-
family proteins have been identified. In a previous Y2H screen, mouse RhoGDI-3 was shown to 
interact with RhoB and RhoG but not with RhoA, RhoC, or Rac1 proteins (Zalcman et al., 1996). 
An alternative study using purified proteins identified interactions between human RhoGDI-3 and 
both RhoA and Cdc42 but not with Rac1 or Rac2 (Adra et al., 1997).  
To verify the interaction seen in previous studies and also identify all the possible targets of 
RhoGDI-3, co-immunoprecipitation was undertaken by co-expressing FLAG-RhoGDI-3 with V5-
tagged versions of all 10 classical Rho-family GTPases into HEK293T cells. The pre-cleared cell 
lysates were incubated with beads cross-linked to an anti-FLAG antibody for ~1 h at 4°C and the 
precipitated proteins were then analysed by western blotting.  
RhoGDI-3 was found to interact with 7 out of 10 classical Rho-family GTPases. The interactions 
with RhoA, RhoB (Figure 8.7A) and RhoG (Figure 8.7B) (data obtained from Ms. Tiffany Fung, 
under supervision of the candidate) that had been observed previously were confirmed, along with 
4 novel interactions: RhoC (Figure 8.7C), Rac1, Rac2 and Rac3 (Figure 8.7D). As shown in Figure 
8.7E, no interaction has been observed between RhoGDI-3 and Cdc42, in contrast to earlier studies 
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Figure 8.7: The interaction of RhoGDI-3 with the typical Rho-family GTPases. FLAG-
RhoGDI-3 was transfected alone or together with V5-tagged (A) RhoA, RhoB, (B) RhoG, (C) 
RhoC, (D) Rac1, Rac2, Rac3, (E) Cdc42, TC10 and TCL into HEK293T cells. Constructs were 
allowed to express for ~40 h before being harvested, lysed and immunoprecipitated with anti-
FLAG antibody cross-linked to pre-washed Protein G Dynabeads. The precipitated proteins were 
identified by western blotting. RalB was used as a negative control. The expression of the 
recombinant protein in the whole cell lysate (WCL) is shown in the bottom 3 panels, while the co-
immunoprecipitated (IP) samples are shown in the top two panels. GAPDH was used to assess the 
equal loading of samples across the wells. Results are representative of at least two independent 
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8.1.4.2 RhoGDI-3 binding to non-classical Rho-family 
GTPases 
Similarly to the other two GDIs, the interactions between RhoGDI-3 and the atypical Rho-family 
GTPases have not been studied, with the exception for RhoH (Li et al., 2002). Thus, co-
immunoprecipitation was performed by co-expressing FLAG-RhoGDI-3 with 9 the atypical 
members of Rho-family GTPases in HEK293T cells. The pre-cleared cell lysates were then 
immunoprecipitated with anti-FLAG antibody cross-linked to pre-washed Protein G Dynabeads. 
Bound Rho-family GTPases were analysed by western blotting.  
The interaction with RhoH (Figures 8.8A and B) that had been observed previously was confirmed 
(Li et al., 2002). Interestingly, RhoGDI-3 was found to interact for the first time with Wrch2 
(Figure 8.8A), RhoD (Figure 8.8B), RhoF (Figure 8.8C), Rnd2 (Figure 8.8D) and Miro2 (Figure 
8.8F). These novel interactions found in this screen are exclusive for RhoGDI-3 and are not seen 
with the other GDIs, suggesting a novel role for RhoGDI-3 in regulating atypical Rho-family 
GTPases.  
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Figure 8.8: The interaction of RhoGDI-3 with the atypical Rho-family GTPases. HEK293T 
cells were transfected with FLAG-RhoGDI-3 alone or in combination with V5-tagged (A) Wrch1, 
Wrch2, RhoH, (B) RhoD, (C) RhoF, (D) Rnd2 (E) Miro1 and (F) Miro2. ~40 h post-transfection, 
cells were harvested and lysed. The pre-cleared cell lysates were then immunoprecipitated with 
anti-FLAG antibody cross-linked to pre-washed Protein G Dynabeads, for ~1 h. The precipitated 
proteins were then analysed by western blotting. RalB was used as a negative control. The 
expression of the recombinant protein in the whole cell lysate (WCL) is shown in the bottom 3 or 
4 panels, while the co-immunoprecipitated (IP) samples are shown in the top two or 3 panels. 
GAPDH was used to assess the equal loading of samples across the wells. Results are 
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8.1.5 The interaction of the RhoGDIs with endogenous 
Rho-family GTPases 
All the data presented so far utilised exogenous expression of Rho-family GTPases. Thus, some 
of the interactions observed in this screen, especially between RhoGDI-3 with its novel targets; 
RhoC and Rac1 were verified in parallel using endogenous Rho-family GTPases. Despite being 
reported in previous studies, the interactions between RhoGDI-1 or -2 and RhoA, RhoC or Rac1 
were also validated using endogenous GTPases. It was still necessary to use the exogenously 
expressed RhoGDI proteins in these experiments due to lack of available specific antibodies 
(section 3.3.1).  
Briefly, His-RhoGDI-1, His-RhoGDI-2 and FLAG-RhoGDI-3 were transfected into HEK293T 
cells and allowed to express for ~40 h. Cells were then harvested and lysed. The pre-cleared cell 
lysates were precipitated with either cobalt-coated magnetic beads or anti-FLAG antibody coupled 
to Protein G Dynabeads. The presence of endogenous Rac1, RhoA or RhoC in co-
immunoprecipitated (co-IP) samples were identified using antibodies specific for each Rho-family 
GTPases by western blotting.  
All three exogenously expressed RhoGDI proteins interacted with endogenous Rac1 (Figure 8.9) 
and RhoC (Figure 8.10). Whereas, only RhoGDI-1 and RhoGDI-3 interacted with endogenous 
RhoA (Figure 8.11) as shown previously in Figures 8.3A and 8.7A. Confirmation of these 
interactions with endogenous Rho-family GTPases also goes some way to validating the 
exogenous system used in the full screen. These data also validate the novel targets of RhoGDI-3, 
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Figure 8.9: The interaction of exogenous RhoGDIs with endogenous Rac1. HEK293T cells 
were transfected with FLAG or His-tagged RhoGDIs and allowed to express for ~40 h before 
being harvested and lysed. The cell lysates were then precipitated with either cobalt-coated 
magnetic beads or anti-FLAG antibody that was cross-linked to a set of pre-washed Protein G 
Dynabeads. The co-immunoprecipitation of endogenous Rac1 was determined using an anti-Rac1 
antibody (top panels). The expression of the recombinant proteins in the whole cell lysate (WCL) 
is shown in the bottom panels along with the level of endogenous Rac1. WCL: whole cell lysate; 
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Figure 8.10: The interaction of exogenous RhoGDIs with endogenous RhoC. All three FLAG 
or His-tagged RhoGDIs were exogenously transfected into HEK293T cells. Constructs were 
allowed to express for ~40 h before being harvested and lysed. The cell lysates were then 
precipitated with either cobalt-coated magnetic beads or anti-FLAG antibody that was cross-linked 
to a set of pre-washed Protein G Dynabeads. The co-immunoprecipitation of endogenous RhoC 
was determined using an anti-RhoC antibody (top panels). The expression of the recombinant 
proteins in the whole cell lysate (WCL) is shown in the bottom panels along with the level of 
endogenous RhoC. WCL: whole cell lysate; IP: immunoprecipitation. (A) RhoGDI-1, (B) 
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Figure 8.11: The interaction of exogenous RhoGDIs with endogenous RhoA. FLAG or His-
tagged RhoGDI-1 were exogenously transfected into HEK293T cells. Constructs were allowed to 
express for ~40 h before being harvested and lysed. The cell lysates were then precipitated with 
either cobalt-coated magnetic beads or anti-FLAG antibody that was cross-linked to a set of pre-
washed Protein G Dynabeads. The co-immunoprecipitation of endogenous RhoA was determined 
using an anti-RhoA antibody (top panels). The expression of the recombinant proteins in the whole 
cell lysate (WCL) is shown in the bottom panels along with the level of endogenous RhoA. WCL: 
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8.1.6 Summary of RhoGDI targets 
The interactions identified in this screen are summarised in Table 8.2; green boxes indicate 
interactions observed in previous studies and confirmed in this work, while yellow boxes 
highlighted the novel interactions identified in this screen.  
Although more effort has to be taken in assessing negative results, this screen also suggests which 
Rho-family GTPases that are not targets for the RhoGDI proteins, including TC10, TCL, Wrch1 
and Miro1 which appear not to interact with any of the RhoGDI proteins.  
All interactions previously reported between RhoGDI-1 and Rho-family GTPases were verified in 
this screen, except for RhoH (Olofsson, 1999). RhoF was shown for the first time to interact with 
RhoGDI-1. There were no interactions identified with any of the atypical Rho-family GTPases.  
RhoGDI-2 appears to be the most selective RhoGDI as it has been shown to interact only with 
RhoC, Rac1 and Rac3. All of these interactions have already been observed in previous studies 
(Scheffzek et al., 2000; Moissoglu et al., 2009; Griner et al., 2015). Similarly to RhoGDI-1, no 
interactions were observed with the atypical Rho-family GTPases.  
The interaction of RhoGDI-3 with RhoA, RhoB and RhoG were also verified in this screen 
(Zalcman et al., 1996; Adra et al., 1997), together with novel interactions with Rac1, Rac2, Rac3, 
RhoD, RhoF, Wrch2, Rnd2 and Miro2. The interactions seen between RhoGDI-3 and atypical 
members of Rho-family GTPases suggest a role for RhoGDI-3 in regulating the activity of these 
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Table 8.2: RhoGDIs targets  
 
Green boxes: interaction identified in previous studies and confirmed in this work. Yellow boxes: 






Type Group Rho GTPase RhoGDI-1 RhoGDI-2 RhoGDI-3 
Classical 
Rho 
RhoA Yes No Yes 
RhoB No No Yes 
RhoC Yes Yes Yes 
Rac 
Rac1 Yes Yes Yes 
Rac2 Yes No Yes 
Rac3 Yes Yes Yes 
RhoG Yes No Yes 
Cdc42 
Cdc42 Yes No No 
TC10/RhoQ No No No 
TCL/RhoJ No No No 
Non-
classical 
RhoD No No Yes 
RhoF/Rif Yes No Yes 
Cdc42 
Wrch1/RhoU No No No 
Wrch2/RhoV/ Chp No No Yes 
Rnd 
Rnd1/RhoS No No N/A 
Rnd2/RhoN No No Yes 
Miro 
Miro1/RhoT1 No No No 
Miro2/RhoT2 No N/A Yes 
RhoH/TTF No No Yes 
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8.2 The subcellular localization of RhoGDI-Rho 
GTPases complexes 
8.2.1 The site of interaction of RhoGDI-1 or -2 with 
Rac1 
RhoGDI-1 has been found to form complexes with RhoA, Rac1, Rac2 and Cdc42 in the cytoplasm 
(Gorvel et al., 1998; Olofsson, 1999). However, the site of interaction for RhoGDI-2 and its targets 
has not been reported. It is likely however that RhoGDI-2 complexes form in the cytoplasm due 
to the exclusive cytoplasmic localization of RhoGDI-2 (section 5.1).  
The site of complex formation of the GDIs and their targets was investigated in this work and Rac1 
was chosen for investigation to allow the study of an endogenous target. To confirm the site of 
interaction for RhoGDI-1 or -2 with Rac1, HEK293T cells were transfected with His-RhoGDI-1 
or -2 and allowed to express for ~24 h before serum starvation overnight. Cells were harvested and 
fractionated into cytoplasmic and nuclear-enriched fractions. Each of the cell fractions were then 
precipitated with cobalt-coated magnetic beads for ~1 h. The presence of endogenous Rac1 in co-
immunoprecipitated fractionated samples was identified by western blotting.  
Rac1 was seen to interact with both RhoGDI-1 (Figure 8.12A) and RhoGDI-2 (Figure 8.12B) only 
in the cytoplasm as expected. Interestingly, although Rac1 was seen in both the cytoplasmic and 
nuclear-enriched fractions in the absence of both RhoGDIs, it was present only in the cytoplasm 
when co-expressed with the RhoGDIs, suggesting a potential role for both of these RhoGDIs in 
sequestering Rac1 in the cytoplasm, as has been reported previously for RhoGDI-1 (Michaelson 
et al., 2001).  
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Figure 8.12: The subcellular localization of RhoGDI-1 or -2 -Rac1 complexes in HEK293T 
cells. His-RhoGDI-1 or -2 were transfected into HEK293T cells and allowed to express for ~24 h 
before serum starvation overnight. Cells were then harvested and fractionated into cytoplasmic 
and nuclear-enriched compartments. Each of the fractions were incubated with cobalt-coated 
magnetic beads for ~1 h. The co-immunoprecipitation of endogenous Rac1 in each fraction were 
determined using an anti-Rac1 antibody (top right panels). The expression of the recombinant 
proteins in the whole cell lysate (WCL) is shown on the left, while their expression in each fraction 
is shown on the bottom 4 panels on the right along with the level of endogenous Rac1. GAPDH 
and Histone H3 were used as cytoplasmic and nuclear markers, respectively. GAPDH was also 
used to assess equal loading of samples across the wells in the total lysate. The western blot shown 
is representative of three independent experiments. WCL: whole cell lysate; IP: 
immunoprecipitation; C: cytoplasmic compartment; N: nuclear-enriched compartment. (A) 
RhoGDI-1 and (B) RhoGDI-2.  
A 
B 
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8.2.2 The site of interaction of RhoGDI-3 with its Rho-
family targets 
8.2.2.1 RhoGDI-3 forms complexes with RhoA, RhoC and 
Rac1 in the cytoplasm 
A previous study undertaken by Morin et al. (2010) showed that RhoGDI-3 and its target, RhoG 
could form a complex on the Golgi and vesicular structures of mammalian cells. Since RhoGDI-3 
was found more in the cytoplasm compared to nuclear-enriched fractions in this work (section 
5.1), it seemed likely that the Rho-RhoGDI-3 complexes would form in the cytoplasm. However, 
as a few of the RhoGDI-3 targets such as RhoA, RhoC and Rac1 have also been shown to be 
present in the nucleus (Dubash et al., 2011; Unsal-Kacmaz et al., 2011; Lanning et al., 2004; 
Pellinen et al., 2015), this posed the question that RhoGDI-3 could also interact with these Rho-
family GTPases in the nucleus and regulate their activities there.   
To test this, subcellular fractionation and co-immunoprecipitation were performed by transfecting 
FLAG-RhoGDI-3 into HEK293T cells. The construct was allowed to express for ~24 h before 
serum starvation overnight. ~40 h post-transfection, cells were harvested and fractionated into the 
cytoplasmic and nuclear-enriched fractions. The lysates were then immunoprecipitated with anti-
FLAG antibody cross-linked to pre-washed Protein G Dynabeads, for ~1 h. The presence of 
endogenous RhoA, RhoC and Rac1 in each fraction and in the immunoprecipitated samples were 
determined by western blotting. 
As shown in Figure 8.13, RhoA and RhoC were found only in the cytoplasm, despite being 
reported previously to be in the nucleus. Rac1 was seen predominantly in the cytoplasm but a small 
amount was detected in the nuclear-enriched fractions. RhoGDI-3-RhoA and -RhoC complexes 
were only identified in the cytoplasm as expected. RhoGDI-3-Rac1 complexes were also only 
observed in the cytoplasm despite the presence of both proteins in both compartments. 
Furthermore, similar to what was seen with RhoGDI-1 and -2, Rac1 nuclear levels decreased when 
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Figure 8.13: The subcellular localization of RhoGDI-3-RhoA, -RhoC and -Rac1 complexes 
in HEK293T cells. FLAG-RhoGDI-3 was transfected into HEK293T cells and allowed to express 
for ~24 h before serum-starved overnight. ~40 h post-transfection, cells were harvested and 
fractionated into cytoplasmic and nuclear-enriched compartments. Each of the fractions were then 
immunoprecipitated with anti-FLAG antibody cross-linked to pre-washed Protein G Dynabeads, 
for ~1 h. The co-immunoprecipitation of endogenous RhoA, RhoC and Rac1 was determined using 
anti-RhoA, anti-RhoC or anti-Rac1 antibodies, respectively (top right panels). The expression of 
the recombinant proteins in the whole cell lysate (WCL) is shown on the left, while their expression 
in each fraction is shown on the bottom 6 panels on the right along with the levels of endogenous 
RhoA, RhoC and Rac1. Histone H3 and GAPDH were used as nuclear and cytoplasmic markers, 
respectively. GAPDH was used to assess equal loading of samples across the wells in the total 
whole cell lysate. The western blot shown is representative of three independent experiments. 
WCL: whole cell lysate; IP: immunoprecipitation; C: cytoplasmic compartment; N: nuclear-
enriched compartment.  
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8.2.2.2 RhoGDI-3 forms a complex with RhoH in both the 
cytoplasmic and nuclear-enriched cellular fractions 
The site of interaction between RhoGDI-3 and the atypical Rho-family GTPases was also 
determined. RhoH is known to be in the nucleus of Jurkat cells and to co-localize with a 
transcriptional regulator, Kaiso, upon chemokine stimulation or after T cell receptor activation to 
regulate actin-cytoskeleton structure and transcriptional activity during T cell migration (Mino et 
al., 2018).  
To identify the subcellular location of complexes formed between RhoGDI-3 and RhoH, FLAG-
RhoGDI-3 and V5-RhoH were transfected into HEK293T cells. ~24 h after serum starvation, cells 
were harvested and fractionated into cytoplasmic and nuclear-enriched fractions. The lysates were 
then immunoprecipitated with anti-FLAG antibody and the site of interaction was determined by 
western blotting.  
As expected, RhoH was observed in both the cytoplasmic and nuclear-enriched fractions (Figure 
8.14). RhoH total protein also decreased when co-expressed with RhoGDI-3 and this was most 
marked in the nuclear-enriched fraction. Interestingly, RhoGDI-3 was seen to interact with RhoH 
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Figure 8.14: The subcellular localization of RhoGDI-3-RhoH complexes in HEK293T cells. 
FLAG-RhoGDI-3 was transfected together with V5-RhoH into HEK293T cells and allowed to 
express for ~24 h before serum-starvation overnight. ~40 h post-transfection, cells were harvested 
and fractionated into cytoplasmic and nuclear-enriched compartments. Each of the fractions were 
then immunoprecipitated with anti-FLAG antibody for ~1 h. The co-immunoprecipitation of V5-
RhoH in each fraction was determined by using anti-V5 antibody (top right panels). The expression 
of the recombinant proteins in the whole cell lysate (WCL) is shown on the left, while their 
expression in each fraction is shown on the bottom 4 panels on the right hand side. Histone H3 and 
GAPDH were used as nuclear and cytoplasmic markers, respectively. GAPDH was used to assess 
equal loading of samples across the wells in the total whole cell lysate. WCL: whole cell lysate; 
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8.3 The effect of the RhoGDIs on the activation 
status of their targets 
Rho-family GTPases function as molecular switches by alternating between active GTP-bound 
and inactive GDP-bound forms. In their active GTP-bound state, Rho-family GTPases transduce 
the signals by interacting with multiple effector proteins. In contrast, Rho-family GTPases are 
maintained in their inactive GDP-bound state by interacting with RhoGDI proteins (Boulter et al., 
2010). Thus, to investigate the inhibitory activity of the RhoGDI proteins towards their Rho 
GTPase targets, pull-down assays using specific effector proteins for each Rho GTPase were 
performed. The activation status of Rac1 was assessed in the presence of exogenous RhoGDI-1 
and -2. For RhoGDI-3, representative targets: Rac1, RhoA, RhoB and RhoC were tested as 
examples of classical Rho GTPases, while RhoH was selected as examples of atypical Rho GTPase 
targets. Rhotekin was used as an effector for all the Rho subfamily proteins, while PAK1 was used 
for Rac1 and RhoH. 
8.3.1 Purification of GST-Rhotekin-RBD from E. coli 
pGEX-2T-Rhotekin-RBD (1-89) was purified as described in section 2.2.2.3. Briefly, E. coli BL21 
(DE3) pLysS cells were induced with 1 mM IPTG for ~16 h at 20 °C. Cells were then harvested 
and lysed. The cleared lysates were collected by centrifugation and incubated with glutathione 
sepharose 4B beads for 5 min with rotation at 4 °C. Unbound proteins were then washed from the 
beads with wash buffer containing 0.5% Triton X-100. The GST-Rhotekin-RBD-bead suspension 
was then stored at -80 °C for future used. 
Figure 8.15 shows the final product of GST- Rhotekin (~1 µg) after separation by SDS-PAGE and 
western blotting with an anti-GST antibody.  
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Figure 8.15: Final product of GST-Rhotekin-RBD (1-89). ~1 µg of the GST-Rhotekin-RBD 
were analysed by 12% SDS-PAGE and western blotting with anti-GST antibody. 
 
8.3.2 Purification of GST-human PAK1-GBD from E. 
coli 
8.3.2.1 Small-scale expression trials of GST-PAK1-GBD in E. 
coli 
pGEX-2TK-PAK1-GBD (56-272) (a kind gift from Dr. Heidi Welch, Babraham Institute, 
Cambridge) was transformed into the E. coli BL21. Expression trials were performed as described 
in section 2.2.1. Briefly, 10 mL cultures were induced with 0.1 mM IPTG for either ~5 h at 37 °C 
or ~16 h at 20 °C. Cells were then harvested, pelleted and lysed. The soluble and insoluble fractions 
were collected and the level of GST-PAK1-PBD was analysed by SDS-PAGE and Coomassie 
staining (Figure 8.16).  
GST-PAK1-GBD was soluble at 37 °C after ~5 h induction with IPTG (red box). These induction 
conditions were used for further large-scale protein production.  
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Figure 8.16: Small-scale expression trial of GST- PAK1-GBD (56-272) in E. coli BL21. E. coli 
BL21 cells transformed with pGEX-2TK-PAK1-GBD (56-272) and then cultures induced with 
IPTG for either ~5 h at 37 °C or ~16 h at 20 °C. Cells were then harvested, pelleted and lysed. Gel 
samples were collected from non-induced (NI), induced (I), insoluble (P) and soluble (S) fractions 
of induced cells. The level of GST-PAK1-GBD and its solubility under each condition was 
assessed by SDS-PAGE and Coomassie staining. M: MW markers.   
 
8.3.2.2 Large-scale expression and purification of GST-
PAK1-GBD (56-272) protein 
GST-PAK1-PBD was expressed in 3 L E. coli BL21 using the optimised conditions and purified 
as described in section 2.2.2.2. Briefly, ~5 h post-induction by IPTG, cells were harvested, lysed 
and the lysate was cleared by centrifugation. The supernatant was incubated with glutathione 
agarose beads for ~30 min. Unbound proteins were washed from the beads with MTPBS 
containing 0.1% Triton X-100. The bound protein was then eluted using 10 mM reduced 
glutathione. Samples from each purification were analysed by SDS-PAGE and Coomassie 
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staining. All the eluted samples were then pooled and concentrated to ~2 mL using an Amicon 
stirred cell. The amount of protein was quantified (section 2.2.3) and stored at -80 °C.  
As shown in Figure 8.17A, most of the GST-PAK1-GBD (~35 kDa) bound to the beads, with a 
small amount of GST-PAK1-GBD appearing in the wash samples. Gel samples of the beads 
showed low levels of contaminating proteins. These non-specific proteins maybe E. coli proteins 
but may also be GST-PAK1-GBD that has been cleaved by E. coli proteases and retained the GST-
affinity tag.  
Following elution with 10 mM glutathione (Figure 8.17B), GST-PAK1-GBD had undergone some 
degradation by proteases and this could also be seen in the final purified product (Figure 8.17C) 
that shows 3 major bands (~27 to 35 kDa). Previous purifications performed in the Welch lab show 
the same pattern of GST-PAK1-GBD degradation (Figure 8.17D), indicating that the construct is 
not fully stable. Attempts were made to reduce the degradation of GST-PAK1-GBD by adding 
protease inhibitors into the buffer used during the purification and also reducing the incubation 
time with the beads, however, there was little improvement in the final product. Nevertheless, the 
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Figure 8.17: Purification of GST-PAK1-GBD from E. coli BL21. E. coli BL21 cells 
transformed with GST-PAK1-GBD (56-272) were induced with IPTG for ~5 h at 37 °C. Cells 
were harvested, pelleted and lysed. The cleared lysates were then added to two sets of glutathione 
agarose beads and incubated for ~30 min at 4 °C with rotation. (A) Beads were washed four times 
to remove unbound proteins and samples run on SDS-PAGE together with samples from the beads 
(B) and supernatant (S) before washes. (B) The bound protein was then eluted with 10 mM reduced 
glutathione and analysed by SDS-PAGE and Coomassie staining. (C) The GST-PAK1-PBD 
undergoes partial degradation as seen by SDS-PAGE analysis but (D) to similar levels seen 
previously in the Welch lab (image kindly shared by Dr. Martin Barker). M: MW markers.   
B 
C D 
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8.3.3 RhoGDIs negatively regulate the GTP levels of 
their targets 
8.3.3.1 RhoGDI-1 and -2 negatively regulate the GTP level of 
Rac1 
RhoGDI-1 has been shown to decrease the GTP loading of Rac1 (Chuang et al., 1993) Depletion 
of RhoGDI-2 has also been seen to promote Rac1 activation in breast cancer cell lines (Zhang et 
al., 2009). To confirm the consequences of RhoGDI-1 and -2 on the GTP levels of their targets, 
Rac1, an effector pull-down assay using GST-PAK1-GBD was performed in HEK293T cells.  
His-RhoGDI-1 or -2 were transfected into cells and allowed to express for ~24 h before serum 
starvation overnight. Cells were harvested and lysed in buffer containing GST-PAK1-GBD (10 
µg/sample), ~40 h post-transfection. The cleared lysates were then precipitated with GST-PAK1-
GBD bound to glutathione sepharose 4B beads for 45 min at 4 °C. Following incubation, the beads 
were washed to remove any unbound proteins and the levels of GTP-bound endogenous Rac1 were 
identified by western blotting with anti-Rac1 antibody.  
RhoGDI-1 and -2 were seen to exhibit classical GDI function by decreasing the GTP levels of 
Rac1 (Figure 8.18).  
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Figure 8.18: RhoGDI-1 and -2 decrease the GTP-bound levels of endogenous Rac1. HEK293T 
cells were transfected with His-RhoGDI-1 or -2 and allowed to express for ~24 h before serum 
starvation overnight. ~40 h post-transfection, cells were harvested, pelleted and lysed with buffer 
containing GST-PAK1-GBD. The lysates were then incubated with glutathione sepharose 4B 
beads. The levels of GTP-bound Rac1 were determined by western blotting with anti-Rac1 
antibody, as shown in top panel. The expression of recombinant proteins in the whole cell lysates 
is shown in the bottom 3 panels along with the total level of endogenous Rac1. GAPDH was used 
to assess equal loading of samples across the wells in the total cell lysate. The western blot shown 
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8.3.3.2 RhoGDI-3 negatively regulates the GTP levels of Rho 
subfamily members 
RhoGDI-3 is known to act as a GDI by negatively regulating the activation status of its binding 
partners. For instance, RhoGDI-3 was shown to inhibit the activation of RhoB by extracting GDP-
bound RhoB from the membrane (Zalcman et al., 1996). Besides RhoB, no studies have been 
performed to verify the GDI activity of RhoGDI-3 towards its other known target, RhoA. Thus, a 
GST-Rhotekin pull-down assay was performed to investigate the inhibitory activity of RhoGDI-3 
on RhoA and the newly identified target, RhoC. The effect of RhoGDI-3 on RhoB activation was 
also included in this assay as a control.  
Briefly, HEK293T cells were transfected with FLAG-RhoGDI-3 and allowed to express for ~24 h 
before serum-starvation overnight. ~40 h post-transfection, cells were harvested, pelleted and 
lysed. The lysates were then incubated with a total of 100 ng/µL of GST-Rhotekin-RBD-bead 
suspension for 45 min at 4 °C. Following incubation, the beads were washed and eluted with 
sample buffer. The GTP levels of endogenous RhoA, RhoB and RhoC were identified by western 
blotting with antibodies specific for each Rho subfamily GTPases.  
RhoGDI-3 behaves as a conventional GDI by decreasing the GTP-levels of RhoB (Figure 8.19B), 
similar to previous study (Zalcman et al., 1996). RhoGDI-3 also seen to inhibit the activation of 
RhoA (Figure 8.19A) and RhoC (Figure 8.19C). Interestingly, the total levels of RhoB increased 
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Figure 8.19: RhoGDI-3 decreases the GTP-bound levels of endogenous Rho subfamily 
members. FLAG-RhoGDI-3 was transfected into HEK293T cells and allowed to express for ~24 
h before serum starvation overnight. Cells were harvested, pelleted and lysed, ~40 h post-
transfection. The lysates were then incubated with GST-Rhotekin-RBD-bead suspension for 45 
min at 4 °C. The levels of GTP-bound Rho subfamily members were determined by western 
blotting with antibodies specific for each Rho-family GTPases, as shown in top panels. The 
expression of recombinant proteins in the whole cell lysates is shown in the bottom 3 panels along 
with the total level of endogenous Rho subfamily proteins. GAPDH was used to assess equal 
loading of samples across the wells in the total cell lysate. The western blot shown is representative 
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8.3.3.3 RhoGDI-3 negatively regulates Rac1 and RhoH GTP 
levels 
Data described in section 8.1.4 shows Rac1 is a new interacting partner for RhoGDI-3.  
Interestingly, the data here also shows that RhoH interacts with RhoGDI-3, even though it is 
thought to exist only as a GTP-bound form due to lacks GTPase activity (Li et al., 2002). Thus, it 
would be assumed that RhoGDI-3 only binds and extracts RhoH from membranes but does not 
negatively regulate the GTP-bound levels of RhoH.  
To analyse the effect of RhoGDI-3 on the activation status of Rac1 and RhoH, effector pull-down 
assays were performed using GST-PAK1-GBD. HEK293T cells were either transfected with 
FLAG-RhoGDI-3 alone or with V5-RhoH. Constructs were allowed to express for ~24 h before 
serum starvation overnight. ~40 h post-transfection, cells were harvested, and lysed in buffer 
containing GST-PAK1-GBD. The lysates were then incubated with glutathione sepharose beads 
for 45 min at 4 °C. The beads were washed and the levels of GTP-bound Rac1 and RhoH were 
analysed by western blotting using anti-Rac1 or anti-V5 antibodies.  
The levels of GTP-bound Rac1 (Figure 8.20A) and RhoH (Figure 8.20B) were shown to decrease 
in cells expressing RhoGDI-3. These data were expected for Rac1, however contrary to 
predictions, RhoGDI-3 is still able to negatively regulate the activation of RhoH, even though it is 
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Figure 8.20: RhoGDI-3 decreases the GTP-bound levels of endogenous Rac1 and V5-RhoH. 
HEK293T cells were transfected with FLAG-RhoGDI-3 alone or with V5-RhoH. Constructs were 
allowed to express for ~24 h before serum-starvation overnight. ~40 h post-transfection, cells were 
harvested and lysed in buffer containing GST-PAK1-GBD. The lysates were then incubated with 
glutathione sepharose beads for 45 min at 4 °C. The levels of GTP-bound Rac1 and RhoH were 
determined by western blotting with anti-Rac1 or anti-V5 antibodies, as shown on top panels. The 
expression of recombinant proteins in the whole cell lysates is shown in the bottom 3 panels along 
with the total level of endogenous Rac1. GAPDH was used to assess equal loading of samples 
across the wells in the total cell lysate. The western blot shown is representative of three 







Chapter 8            The effect of RhoGDIs 
  on their target 
      
 224 
8.3.4 Subcellular localization of RhoGDI-3’s inhibitory 
activity  
8.3.4.1 Subcellular localization of RhoGDI-3’s inhibitory 
activity on RhoA 
Both RhoGDI-1 and -2 were found only in the cytoplasm and shown to interact with Rac1 in the 
same compartment. Thus, it is likely that both of these RhoGDIs negatively inhibiting the GTP 
levels of Rac1 in the cytoplasm, at least in the system used here, in a similar manner observed for 
RhoGDI-1 (Chuang et al., 1993).  
Data in this study shows RhoGDI-3 bind to RhoA exclusively in the cytoplasm and decrease its 
GTP levels. Thus, it is predicted that RhoGDI-3 will exert its GDI function towards RhoA in the 
cytoplasm. To confirm this, a subcellular fractionation and GST-Rhotekin-RBD pull-down assay 
was performed (section 2.3.11). 
Briefly, FLAG-RhoGDI-3 was transfected into HEK293T cells and allowed to express for ~24 h 
before serum starvation overnight. ~40 h post-transfection, cells were harvested and fractionated 
into cytoplasmic and nuclear-enriched fractions. The lysates were then incubated with GST-
Rhotekin-RBD-bead suspension for 45 min at 4 °C. The level of GTP-bound RhoA in each fraction 
was determined by western blotting with an anti-RhoA antibody.  
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Figure 8.21: The site of action of RhoGDI-3 towards RhoA. HEK293T cells were transfected 
with FLAG-RhoGDI-3 and allowed to express for ~24 h before serum-starved overnight. Cells 
were harvested and fractionated into cytoplasmic and nuclear-enriched fractions, ~40 h post-
transfection. Each of the fractions was incubated with GST-Rhotekin-RBD-bead suspension for 
45 min at 4 °C. The level of GTP-bound RhoA in each fraction was identified by western blotting 
with an anti-RhoA antibody. (A) The expression of recombinant proteins in the whole cell lysates 
(WCL). GAPDH was used to assess equal loading of samples across the wells in the total whole 
cell lysate. (B) Total proteins levels in each fraction are shown in the bottom 4 panels along with 
the level of endogenous RhoA. The GTP-bound RhoA in each fraction are shown in the top panel. 
Hsp56 and Histone H3 were used as cytoplasmic and nuclear-enriched markers, respectively. The 
western blot shown is representative of three independent experiments. WCL: whole cell lysate; 
C: cytoplasmic compartment; N: nuclear-enriched compartment.  
A 
B 
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8.3.4.2 Subcellular localization of RhoGDI-3’s inhibitory 
activity on Rac1 and RhoH 
RhoGDI-3 was shown to bind to Rac1 only in the cytoplasm, (section 8.2.2.1) while it forms 
complexes with RhoH in both the cytoplasmic and nuclear-enriched compartment (section 
8.2.2.2). The data for RhoA suggest that RhoGDI-3 might negatively regulate the activity of both 
Rac1 and RhoH at the site of interaction. This hypothesis was investigated using effector pull-
down assays utilizing GST-PAK1-GBD to identify the GTP-bound fractions of Rac1 and RhoH. 
~40 h post-transfection, cells were harvested and fractionated into cytoplasmic and nuclear-
enriched fractions with buffer containing GST-PAK1-PBD. The lysates were then incubated with 
glutathione sepharose beads for 45 min. The levels of GTP-bound Rac1 and RhoH in each fraction 
were determined by western blotting with anti-Rac1 or anti-V5 antibodies.  
The data in Figure 8.22 shows that Rac1 was active in both the cytoplasmic and nuclear-enriched 
fractions. Co-expression with RhoGDI-3 decreased the GTP-bound Rac1 in the cytoplasm. The 
level of Rac1 in the nuclear-enriched fraction is substantially decreased in cells expressing 
RhoGDI-3 but this pool of nuclear Rac1 appears to be relatively active.    
RhoH alone was active in both the cytoplasmic and nuclear-enriched compartments (Figure 8.23). 
However, co-expression with RhoGDI-3 decreased RhoH total proteins and GTP-bound levels in 
both compartments. These data suggest a dual nuclear and cytoplasmic role for RhoGDI-3 in 
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Figure 8.22: The site of action of RhoGDI-3 towards Rac1. HEK293T cells were transfected 
with FLAG-RhoGDI-3 and allowed to express for ~24 h before serum starvation overnight. ~40 h 
post-transfection, cells were fractionated into cytoplasmic and nuclear-enriched fractions in buffer 
containing GST-PAK1-GBD. Each of the fractions was incubated with glutathione sepharose 
beads. The levels of GTP-bound Rac1 in both the fractions were determined by western blotting 
with anti-Rac1 antibody. (A) The expression of recombinant proteins in the whole cell lysates 
(WCL). GAPDH was used to assess equal loading of samples across the wells in the total whole 
cell lysate. (B) Total proteins in each fraction are shown in the bottom 4 panels along with the 
level of endogenous Rac1. The GTP-bound Rac1 in each fraction are shown in the top panel. 
GAPDH and Histone H3 were used as cytoplasmic and nuclear-enriched markers, respectively. 
The western blot shown is representative of three independent experiments. WCL: whole cell 
lysate; C: cytoplasmic compartment; N: nuclear-enriched compartment.  
A 
B 
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Figure 8.23: The site of action of RhoGDI-3 towards RhoH. FLAG-RhoGDI-3 was transfected 
alone or with V5-RhoH. Constructs were allowed to express for ~24 h before serum starvation 
overnight. ~40 h post-transfection, cells were fractionated into cytoplasmic and nuclear-enriched 
fractions in buffer containing GST-PAK1-GBD. Each of the fractions was incubated with 
glutathione sepharose beads. The levels of GTP-bound RhoH in both the fractions were determined 
by western blotting with anti-V5 antibody. (A) The expression of recombinant proteins in the 
whole cell lysates (WCL). GAPDH was used to assess equal loading of samples across the wells 
in the total whole cell lysate. (B) Total proteins in each fraction are shown in the bottom 4 panels, 
while the GTP-bound RhoH in each fraction are shown in the top panel. GAPDH and Histone H3 
were used as cytoplasmic and nuclear-enriched markers, respectively. The western blot shown is 
representative of two independent experiments. WCL: whole cell lysate; C: cytoplasmic 
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8.4 The role of the N-terminus of RhoGDI-3 in 
regulating its functions 
The first 22 amino acids of RhoGDI-1 were shown to regulate the binding with its targets, while 
deletions of the first 45 or 60 residues completely abolished both binding to target proteins and its 
GDI activity (Nomanbhoy and Cerione, 1996). These data hence indicate a role for the N-terminus 
regulatory arm of the RhoGDI in regulating binding to their targets. RhoGDI-3 has an additional 
26 amino acids at its N-terminus that has been shown to stabilise the RhoG-RhoGDI-3 complex 
(Brunet et al., 2002). However, no study has been undertaken to identify the role for this amino-
terminal extension in regulating RhoGDI-3 inhibitory function. Therefore, to further investigate 
the involvement of the N-terminus of RhoGDI-3 in mediating the interaction and activation status 
of its binding partner, Rac1, co-immunoprecipitation and effector pull-down assay were performed 
by utilizing the DNRhoGDI-3 construct (section 5.2). 
Briefly, cells were transfected with FLAG-DNRhoGDI-3 or FLAG-wtRhoGDI-3 and allowed to 
express for ~24 h before serum starvation overnight. Cells were harvested and either 
immunoprecipitated with anti-FLAG antibody cross-linked to Protein G Dynabeads or precipitated 
with GST-PAK1-GBD and glutathione sepharose beads, ~40 h post-transfection. Co-
immunoprecipitated Rac1 and GTP-bound Rac1 were identified by western blotting with anti-
Rac1 antibody. The Rac1-DNRhoGDI-3 binding ratio was quantified with ImageJ and compared 
to the wt.  
Analysis of the data by densitometry indicate that the DNRhoGDI-3 potentially binds Rac1 less 
effectively than the wt (Figure 8.24A). There is no difference in the GTP levels of Rac1 (Figure 
8.24B) when co-expressed with either wt or N-terminally truncated RhoGDI-3, suggesting that the 
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Figure 8.24: The role of N-terminus of RhoGDI-3 in regulating the binding and activation 
status of Rac1. HEK293T cells were transfected with FLAG-DNRhoGDI-3 or with FLAG-
wtRhoGDI-3 and allowed to express for ~24 h before serum starvation overnight. ~40 h post-
transfection, cells were harvested and proceed to (A) immunoprecipitation with anti-FLAG 
antibody cross-linked to Protein G Dynabeads or (B) precipitated with GST-PAK1-GBD and 
glutathione sepharose beads for ~45 min at 4 °C. Co-immunoprecipitated Rac1 and the levels of 
GTP-bound Rac1 were identified by western blotting with anti-Rac1 antibody. The expression of 
recombinant proteins in the whole cell lysate (WCL) is shown in the bottom 3 panels (left and 
right), along with the total levels of endogenous Rac1. The co-immunoprecipitated (IP) samples 
are shown in the top two panels in (A), while the GTP-bound Rac1 is shown in the top panel in 
(B). The Rac1-DNRhoGDI-3 binding ratio was quantified by ImageJ and compared to the wt. 
GAPDH was used to assess equal loading of samples across the wells in the total whole cell lysate. 
The western blot shown is representative of at least two independent experiments. WCL: Whole 
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8.5 Summary 
Subcellular fractionation data in this study shows that RhoA and RhoC are only localized in the 
cytoplasm, while Rac1 and RhoH were found to be in both the cytoplasm and nuclear-enriched 
extracts. Co-expression with any of the RhoGDIs decreases the nuclear-enriched levels of Rac1, 
suggesting the ability for the RhoGDIs to sequester Rac1 in the cytoplasm and prevent its nuclear 
targeting.  
Both RhoGDI-1 and -2 bind to and negatively regulate their target, Rac1 exclusively in the 
cytoplasm despite Rac1 being present in both the cytoplasmic and nuclear-enriched compartments. 
This is the first observation on the subcellular location of the RhoGDI-2-Rac1 complex.  
RhoGDI-3 was found to interact with RhoA and RhoC only in the cytoplasm although RhoGDI-3 
was found in both the cytoplasmic and nuclear-enriched compartments, and this was due to 
exclusive cytoplasmic distribution of both RhoA and RhoC. Rac1 was found to interact with 
RhoGDI-3 in the cytoplasm despite both Rac1 and RhoGDI-3 being located in both the 
cytoplasmic and nuclear-enriched fractions. Furthermore, RhoGDI-3 has been shown here to exert 
its inhibitory activity towards RhoA and Rac1 in the cytoplasm and this does not involve the extra 
26 residues at the N-terminus of RhoGDI-3.  
Interestingly, RhoGDI-3 has been shown to interact and negatively regulate the activity of RhoH 
in both the cytoplasmic and nuclear-enriched fractions. RhoH was assumed to be a GTPase 
defective Rho-family protein due to lack of Gly12, Ala59 and Gln61 (Ras numbering) (Table 1.7), 
shared by the typical Rho-family GTPases. These data hence suggest a novel role for RhoGDI-3 
protein to interact with its target protein, RhoH in the nucleus and maintaining it in the inactive 
GDP-bound form. 
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The effect of ACK on RhoGDI functions 
 
As ACK has been demonstrated to be involved in cancer progression (Mahajan and Mahajan, 
2014), it was hypothesized that the interaction between the RhoGDIs and ACK could modulate 
RhoGDI function as regulator of Rho-family GTPases, which are implicated in many oncogenic 
processes.  
Since ACK has been shown to facilitate the degradation of RhoGDI-3 (section 6.2), this would 
result in less RhoGDI-3 available to bind to its target proteins and subsequently alter their 
activation status. For RhoGDI-1 and -2, any effect of ACK on their activity towards their target 
proteins must be through an alternative mechanism.   
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9.1 The effect of ACK on the binding of RhoGDI-
1 and -2 to Rac1  
To investigate the functional consequences of ACK on the ability of RhoGDI-1 and -2 to form 
complexes with their targets, co-immunoprecipitation assays were performed.  Briefly, cells were 
transfected with His-RhoGDI-1 and His-RhoGDI-2 either alone or together with increasing 
amounts of HA-ACK (0.5 to 5 µg). Cells were then harvested and lysed, ~40 h post-transfection. 
The lysates were precipitated with cobalt-coated magnetic beads for ~1 h at 4°C. The presence of 
endogenous Rac1 in co-immunoprecipitated samples was determined by western blotting using an 
anti-Rac1 antibody. The ability of both RhoGDI-1 and -2 to bind to Rac1 in the presence or absence 
of ACK was quantified with ImageJ.  
Figure 9.1A shows the levels of Rac1 bound to RhoGDI-1 significantly decreased with increasing 
amounts of ACK. However, this could be due to low levels of RhoGDI-1, which is contrast to the 
data presented in section 6.1.  
ACK seemed not to significantly affect the binding between Rac1 and RhoGDI-2 (Figure 9.1B). 
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Figure 9.1: The effect of ACK on the binding of RhoGDI-1 and -2 to Rac1. HEK293T cells 
were transfected with His-RhoGDI-1 or His-RhoGDI-2 alone, or with 0.5 to 5 µg HA-ACK and 
allowed to express for ~40 h. Cells were then harvested and lysed before precipitated with cobalt 
coated magnetic beads for ~1 h at 4 °C. Co-immunoprecipitated Rac1 was identified by western 
blotting with an anti-Rac1 antibody. The co-immunoprecipitated (IP) samples are shown in the top 
two panels, while the expression of recombinant proteins in the whole cell lysate (WCL) is shown 
in the bottom 4 panels, along with the total levels of endogenous Rac1. The binding of Rac1 to 
each RhoGDIs in the presence of ACK was quantified with ImageJ and normalised to cells 
expressing RhoGDI alone. GAPDH was used to assess equal loading of samples across the wells 
in the total whole cell lysate. The relative amounts are shown as average values ± SEM of three 
independent experiments, *p£ 0.05. WCL: whole cell lysate; IP: immunoprecipitation. (A) 
RhoGDI-1 and (B) RhoGDI-2.  
A 
B 








































































Chapter 9            The effect of ACK on RhoGDI function 
      
 235 
9.2 The effect of ACK on the binding of RhoGDI-
3 to its targets  
Previously, RhoGDI-3 protein levels were shown to reduce when co-expressed with ACK, which 
would result in less RhoGDI-3 available for binding with its target proteins. This would potentially 
alter the activation of any unbound Rho-family GTPases targets of RhoGDI-3.  
To formally investigate this hypothesis, co-immunoprecipitation was performed by expressing 
FLAG-RhoGDI-3 alone or with V5-RhoH or HA-ACK in HEK293T cells. Constructs were 
allowed to express for ~40 h before being harvested and lysed. The lysates were then 
immunoprecipitated with beads cross-linked to an anti-FLAG antibody for ~1 h at 4 °C. The 
presence of V5-RhoH, endogenous Rac1 and RhoA in co-immunoprecipitated samples were 
identified by western blotting.  
The levels of RhoGDI-3 decrease when co-expressed with ACK as seen in previous results (section 
6.2). Interestingly, the levels of RhoH also decreased in the presence of RhoGDI-3 alone and 
decreased even more when ACK and RhoGDI-3 were co-expressed (Figure 9.2C). The amount of 
RhoA (Figure 9.2A), Rac1 (Figure 9.2B) and RhoH (Figure 9.2C) co-immunoprecipitated were 






Chapter 9            The effect of ACK on RhoGDI function 
















Figure 9.2: The effect of ACK on the binding of RhoGDI-3 to its targets. HEK293T cells were 
transfected with FLAG-RhoGDI-3 alone or with V5-RhoH and/or HA-ACK. ~40 h post-
transfection, cells were harvested, lysed and immunoprecipitated with beads cross-linked to an 
anti-FLAG antibody for ~1 h at 4 °C. Co-immunoprecipitated RhoA, Rac1 and RhoH were 
identified by western blotting with anti-RhoA, anti-Rac1 or anti-V5 antibodies, respectively. The 
co-immunoprecipitated (IP) samples are shown in the top two panels, while the expression of 
recombinant proteins in the whole cell lysate (WCL) is shown in the bottom 4 panels, along with 
the total levels of endogenous RhoA and Rac1. GAPDH was used to assess equal loading of 
samples across the wells in the total whole cell lysate. The western blot shown is a representative 
of at least two independent experiments. WCL: whole cell lysate; IP: immunoprecipitation. (A) 
RhoA, (B) Rac1 and (C) RhoH.  
C 
A B 
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9.3 The effect of ACK on the GTP levels of 
RhoGDI target proteins  
9.3.1 The effect of ACK on the GTP levels of RhoGDI-
1 and -2 targets  
To identify the consequences of exogenous expression of ACK on the activation status of RhoGDI-
1 and -2 binding partner, Rac1, a PAK1-GBD pull-down assay was conducted. The results are 
shown in Figure 9.3.  
Cells transfected with either RhoGDI-1 (Figure 9.3A) or RhoGDI-2 (Figure 9.3B) show low levels 
of GTP-bound Rac1, whereas cells expressing ACK alone have similar levels of Rac1•GTP to 
control cells. There was no difference in the GTP levels of Rac1 when RhoGDI-1 and ACK were 
co-expressed compared to RhoGDI-1 alone (Figure 9.3A), suggesting that ACK does not regulate 
the activation of Rac1 through RhoGDI-1. Co-expression of RhoGDI-2 and ACK increased 
Rac1•GTP levels marginally, however, this effect probably due to low levels of RhoGDI-2 in the 
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Figure 9.3: The effect of ACK on the GTP levels of RhoGDI-1 and -2 target, Rac1. HEK293T 
cells were transfected with His-RhoGDI-1 or -2 alone or with HA-ACK and allowed to express 
for ~24 h before serum starvation overnight. ~40 h post-transfection, cells were harvested, lysed 
in buffer containing GST-PAK1-GBD and precipitated with glutathione sepharose beads. The 
levels of GTP-bound Rac1 were determined by western blotting with anti-Rac1 antibody. The 
expression of recombinant proteins in the whole cell lysates (WCL) is shown in the bottom 4 
panels along with the total level of endogenous Rac1, while the levels of GTP-bound Rac1 are 
shown in the top panels. GAPDH was used to assess equal loading of samples across the wells in 
the total whole cell lysate. The western blot shown is a representative of three independent 
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9.3.2 The effect of ACK on the GTP levels of RhoGDI-
3 targets 
Previous data in section 9.2 demonstrated that ACK expression results in decreased binding of 
RhoGDI-3 to its target proteins. Thus, it was hypothesized that any unbound small GTPase targets 
of RhoGDI-3 will be free to be membrane-bound and activated. To investigate this, the effect of 
ACK on the activation of RhoGDI-3 target proteins: RhoA, RhoB, Rac1 and RhoH was assessed.  
9.3.2.1 The effect of ACK on the GTP levels of RhoGDI-3 
targets, RhoA and RhoB  
To investigate the effect of ACK on the activation of RhoGDI-3 binding targets, HEK293T cells 
were transfected with RhoGDI-3 alone or with HA-ACK. GTP-bound RhoA and RhoB were 
identified by effector pull-down assays utilizing GST-Rhotekin-RBD and western blotting.  
The overall level of RhoA was unaffected following co-expression with RhoGDI-3 or ACK 
(Figure 9.4A). GTP-bound RhoA was slightly lower in cells expressing ACK and decreased 
prominently with RhoGDI-3, compared to the control. However, RhoA GTP levels were seen to 
increase in cells co-expressing ACK and RhoGDI-3 compared to RhoGDI-3 alone, suggesting that 
ACK can counteract at least some of the inhibitory effect of RhoGDI-3 towards RhoA.  
In contrast, total levels of RhoB increased in the presence of exogenous RhoGDI-3 or ACK, either 
alone or in combination (Figure 9.4B). In contrast, GTP-bound RhoB was shown to decrease in 
the presence of either RhoGDI-3 or ACK alone or when co-expressed together.   
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Figure 9.4: The effect of ACK on the GTP levels of the RhoGDI-3 targets, RhoA and RhoB. 
HEK293T cells were transfected with FLAG-RhoGDI-3 alone or with HA-ACK and allowed to 
express for ~24 h before serum starvation, overnight. Cells were harvested and lysed, ~40 h post-
transfection. The lysates were precipitated with GST-Rhotekin-RBD-bead suspension. The levels 
of GTP-bound RhoA and RhoB were determined by western blotting with anti-RhoA and anti-
RhoB, respectively. The expression of recombinant proteins in the whole cell lysates (WCL) is 
shown in the bottom 4 panels along with the total levels of endogenous RhoA and RhoB, while 
the GTP-bound proteins in pull-down samples are shown in the top panels. GAPDH was used to 
assess the equal loading of samples across the wells in the total cell lysates. The western blot shown 
is representative of at least two independent experiments. (A) RhoA and (B) RhoB.  
 
These data suggest that ACK differentially regulates the activation of RhoGDI-3 target proteins, 
which are known to act synergistically in promoting cancer progression. RhoA is predominantly 
pro-proliferative (Zohn et al., 1998; Orgaz et al., 2014), while RhoB action is generally anti-
proliferative (Chen et al., 2000). Thus, difference regulation of ACK on these Rho subfamily 
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9.3.2.2 The effect of ACK on the GTP levels of RhoGDI-3 
targets, Rac1 and RhoH 
The effect of ACK and RhoGDI-3 co-expression on the activation status of Rac1 and RhoH were 
also determined by GST-PAK1-GBD pull-down assays.  
The total levels of Rac1 protein was unaffected in the presence of either RhoGDI-3 or ACK alone 
or when both proteins together (Figure 9.5A). Rac1 was active in control cells but levels decreased 
with ACK alone and decreased substantially more with RhoGDI-3 alone. Co-expression of ACK 
and RhoGDI-3 showed Rac1•GTP levels similar to ACK alone, suggesting that ACK counteract 
the inhibitory effect of RhoGDI-3.  
Data in Figure 9.5B shows the total levels of RhoH decreased in the presence of RhoGDI-3 but 
decreased even more when co-expressed with ACK, as seen previously. Compared to the control, 
RhoH•GTP levels decreased in the presence of RhoGDI-3 but increased with ACK. Cells 
expressing both ACK and RhoGDI-3 show high amount of GTP-bound RhoH compared to 
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Figure 9.5: The effect of ACK on the GTP levels of RhoGDI-3 targets, Rac1 and RhoH. 
HEK293T cells were transfected with FLAG-RhoGDI-3 alone or with V5-RhoH and/or HA-ACK. 
Constructs were allowed to express for ~24 h before serum starvation overnight. Cells were then 
harvested and lysed in buffer containing GST-PAK1-GBD, ~40 h post-transfection. The lysates 
were incubated with glutathione sepharose beads, washed and eluted. The levels of GTP-bound 
Rac1 and RhoH were determined by western blotting with anti-Rac1 or anti-V5 antibodies. The 
expression of recombinant proteins in the whole cell lysates (WCL) is shown in the bottom 4 
panels along with the total level of endogenous Rac1, while the GTP-bound proteins in pull-down 
samples are shown in the top panels. The amounts of total and GTP-bound Rho-family GTPases 
were analysed by densitometry using Image J and compared to the control. The western blot shown 











FLAG-RhoGDI-3 ⎯ ＋ ⎯ ＋
HA-ACK ⎯ ⎯ ＋ ＋
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9.4 The effects of ACK and RhoGDI-3 on the 
subcellular pools of GTP-bound Rac1 and RhoH 
Rho-family GTPases have been found to localize to and regulate various functions in the nucleus. 
For instance, nuclear accumulation of Rac1 is shown to maintain the balance between Rac1-RhoA 
cellular activity and control cell morphology and invasiveness (Ohta et al., 2006; Chauhan et al., 
2011). A pool of active Rac1 in the nucleus is needed to regulate actin polymerization in the 
nucleus (Navarro- Lérida et al., 2015).  
Previous data described in section 8.2.2.1 and 8.3.4.2 show the ability of RhoGDI-3 to interact 
with, sequestered and negatively regulate Rac1 activation in the cytoplasm. Since ACK was shown 
to increase Rac1•GTP levels, it is possible that ACK inhibits the sequestering ability of RhoGDI-
3 towards Rac1 and therefore promotes its activation in the nucleus. RhoGDI-3 was also shown to 
interact and decreased the GTP levels of RhoH in both cytoplasmic and nuclear-enriched fractions 
(sections 8.2.2.2 and 8.3.4.2). When co-expressed with ACK, RhoH•GTP levels were found to 
increase compared to RhoGDI-3 alone, suggesting that ACK could promote the activation of RhoH 
in both cytoplasmic and nuclear-enriched compartments. To test these hypotheses, subcellular 
fractionations and effector pull-down assays were conducted. 
As shown in Figure 9.6, the nuclear-cytoplasmic ratio of Rac1 was decreased in cells expressing 
RhoGDI-3 alone, compared to the control. GTP-bound Rac1 was also seen to decrease 
considerably in the cytoplasm of RhoGDI-3-transfected cells, indicating that RhoGDI-3 exerts its 
inhibitory activity towards Rac1 mainly in the cytoplasm. In contrast, Rac1 was able to retain its 
nuclear localization in the presence of ACK alone but the nuclear-cytoplasmic ratio was still 
slightly lower compared to the control. The GTP-levels of Rac1 were also seen to decrease in both 
compartments of cell expressing ACK alone but more prominently in the nucleus. Co-expression 
of ACK and RhoGDI-3 increased Rac1 nuclear levels partially, suggesting that ACK has the ability 
to counteract the sequestering ability of RhoGDI-3 towards Rac1, at least partially. However, 
Rac1•GTP levels were found to increase primarily in the cytoplasm compared to the nucleus-
enriched fractions. These data suggest that ACK inhibit the GDI function of RhoGDI-3 towards 
Rac1 activation mainly in the cytoplasm.  
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Figure 9.6: The effects of ACK on the subcellular pools of GTP-bound Rac1. HEK293T cells 
were transfected with FLAG-RhoGDI-3 or HA-ACK alone, or with both proteins. Constructs were 
allowed to express for ~24 h before serum starvation overnight. Cells were harvested and 
fractionated into cytoplasmic and nuclear-enriched fractions in buffer containing GST-PAK1-
GBD, ~40 h post-transfection. Cells were then incubated with glutathione sepharose beads for 45 
min. The levels of GTP-bound Rac1 in both the fractions were determined by western blotting 
with an anti-Rac1 antibody. The expression of recombinant proteins in the whole cell lysates 
(WCL) is shown in top left, while total proteins in each fraction are shown in the bottom 5 panels 
along with the level of endogenous Rac1. The level of GTP-bound Rac1 in each fraction is shown 
in the top right panel. GAPDH was used to assess equal loading of samples across the wells in the 
total whole cell lysate and used as a cytoplasmic marker. Histone H3 was used as a nuclear-
enriched marker. The western blot shown is representative of three independent experiments. 
WCL: whole cell lysate; C: cytoplasmic compartment; N: nuclear-enriched compartment.  
 
Figure 9.7 shows total levels of RhoH decreased with RhoGDI-3 alone but decreased even more 
when co-expressed with ACK, as seen previously. Less GTP-bound RhoH was also observed in 
both the cytoplasmic and nuclear-enriched fractions when expressing RhoGDI-3 alone compared 
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compartments in the presence of ACK alone. Although co-expression of ACK and RhoGDI-3 












Figure 9.7: The effects of ACK on the subcellular pools of GTP-bound RhoH. HEK293T cells 
were transfected with V5-RhoH alone or together with FLAG-RhoGDI-3 and/or HA-ACK 
Constructs were allowed to express for ~24 h before serum starvation overnight. Cells were 
harvested and fractionated into cytoplasmic and nuclear-enriched fractions in buffer containing 
GST-PAK1-GBD, ~40 h post-transfection. Cells were then incubated with glutathione sepharose 
beads. The levels of GTP-bound RhoH in both the fractions were determined by western blotting 
with an anti-V5 antibody. The expression of recombinant proteins in the whole cell lysates (WCL) 
is shown in top left, while total proteins in each fraction are shown in the bottom 5 panels. The 
GTP-bound RhoH in each fraction are shown in the top right panel. GAPDH was used to assess 
equal loading of samples across the wells in the total whole cell lysate and used as a cytoplasmic 
marker. Histone H3 was used as a nuclear-enriched marker. The western blot shown is 
representative of two independent experiments. WCL: whole cell lysate; C: cytoplasmic 
compartment; N: nuclear-enriched compartment.  
V5-RhoH ＋ ＋ ＋ ＋
FLAG-RhoGDI-3 ⎯ ＋ ⎯ ＋
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9.5 Summary  
Data presented here shows that low levels of RhoGDIs in the presence of ACK resulted in a 
decreased binding between RhoGDIs and their targets. The levels of the RhoGDI-1-Rac1 complex 
decreased significantly with increasing amounts of transfected ACK. Conversely, ACK was shown 
to affect the formation of RhoGDI-2-Rac1 complex marginally. Both of these effects could be due 
to low levels of RhoGDI-1 and -2 seen in the presence of ACK. Furthermore, co-expression of 
RhoGDI-1, -2 and ACK did not increased Rac1 activation, suggesting that ACK might not regulate 
Rac1 activity through these two RhoGDIs.  
ACK-mediated RhoGDI-3 degradation was found to decrease the RhoGDI-3 complexes with 
RhoA, Rac1 and RhoH, consistent with this was an increased in the GTP-bound levels of these 
Rho-family GTPases. In contrast, RhoB•GTP levels were shown to decrease in cells expressing 
RhoGDI-3 or ACK alone and also when both were co-expressed. These data suggest ACK 
differentially regulates the activation of these small G proteins. Furthermore, RhoB protein level 
was also found to increase in the presence of RhoGDI-3 or ACK alone and increased even more 
upon combination, suggesting a synergistic role for these proteins in stabilising RhoB.  
Co-expression with ACK has been shown to reverse the sequestering ability of RhoGDI-3 towards 
Rac1 and promotes its activation predominantly in the cytoplasm. RhoH•GTP levels were also 
found to increase in both cytoplasmic and nuclear-enriched compartments when co-expressed 
RhoGDI-3 and ACK.  
All the data described in this chapter suggest a role for ACK in cancer progression is potentially 
underpinned by its interaction with the RhoGDI protein and its effect on RhoGDI ability to regulate 
Rho-family proteins activity in various cellular compartments.  
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Discussion and future directions 
 
Through this study, all three RhoGDIs have been found to interact with ACK. Although the 
RhoGDI-ACK interactions were first investigated using exogenous proteins, the interaction 
between RhoGDI-1 and ACK was also confirmed using endogenous proteins. It was not possible 
to work with endogenous RhoGDI-2 and -3 due to the non-specificity of the available commercial 
antibodies. The interaction between endogenous ACK and RhoGDI-1 was detected in LNCaP 
cells. There is substantial evidence in the literature suggesting roles for ACK and the RhoGDIs in 
prostate cancer. ACK has been found to phosphorylate the AR at Tyr267 and promote AR 
recruitment to the ARE, resulting in the transcription of AR target genes in the absence of 
androgen, to drive prostate cancer progression (Mahajan et al., 2007). Meanwhile, RhoGDI-1 has 
been shown to negatively regulate the AR signalling pathway by preventing AR nuclear 
translocation and inhibiting transactivation of AR target genes (Zhu et al., 2013). These opposing 
functions of both proteins in regulating AR signalling would result in antagonistic effects 
especially on the transcription of AR target genes to drive prostate cancer progression. Thus, ACK 
may interact with RhoGDI-1 to prevent its association with the AR and hence promote the 
transactivation of AR target genes.  
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The cellular site of interaction of ACK with the RhoGDI was also determined in this study. 
Similarly to a previous study from Ahmed et al. (2004), ACK was found in both the cytoplasmic 
and nuclear-enriched fractions and this localisation was shown to be kinase-independent. ACK is 
known to have an NES towards its N-terminus, which facilitates nuclear export but how ACK 
enters the nucleus is still unknown. However, the interaction of ACK with Cdc42 may contribute 
to ACK’s nuclear translocation (Ahmed et al., 2004). 
All three RhoGDIs have been found previously to localize in both the nucleus and cytoplasm 
(Marzouk et al., 2007; Krieser and Eastman, 1999). However, their functional roles are more 
defined in the cytoplasm (Dovas and Couchman, 2005). RhoGDI-1 has been shown to bind and 
regulate ERa in MCF-7 cells, while N-terminally truncated RhoGDI-2 was shown to accumulate 
in the nucleus during apoptosis (Marzouk et al., 2007; Krieser and Eastman, 1999). Despite these 
previous observations, in this study, both RhoGDI-1 and -2 were shown to be exclusively in the 
cytoplasm, under the conditions tested. This disparity is probably due to differences in the types 
of cells and growth conditions used in different studies. Furthermore, only the N-terminally 
truncated version of RhoGDI-2 has been found in the nucleus previously (Krieser and Eastman, 
1999), whereas in this study, full-length RhoGDI-2 was analysed and was only identified in the 
cytoplasm.  
In contrast, RhoGDI-3 was found in both the cytoplasmic and nuclear-enriched fractions in this 
work, which is consistent with previous findings that show RhoGDI-3 to associate with the 
nucleus, Golgi, plasma membrane and cytoskeleton (Adra et al., 1997; de León-Bautista et al., 
2016; Brunet et al., 2002; Zalcman et al., 1996). This unique subcellular localization of RhoGDI-
3 among the RhoGDIs has been assumed to involve the unique hydrophobic N-terminus of 
RhoGDI-3, which is predicted to contain a small additional amphipathic helix extending from 
residue 5 to 28. Brunet et al. (2002) demonstrated that the first 41 amino acids of RhoGDI-3 were 
involved in Golgi targeting. However, in results presented here, the first 26 amino acids of 
RhoGDI-3 were shown to be involved in the nuclear export of RhoGDI-3, consistent with 
prediction data that found a potential NES, spanning amino acids 14 to 21 (LELLRLAL) in 
RhoGDI-3. The nuclear targeting of RhoGDI-3 was initially reported by Adra et al. (1997), who 
found RhoGDI-3 to cluster around the nucleus, suggesting that this protein might be targeted to 
the nucleus (de León-Bautista et al., 2016).   
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The role of RhoGDI-3 in the nucleus is still unknown. However, it has been hypothesised that 
RhoGDI-3 might regulate the activation of several Rho-family GTPases also found to reside in the 
nucleus, including RhoA, RhoB, RhoC, Rac1 and Rac3 (Adini et al., 2003; Sandrock et al., 2010; 
Dubash et al., 2011; Kim et al., 2013). Rac1 accumulation in the nucleus is important to control 
nuclear membrane morphology and is involved in promoting cell division and migration 
(Michaelson et al., 2008; Navarro-Lérida et al., 2015). Nuclear RhoA has also been found to be 
involved in the DNA damage response (Dubash et al., 2011). One of the atypical Rho-family 
GTPases, RhoH has also been found in the nucleus of Jurkat cells (Mino et al., 2018).  
In this study, RhoA and RhoC were exclusively found in the cytoplasm, while Rac1 and RhoH 
were found to localise in both the cytoplasm and nuclear-enriched compartments. However, 
RhoGDI-3 was found to interact with Rac1 only in the cytoplasm. Both RhoGDI-1 and -2 were 
also shown to interact with Rac1 exclusively in the cytoplasm. In cells expressing each of the 
RhoGDIs, Rac1 nuclear levels decreased, suggesting a role for the RhoGDI proteins to sequester 
Rac1 in the cytoplasm and prevent its nuclear targeting. Similar data has been published previously 
for RhoGDI-1 towards Rac1 and RhoA (Michaelson et al., 2001; Dubash et al., 2011).  
RhoGDI-3 was found to form a complex with ACK predominantly in the nuclear-enriched 
fraction, indicating a role for ACK in regulating RhoGDI-3 nuclear function. However, presently, 
the possibility that ACK might also interact with RhoGDI-3 in early endosomes cannot be 
excluded as previous studies have shown the localisation of both proteins in that particular 
compartment (Schröter et al., 1999; Brunet et al., 2002; Shen et al., 2007). The subcellular 
fractionation assay used in this study only separates the cytoplasm of the cells from other 
subcellular structures. The nuclear-enriched fractions will therefore contain other subcellular 
structures such as the mitochondria, endosomes, Golgi network and endoplasmic reticulum. Thus, 
to identify a more precise location of ACK-RhoGDI-3 complex, further work could possibly 
include a bimolecular fluorescence complementation (BiFC) assay, a fluorescence imaging 
technique. In BiFC, the interacting proteins are fused to nonfluorescent halves of a fluorescent 
protein. If they interact, the nonfluorescent fragments are brought into close proximity, the 
fluorophore is reconstituted and a fluorescent signal can be detected using confocal microscopy 
(Pratt et al., 2016). The site of interaction between ACK and both RhoGDI-1 and -2 was not tested 
in this study due to time constraints, however it is likely that they interact in the cytoplasm due to 
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the cytoplasmic localisation of both RhoGDIs found here. Furthermore, co-expression with ACK 
did not alter the cytoplasmic localization of RhoGDI-1 and -2. 
Despite ACK being a kinase, all mutagenesis data analysing mutant variants in cells suggest that 
RhoGDI-2, at least, is not a substrate for ACK. ACK has been shown to phosphorylate a single 
tyrosine within the attB1 site of pDEST26-RhoGDI-2 construct, which was detected by a pan anti-
pTyr antibody. TyrosineattB1 is crucial for LR recombination between Gateway entry clones and 
Gateway expression vectors, therefore it will be in all expression constructs following 
recombination. Since TyrattB1 has been shown to be a major phosphorylation site for ACK in this 
study, it is important for all future work analysing the effect of ACK on the phosphorylation status 
of its binding targets to use an expression construct with a mutated TyrattB1. In parallel with the 
cell assays, an in vitro kinase assay was also performed using GST-tagged RhoGDI-1 and -2. This 
assay confirmed that neither RhoGDIs were substrates for ACK kinase activity. The 
phosphorylation status of RhoGDI-3 by ACK is currently unknown as time constraints disallowed 
further analysis in cells and the protein was not soluble in E. coli preventing its purification. 
However, it seems likely that ACK will not phosphorylate RhoGDI-3 due to the high sequence 
similarity between all three RhoGDIs. Furthermore, all the tyrosine residues present within 
RhoGDI-3 are conserved between the RhoGDIs. ACK has been shown to have a dual kinase 
activity as it was found to phosphorylate WASP at both Tyr256 and Ser242 (Yokoyama et al., 
2005). Thus, it is possible that ACK phosphorylates the RhoGDIs at serine or threonine residues. 
However, it will be difficult to test this hypothesis due to lack of reliable antibodies. Future work 
with mass spectrometry could help to generate a definitive answer.  
The interaction with ACK has been shown in this work to promote RhoGDI-3 degradation; this 
does not appear to be the case with RhoGDI-1 or -2. RhoGDI-3 degradation facilitated by ACK 
potentially involves the N-terminus of RhoGDI-3, as an N-terminally truncated version of 
RhoGDI-3 was shown to be more stable with ACK compared to wt RhoGDI-3. RhoGDI-3 and a 
DNRhoGDI-3 mutant were found to be relatively stable proteins with half-lives >8 h. However, 
co-expression with ACK significantly decreased the half-life of wt RhoGDI-3 to ~3.5 h, while 
having no effect on the DNRhoGDI-3 mutant. These data suggest that the interaction between 
ACK and RhoGDI-3 might stimulate RhoGDI-3 conformational changes that allow the first 26 
amino acids of RhGDI-3 to act as a degradation signal. ACK-mediated RhoGDI-3 degradation has 
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been shown to occur predominantly in the nucleus, which might affect the nuclear function of 
RhoGDI-3. Interestingly, loss of RhoGDI-3 in the nucleus was found to be associated with 
pancreatic cancer progression (de León-Bautista et al., 2016), suggesting that ACK-mediated 
RhoGDI-3 degradation in the nucleus might contribute to ACK-driven oncogenicity.  
ACK-mediated RhoGDI-3 degradation has been shown to be proteasomal-dependent and this 
could be achieved by regulating RhoGDI-3 ubiquitination. Data presented here suggest that 
RhoGDI-3 can be modified by either linear ubiquitination, Lys48 poly-Ub or linear-Lys48 mixed 
poly-Ub, which occur in both the cytoplasm and nuclear-enriched fractions. Currently, there is no 
definitive answer for the type of RhoGDI-3 ubiquitination due to the discrepancy in the data 
obtained but further work with mass spectrometry would be helpful to properly identify the type 
of RhoGDI-3 ubiquitination. A poly-Ub via a Lys48 linkage has been shown to promote its 
degradation. It was initially assumed that ACK would promote RhoGDI-3 degradation by 
enhancing RhoGDI-3 ubiquitination, consistent with a previous study that showed ACK to 
phosphorylate and induced Wwox poly-ubiquitination and degradation (Mahajan et al., 2005). 
However, in this study, the presence of ACK resulted in noticeably decreased RhoGDI-3 
ubiquitination, visible even though there were lower levels of RhoGDI-3 present in the cells. The 
association between the loss of RhoGDI-3 ubiquitination and a decrease in its protein levels was 
unexpected but ACK may regulate RhoGDI-3 ubiquitination and promote its degradation by 
binding to the Ub-RhoGDI-3 complex, potentially via its UBA domain. 
The UBA domain of ACK has been shown to interact with Ub-conjugated proteins (Shen et al., 
2007). Consistent with this, a somatic mutation, S985N, in the UBA domain of ACK has been 
shown to prevent its interaction with ubiquitinated proteins (Tin et al., 2010). However, a study 
by Shen et al. (2007) found that, while the UBA domain of ACK did not determine the interaction 
with ubiquitinated EGFR, it was involved in regulating the EGFR degradation in response to EGF 
stimulation. This would be important to prevent excessive EGF signalling that is frequently 
observed in cancer (Fox et al., 2019). EGFR degradation has been shown to occur together with 
ACK degradation and this is mediated by ACK ubiquitination (Tin et al., 2010; Chan et al., 2009; 
Lin et al., 2010). Conversely, a lack of the UBA domain was shown to promote ACK and EGFR 
stability even after EGF stimulation (Tin et al., 2010). These data suggest that ACK ubiquitination 
might serve as a degradation signal for RhoGDI-3 and its UBA domain might therefore be involved 
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in the regulation of RhoGDI-3 ubiquitination and stability. Nonetheless, in this study, a UBA 
mutant of ACK was unable to restore RhoGDI-3 poly-ubiquitination status but instead was found 
to partially increase RhoGDI-3 stability. These data indicate that the UBA domain of ACK does 
not regulate RhoGDI-3 ubiquitination by binding to the Ub-RhoGDI-3 complex but potentially 
involved in modulating RhoGDI-3 stability.  
In this study, ACK protein levels were also shown to decrease when co-expressed with any of the 
RhoGDIs, suggesting that the RhoGDIs also promote ACK degradation. ACK can be ubiquitinated 
by several E3 ligases including NEDD4-1 (Lin et al., 2010), NEDD4-2 (Chan et al., 2009), SIAH1 
and SIAH2 (Buchwald et al., 2013), which then leads to its ubiquitination and degradation. A 
study by Lin et al. (2010) showed the potential involvement of the SAM domain of ACK in 
regulating ACK ubiquitination, as well as the necessity of the UBA domain for the interaction with 
NEDD4-1. Since the interaction with ACK has been found to enhance RhoGDI-3 proteasomal 
degradation, it is possible that ACK blocks some ubiquitination sites on RhoGDI-3 and that 
degradation of the ACK-RhoGDI-3 complex is facilitated by the ubiquitination of ACK at sites in 
its SAM domain (Figure 10.1). Future work involving the SAM domain of ACK will be needed to 
identify any potential role in regulating RhoGDI-3 ubiquitination.  
RhoGDI-1 protein levels do not appear to be affected by ACK. However, in contrast to RhoGDI-
3, the levels of RhoGDI-2 slightly increased when co-expressed with ACK. This is consistent with 
previous findings that show overexpression of RhoGDI-2 promotes ovarian cancer, gastric cancer 
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Figure 10.1: Regulation of RhoGDI-3 ubiquitination by ACK. (A) RhoGDI-3 undergoes 
ubiquitination. (B) The interaction with ACK block RhoGDI-3 ubiquitination sites but the 
degradation of the ACK-RhoGDI-3 complex can be regulated by the interaction with an E3 ligase 
(example here NEDD4-1) through the ACK UBA domain, which results in ACK ubiquitination at 
the SAM domain. This will then enhance the degradation of ACK-RhoGDI-3 complex. Ub: 
Ubiquitin, AH: Amphiphatic helix, RA: Regulatory arm domain, IL: Immunoglobulin-like 
domain, SAM: sterile α motif domain, NES: nuclear export signal, Kinase: tyrosine kinase domain, 
SH3: Src Homology 3 domain, CRIB: Cdc42/Rac interacting binding region, CL: Clathrin-
interacting region, EBD: EGFR binding domain and UBA: ubiquitin-association domain.  
 
The effect of ACK on RhoGDI target proteins was also determined in this study. Several targets 
have been identified for the RhoGDIs which mainly come from the typical or classical Rho GTPase 
subfamilies such as Rho, Rac and Cdc42. Less is known about any RhoGDI interactions with the 
atypical Rho GTPases, except for RhoH, which has been reported to interact with all three 
RhoGDIs (Li et al., 2002). Thus, it was reasoned that knowledge of the full spectrum of the 
A 
B 
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interacting partners for each RhoGDIs would be crucial to determining the cellular effect that may 
results from the regulation of the RhoGDIs by ACK.  
Aberrant activity of RhoGDIs, either through changes in expression levels or modification of their 
binding to target proteins has been found to be associated with cancer. For instance, the interaction 
of RhoGDI-1 with EphrinB1 has been shown to stimulate RhoA displacement from the RhoA-
RhoGDI-1 complex leading to RhoA activation, which promotes breast cancer cell migration (Cho 
et al., 2018). Furthermore, the RhoGDI-1 interaction with 14-3-3τ was also shown to support cell 
migration and invasion in breast cancer by disturbing RhoGDI-1 association with its targets, RhoA, 
Rac1 and Cdc42 (Xiao et al., 2014). These data suggest that more detailed knowledge of RhoGDI 
target proteins could help in the search for new therapeutic targets especially for ACK-driven 
cancer progression (Cho et al., 2019).  
Here RhoGDI-1 was shown to form complexes with RhoA, RhoC, Rac1, Rac2, Rac3, RhoG, 
Cdc42 and RhoF. RhoF is a newly identified target for RhoGDI-1 and this is consistent with its 
similarity to Rac and Rho subfamilies members (~50%).  
Data presented here indicate that RhoGDI-2 has a more limited target profile, which includes 
RhoC, Rac1 and Rac3. Early studies suggested that RhoGDI-2 had a restricted expression profile 
and was confined to haematopoietic cells, however more recent data show expression in a wider 
range of tissues and cancer cell types (Cho et al., 2010). A previous study also identified Cdc42 
(Scheffzek et al., 2000) and RhoA (Griner et al., 2015) as RhoGDI-2 targets. However, these were 
not observed in the system used in this study. RhoGDI-2 has been reported to make weaker affinity 
complexes with its Rho GTPase targets. For instance, RhoGDI-2 was shown to bind to Cdc42 with 
10- to 20-fold weaker affinity than RhoGDI-1 (Platko et al., 1995) potentially due to non-
conservation of amino acids between these RhoGDIs (Platko et al., 1995; Nomanbhoy et al., 
1996). Due to the potential weak affinity between RhoGDI-2 and its binding targets, it cannot be 
ruled out that some RhoGDI-2 targets may have been missed in this study.  
Here, RhoGDI-1 and RhoGDI-2 were found not to interact with the other Rho-family GTPases: 
TC10, TCL, Wrch1, Wrch2, the Rnd subfamily, the Miro subfamily, RhoD and RhoH. Initially, 
RhoD was postulated to be a target for RhoGDI in this study due to its high similarity with the Rac 
and Rho subfamilies (~50%), however no interaction was identified. An interaction between 
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RhoGDI-2 and Rac2 was also predicted prior to this screen as a crystal structure of the RhoGDI-
2-Rac2 complex has been solved. However, there was no interaction observed between these two 
proteins in this study, potentially indicating that they do not interacting in a cellular environment.  
The least studied RhoGDI, RhoGDI-3 was shown to engage with all the typical members of the 
Rho-family GTPases, excluding Cdc42, TC10 and TCL. It was also found to associate with several 
atypical Rho-family GTPases such as RhoD, RhoH, Wrch2, Rnd2 and Miro2. Interestingly, one 
of the targets, Wrch2, has been shown to be modified solely by palmitoylation. Previously, 
palmitoylation had been reported to completely abrogate the interaction between RhoGDI-1 and 
RhoA (Michaelson et al., 2001). Conversely, a study by Navarro‐Lérida et al. (2012) showed that 
RhoGDI-1 was also able to bind to palmitoylated Rac1. Since Wrch2 was only found to interact 
with RhoGDI-3 and not with the other RhoGDIs, it is possible that RhoGDI-3 favours 
palmitoylated Rho GTPases and is potentially involved in targeting them to specific subcellular 
compartments. 
The interaction between RhoGDI-3 and the GTPase defective Rho-family GTPases such as RhoH 
and Rnd2 was not expected as these Rho GTPases have been shown to be constitutively active due 
to their high intrinsic GDP dissociation rate (Fueller and Kubatzky, 2008; Aspenström, 2017). 
Additionally, Chenette et al. (2006) also showed that all three RhoGDIs failed to prevent Wrch2 
membrane association, suggesting that Wrch2 is not regulated by the RhoGDI. However, RhoGDI-
1 has been observed to accommodate both the GTP- and GDP-bound forms of Rac1, RhoA 
(Hancock and Hall, 1993) and Cdc42 (Nomanbhoy and Cerione, 1996). This was supported by 
structural studies that show the main interface between RhoGDI-1 and Cdc42 is not affected by 
the nucleotide state of Cdc42 (Phillips et al., 2008). There is also a possibility that RhoGDI-3 
regulates the activity of these unusual Rho-family GTPases via an adaptor protein, 14-3-3, 
consistent with previous studies that showed 14-3-3ß negatively regulates Rnd activation (Riou et 
al., 2013) and also binds to RhoGDI-1 (Xiao et al., 2014). 
Miro2, a mitochondria-associated small GTPase, was shown to be a target for RhoGDI-3 in this 
study but not Miro1, although both are structurally similar and localize to the same cell 
compartment. Nevertheless, these proteins have been shown to be functionally different with the 
degradation of Miro2 and not Miro1 found to inhibit mitochondrial retrograde trafficking 
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(O'Mealey et al., 2017). Furthermore, Nguyen et al. (2014) also found that Miro2 did not rescue 
neural respiratory defects due to the loss of Miro1 function in Miro1 KO mice. The molecular 
details of the RhoGDI-3-Miro2 interaction are however unclear as Miro2 does not undergo any 
lipid modification due to the lack of a CAAX motif and palmitoylated cysteines. Nevertheless, 
these data indicate a potential new role for RhoGDI-3 in regulating mitochondrial processes 
through its target, Miro2.  
As mentioned previously, RhoGDI-3 has been found on endomembranes and early endosomes 
(Brunet et al., 2002). Several Rho-family GTPases have also been found to localize at these same 
sites, for example, RhoB (Adamson et al., 1992), Rac3 (Chan et al., 2005), RhoG (Morin et al., 
2010), Wrch2 (Hodge and Ridley, 2017), Rnd2 (Tanaka et al., 2002) and RhoD (Gasman et al., 
2003). This suggests that RhoGDI-3 might interact with its partners in these compartments and 
possibly play a new role in regulating their intracellular trafficking.  
The differences in the binding capabilities of the RhoGDIs are still not well understood. However, 
despite sharing 70% sequence similarities, the divergent amino acids between the three RhoGDIs 
are found to concentrate within their N-termini (Figure 1.12) and this might contribute to their 
binding preferences. The first 25 amino acids of RhoGDI-1 have been shown to play a pivotal role 
in retaining RhoGDI-1 in the cytoplasm, suggesting that the N-termini of the RhoGDIs are 
important in regulating their subcellular localization and therefore facilitate the binding with Rho 
GTPases that reside within the same compartments (Ueyama et al., 2013). In the same study it was 
found that RhoGDI-1 also localised to phagosomes and this required an interaction with Rac1, 
indicating that the RhoGDIs and Rho GTPases were mutually involved in the signal directing them 
to specific cell compartments.  
The effect of the RhoGDIs on the activation status of their binding targets was also investigated 
here. In this study, co-expression with any of the RhoGDIs was found to decrease the GTP levels 
of their binding partners, even for small G proteins considered constitutively active such as RhoH. 
Both RhoGDI-1 and -2 were able to inhibit the activation of Rac1 in the cytoplasm, consistent with 
a previous study (Quinn et al., 1993). RhoGDI-3 was also found to interact and inhibit the 
activation of its target proteins, Rac1 and RhoA in the cytoplasm. Conversely, the RhoH-RhoGDI-
3 complex was found in both the cytoplasm and nuclear-enriched compartments and resulted in 
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RhoH deactivation in both locations. The nuclear function of RhoH is still not well understood but 
it is required to regulate the nuclear translocation of Kaiso, a transcriptional regulator, in response 
to chemokine stimulation and T cell receptor activation during T cell migration (Mino et al., 2018). 
This suggests a role for RhoH in modulating the localization of its binding partners, which might 
also apply to RhoGDI-3.  
With increased knowledge of the targets of the RhoGDIs and the outcome of the interactions, this 
work now focused on the effect of ACK as a new player that might influence the binding and 
inhibitory capabilities of RhoGDIs. The presence of ACK does not promote Rac1 dissociation 
from Rac1-RhoGDI-1 or -2 complexes which is consistent with the low levels of active Rac1 
observed in cells where ACK and the RhoGDIs are co-expressed, similar to levels in cells 
expressing the RhoGDIs alone.  
ACK has been shown to mediate RhoGDI-3 degradation and thereby reduce the levels of RhoGDI-
3 available for binding with its target proteins. Subsequently, this should promote the activation 
of the unbound small GTPases. As hypothesized, the amount of RhoGDI-3 in complex with RhoA, 
Rac1 and RhoH was seen to decrease when co-expressed with ACK, and this resulted in the 
increased activation of these small GTPases. In contrast, the activation of tumour suppressor RhoB 
decreased in the presence of ACK. These Rho subfamily proteins have been shown to act in 
opposition in cancer, with RhoA being mainly pro-oncogenic and RhoB commonly anti-oncogenic 
(Zohn et al., 1998; Orgaz et al., 2014; Chen et al., 2000). Thus, it is likely that the opposing effects 
of ACK on these proteins would lead to a harmonised outcome and promote ACK-driven cancer 
progression.  
Usually, RhoA and Rac1 activity to control cytoskeleton dynamics is regulated in a co-ordinated 
manner with suppression of RhoA and upregulation of Rac1 activity or vice versa. For instance, 
RhoA is commonly active towards the rear of the cell and involved in cell retraction, whereas Rac1 
is active towards the front of the cell during migration (Machacek et al., 2009; Nguyen et al., 
2018). This spatial activation is commonly regulated through GEF, GAP, GDI or effector proteins 
shared by both Rho GTPases (Guilluy et al., 2011). Their activation has also been found to be 
dependent on each other, for example active Rac1 interacts with the RhoA GEF, Dbs, resulted in 
the activation of RhoA (Horii et al., 1994; Cheng et al., 2004). Furthermore, the RhoA effector 
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proteins, mDia1 and ROCK have also been shown to act in opposition to promote Rac1 activation 
and hence membrane ruffle formation in fibroblasts (Tsuji et al., 2002). Although RhoA is 
predominantly active at the rear of the cell, a pool of active RhoA has also been found at the leading 
edge of cells during migration to initiate cell protrusion, preceding the activation of Rac1, which 
supports the newly expanded protrusion (Machacek et al., 2009). Therefore, it is possible that ACK 
spatially regulates the activity of both RhoA and Rac1 through RhoGDI-3 especially during cell 
invasion and metastasis.  
The presence of ACK has been shown to promote RhoGDI-3 degradation, predominantly in the 
nucleus. Thus, it is expected that the activation of Rho GTPase localized in the nucleus would be 
elevated. High levels of active Rac1 in the nucleus have been found to promote cell division and 
invasion (Michaelson et al., 2008; Navarro-Lerida et al., 2015). Thus, it was hypothesized that 
ACK would increase Rac1•GTP levels in the nucleus and this could contribute to its association 
with cancer cell proliferation (Clayton et al., 2019), migration and invasion (Xu et al., 2015; Lei 
et al., 2015). Furthermore, in this study, co-expression with ACK has been shown to partially 
inhibit the ability of RhoGDI-3 to sequester Rac1 in the cytoplasm, promoting its nuclear 
localisation. However, co-expression with ACK did not increase Rac1•GTP in the nucleus but 
surprisingly, GTP-bound Rac1 was shown to increase in the cytoplasm. These data suggest that 
ACK might modulate the activation of other Rho GTPases that are known to be in the nucleus.  
As described previously, RhoA showed a restricted cytoplasmic distribution in the system used 
here, while RhoH can be found in both cytoplasmic and nuclear-enriched fractions. RhoH has been 
shown to promote prostate cancer cell migration by forming a ternary complex with Rac1 and its 
effector, PAK2, to direct GTP-bound Rac1 to membrane protrusion (Tajadura-Ortega et al., 2018). 
Effector proteins shared by these two Rho GTPases (Wang et al., 2010; Kuželová et al., 2014) 
suggest a signalling crosstalk which could be regulated by ACK. Furthermore, since ACK has 
been shown to increase RhoH activity in both the cytoplasmic and nuclear-enriched by regulating 
RhoGDI-3 stability, it is possible that ACK mediates PAK1 activation in the nucleus through 
RhoH and in the cytoplasm via Rac1. The activation of both of these Rho GTPases occurs due to 
low levels of RhoGDI-3 present in and shuttled out from the nucleus. This would then result in the 
increased activation of PAK1 in both compartments, a situation which is frequently observed in 
cancer (Kumar et al., 2006). For instance, an over activated Rac1/PAK1 cascade has been shown 
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to promote ß-catenin phosphorylation at Ser675 in the cytoplasm, leading to increase colon cancer 
cell proliferation (Zhu et al., 2012). Nuclear PAK1 has been shown to promote transcription 
repressor activity of Snail from E-cadherin, occludin and aromatase promoters, leading to 
increased EMT process and cell invasion (Yang et al., 2005).  
 
Figure 10.2: A proposed mechanism for the effect of ACK on RhoGDI-3 functions. (A) 
RhoGDI-3 is found in both the cytoplasm and the nucleus, indicating it undergoes nuclear-
cytoplasmic shuttling. (B) RhoGDI-3 undergoes ubiquitination in both the cytoplasm and the 
nucleus. (C) ACK interacts with RhoGDI-3 exclusively in the nucleus and regulates its 
ubiquitination. This results in degradation of RhoGDI-3 by the proteasome. (D) Subsequently, the 
levels of free RhoGDI-3 will decrease, disallowing complex with RhoH in the nucleus and 
promoting RhoH activation in the nucleus. (E) Furthermore, less RhoGDI-3 will be export out 
from the nucleus, making free RhoGDI-3 less available for binding with Rac1 and therefore 
promotes Rac1 activation.   
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Collectively, all the data presented in this study show a new kinase-independent function for ACK 
in regulating RhoGDI proteins. In particular ACK plays a role in controlling levels of RhoGDI-3 
and thereby modulates its function as a regulator for Rho GTPases (Figure 10.2). Since RhoGDI-
3 has been shown to interact with Miro2, a mitochondria-associated Rho GTPase, it is possible 
that ACK might deregulate the function of Miro2 in maintaining mitochondria homeostasis 
through RhoGDI-3, which has been commonly observed in cancer (Caino and Altieri, 2017).  
Further investigation is also needed to fully identify the biological consequences of the action of 
ACK towards the RhoGDIs’ target proteins especially in regard to cell proliferation and migration. 
Attempts were made to study the effect of knockdown of each RhoGDIs on ACK-induced cell 
proliferation and migration. However, since there was only a specific antibody available for 
RhoGDI-1, successful knockdown was monitored using mRNA levels for each RhoGDIs in the 
breast cancer cell lines, MCF-7 and MDA-MB-436. Both of these cell lines were shown to have 
high mRNA levels of ACK and all three RhoGDIs in a screen by Dr. Anna Git (Department of 
Biochemistry, University of Cambridge, personal communication). However, due to time 
constraints, the RT-PCR for each RhoGDIs was not optimised. Thus, future studies including 
siRNA or CRISPR cell lines of RhoGDIs would be useful to identify a role for the RhoGDIs in 
underpinning the oncogenic properties of ACK especially in cell proliferation and migration. 
Furthermore, it would be especially useful to raise a specific antibody for both RhoGDI-2 and -3 
especially RhoGDI-3, which would facilitate endogenous studies with ACK. 
This work set out to investigate a potential role of the RhoGDI proteins in underpinning the 
oncogenic potential of ACK. Although ACK has been shown to interact with all three RhoGDIs, 
the outcome of the interaction is more pronounced for RhoGDI-3. Future work looking at different 
targets of both RhoGDI-1 and -2 would be useful to understand a role for these RhoGDIs in 
supporting ACK oncogenic properties. Overall, all the data presented here show the involvement 
of ACK in disturbing the balance between the levels of RhoGDIs, especially RhoGDI-3, and the 
Rho-family proteins, allowing free Rho-family GTPases to become membrane-bound and 
activated. This happens because RhoGDIs protein levels have been shown to be approximately 
equal to the levels of RhoA, Rac1 and Cdc42 in the cells and any disturbance in this equilibrium 
alters the activation of Rho-family proteins, which have been observed frequently in cancer. 
Although the role of RhoGDI-3 in mediating the effects of ACK on cell proliferation and migration 
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has not yet been studied, it can now be postulated that ACK mediates the degradation of RhoGDI-
3, resulting in an increased pool of its active target Rho GTPases. This leads to the activation of 
the Rho-family effector proteins such as Rhotekin and PAK1, which could underpin ACK 
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1 TC10 TCL Cdc42 RhoG Rac2 Rac1 Rac3 
RhoBTB3  15 14 25 25 26 16 16 17 19 17 19 17 19 15 17 22 19 17 19 19 20 18 
Miro1 15  60 17 18 21 19 17 21 28 26 22 22 23 25 27 25 24 24 24 24 25 25 
Miro2 14 60  16 19 20 23 20 22 27 24 25 25 27 26 26 22 22 24 27 27 26 28 
RhoBTB1 25 17 16  70 34 33 31 30 34 28 38 37 38 34 32 38 35 40 40 41 42 41 
RhoBTB2 25 18 19 70  32 32 31 29 34 28 39 37 38 33 32 39 37 40 40 42 42 41 
RhoH 26 21 20 34 32  29 32 36 38 33 40 40 41 41 38 40 39 42 40 40 41 40 
Rnd1 16 19 23 32 32 29  53 61 37 39 41 42 41 31 32 36 34 37 37 39 39 38 
Rnd2 16 17 20 31 31 32 53  63 39 41 46 47 43 28 31 36 35 37 41 40 41 39 
Rnd3 17 21 22 29 29 36 61 63  37 40 48 48 47 31 32 39 35 38 41 39 42 40 
RhoD 19 28 27 34 35 38 37 39 37  49 49 49 49 39 36 42 38 43 44 46 49 49 
RhoF 17 26 24 28 28 33 39 41 40 49  47 48 47 36 37 46 43 43 46 50 59 47 
RhoA 19 22 25 38 39 40 41 46 48 49 47  92 85 40 44 51 48 53 55 53 57 55 
RhoC 17 22 25 37 37 40 42 47 48 49 48 92  85 40 44 50 49 51 55 53 57 54 
RhoB 19 23 27 38 38 41 41 43 47 49 47 85 85  42 45 51 48 50 53 54 55 54 
Wrch2 15 25 26 34 33 41 31 28 31 39 36 40 40 42  59 51 48 53 46 51 52 53 
Wrch1 17 27 26 32 32 37 32 31 32 36 37 44 44 45 59  50 46 56 48 54 54 54 
TC10 22 25 22 38 39 40 36 36 39 42 46 51 50 51 51 50  76 66 54 60 62 61 
TCL 19 24 22 35 37 39 34 35 35 38 44 48 49 48 48 46 76  63 53 58 60 59 
Cdc42 17 24 24 40 40 42 37 37 38 43 43 53 51 50 53 56 66 63  61 69 71 70 
RhoG 19 24 27 39 40 40 37 41 41 44 46 55 55 53 46 48 54 53 60  72 72 70 
Rac2 19 24 27 41 42 40 39 40 39 46 50 53 53 54 50 54 60 58 69 72  92 89 
Rac1 20 25 26 42 42 41 39 41 42 49 49 57 57 55 52 54 62 60 71 72 92  93 
Rac3 18 25 28 41 41 40 38 39 40 49 47 55 54 54 53 54 61 59 70 70 89 93  
